{"PMC3635991": [["IntroductionThe innate immune system has evolved numerous molecular sensors and signaling pathways to detect, contain and clear viral infections [1]\u2013[4].", [["viral infections", "DISEASE", 128, 144], ["The innate immune system", "TREATMENT", 12, 36], ["clear viral infections", "PROBLEM", 122, 144]]], ["Viruses are sensed by a subset of pattern recognition receptors (PRRs) that recognize evolutionarily conserved structures known as pathogen-associated molecular patterns (PAMPs).", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 34, 63], ["PRRs", "GENE_OR_GENE_PRODUCT", 65, 69], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 131, 169], ["pattern recognition receptors", "PROTEIN", 34, 63], ["PRRs", "PROTEIN", 65, 69], ["pathogen-associated molecular patterns", "PROTEIN", 131, 169], ["PAMPs", "PROTEIN", 171, 176], ["Viruses", "PROBLEM", 0, 7], ["pathogen", "PROBLEM", 131, 139]]], ["Classically, viral nucleic acids are the predominant PAMPs detected by these receptors during infection.", [["nucleic acids", "CHEMICAL", 19, 32], ["infection", "DISEASE", 94, 103], ["PAMPs", "GENE_OR_GENE_PRODUCT", 53, 58], ["PAMPs", "PROTEIN", 53, 58], ["viral nucleic acids", "TEST", 13, 32], ["the predominant PAMPs", "PROBLEM", 37, 58], ["infection", "PROBLEM", 94, 103], ["viral", "OBSERVATION", 13, 18], ["nucleic acids", "OBSERVATION", 19, 32], ["predominant", "OBSERVATION_MODIFIER", 41, 52], ["PAMPs", "OBSERVATION", 53, 58], ["infection", "OBSERVATION", 94, 103]]], ["These sensing steps contribute to the activation of signaling cascades that culminate in the early production of antiviral effector molecules, cytokines and chemokines responsible for the inhibition of viral replication and the induction of adaptive immune responses [2], [5]\u2013[7].", [["[5]\u2013[7]", "SIMPLE_CHEMICAL", 272, 279], ["antiviral effector molecules", "PROTEIN", 113, 141], ["cytokines", "PROTEIN", 143, 152], ["chemokines", "PROTEIN", 157, 167], ["signaling cascades", "PROBLEM", 52, 70], ["antiviral effector molecules", "TREATMENT", 113, 141], ["cytokines and chemokines", "TREATMENT", 143, 167], ["viral replication", "TREATMENT", 202, 219], ["the induction of adaptive immune responses", "TREATMENT", 224, 266]]], ["In addition to the nucleic acid sensing by a subset of endosome-associated Toll-like receptors (TLR), viral RNA structures within the cytoplasm are recognized by members of the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) family, including the three DExD/H box RNA helicases RIG-I, Mda5 and LGP-2 [2], [3], [5], [8]\u2013[12].IntroductionRIG-I is a cytosolic multidomain protein that detects viral RNA through its helicase domain [13], [14].", [["endosome", "ANATOMY", 55, 63], ["cytoplasm", "ANATOMY", 134, 143], ["cytosolic", "ANATOMY", 360, 369], ["nucleic acid", "CHEMICAL", 19, 31], ["endosome", "CELLULAR_COMPONENT", 55, 63], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 75, 94], ["TLR", "GENE_OR_GENE_PRODUCT", 96, 99], ["cytoplasm", "ORGANISM_SUBSTANCE", 134, 143], ["retinoic acid-inducible gene-I", "GENE_OR_GENE_PRODUCT", 177, 207], ["RIG-I)-like receptors", "GENE_OR_GENE_PRODUCT", 209, 230], ["RLRs", "GENE_OR_GENE_PRODUCT", 232, 236], ["DExD", "GENE_OR_GENE_PRODUCT", 266, 270], ["RIG-I", "GENE_OR_GENE_PRODUCT", 291, 296], ["Mda5", "GENE_OR_GENE_PRODUCT", 298, 302], ["LGP-2 [2]", "SIMPLE_CHEMICAL", 307, 316], ["[3]", "SIMPLE_CHEMICAL", 318, 321], ["[5], [8]\u2013[12]", "SIMPLE_CHEMICAL", 323, 336], ["RIG-I", "GENE_OR_GENE_PRODUCT", 349, 354], ["endosome-associated Toll-like receptors", "PROTEIN", 55, 94], ["TLR", "PROTEIN", 96, 99], ["retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) family", "PROTEIN", 177, 244], ["DExD", "DNA", 266, 270], ["H box RNA helicases", "PROTEIN", 271, 290], ["RIG", "PROTEIN", 291, 294], ["Mda5", "DNA", 298, 302], ["LGP", "DNA", 307, 310], ["RIG-I", "PROTEIN", 349, 354], ["cytosolic multidomain protein", "PROTEIN", 360, 389], ["viral RNA", "RNA", 403, 412], ["helicase domain", "PROTEIN", 425, 440], ["the nucleic acid sensing", "PROBLEM", 15, 39], ["viral RNA structures", "PROBLEM", 102, 122], ["the retinoic acid-", "TEST", 173, 191], ["Mda5", "TEST", 298, 302], ["LGP", "TEST", 307, 310], ["a cytosolic multidomain protein", "TEST", 358, 389], ["viral RNA", "PROBLEM", 403, 412], ["viral RNA", "OBSERVATION", 102, 111], ["viral RNA", "OBSERVATION", 403, 412]]], ["In addition to its RNA sensing domain, RIG-I also possesses an effector caspase activation and recruitment domain (CARD) that interacts with the mitochondrial adaptor MAVS, also known as VISA, IPS-1, Cardif [15], [16].", [["mitochondrial", "ANATOMY", 145, 158], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["caspase", "GENE_OR_GENE_PRODUCT", 72, 79], ["CARD", "GENE_OR_GENE_PRODUCT", 115, 119], ["mitochondrial", "CELLULAR_COMPONENT", 145, 158], ["MAVS", "GENE_OR_GENE_PRODUCT", 167, 171], ["IPS-1", "GENE_OR_GENE_PRODUCT", 193, 198], ["RNA sensing domain", "PROTEIN", 19, 37], ["RIG-I", "PROTEIN", 39, 44], ["caspase", "PROTEIN", 72, 79], ["recruitment domain", "PROTEIN", 95, 113], ["CARD", "PROTEIN", 115, 119], ["mitochondrial adaptor MAVS", "PROTEIN", 145, 171], ["VISA", "PROTEIN", 187, 191], ["IPS", "PROTEIN", 193, 196], ["an effector caspase activation", "TREATMENT", 60, 90], ["the mitochondrial adaptor MAVS", "TREATMENT", 141, 171], ["IPS", "TEST", 193, 196], ["effector caspase", "OBSERVATION", 63, 79]]], ["Viral RNA binding alters RIG-I conformation from an auto-inhibitory state to an open conformation exposing the CARD domain, resulting in the generation of an activated state characterized by ATP hydrolysis and ATP-driven translocation on RNA [17]\u2013[19].", [["ATP", "CHEMICAL", 191, 194], ["ATP", "CHEMICAL", 210, 213], ["ATP", "CHEMICAL", 191, 194], ["ATP", "CHEMICAL", 210, 213], ["RIG-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["ATP", "SIMPLE_CHEMICAL", 191, 194], ["ATP", "SIMPLE_CHEMICAL", 210, 213], ["RIG-I", "PROTEIN", 25, 30], ["CARD domain", "PROTEIN", 111, 122], ["Viral RNA binding", "PROBLEM", 0, 17], ["an auto-inhibitory state", "TREATMENT", 49, 73], ["ATP hydrolysis", "PROBLEM", 191, 205], ["ATP", "PROBLEM", 210, 213]]], ["Activation of RIG-I also allows ubiquitination and/or binding to polyubiquitin.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 14, 19], ["polyubiquitin", "GENE_OR_GENE_PRODUCT", 65, 78], ["RIG-I", "PROTEIN", 14, 19], ["polyubiquitin", "PROTEIN", 65, 78], ["ubiquitination", "PROBLEM", 32, 46], ["polyubiquitin", "TREATMENT", 65, 78]]], ["In recent studies, polyubiquitin binding has been shown to induce formation of RIG-I tetramers that activate downstream signaling by inducing the formation of prion-like fibrils composed of the MAVS adaptor [20].", [["polyubiquitin", "GENE_OR_GENE_PRODUCT", 19, 32], ["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["prion-like fibrils", "GENE_OR_GENE_PRODUCT", 159, 177], ["MAVS", "GENE_OR_GENE_PRODUCT", 194, 198], ["RIG-I tetramers", "PROTEIN", 79, 94], ["prion-like fibrils", "PROTEIN", 159, 177], ["MAVS", "PROTEIN", 194, 198], ["recent studies", "TEST", 3, 17], ["polyubiquitin binding", "PROBLEM", 19, 40], ["RIG-I tetramers", "TREATMENT", 79, 94], ["prion-like fibrils", "TREATMENT", 159, 177], ["the MAVS adaptor", "TREATMENT", 190, 206]]], ["MAVS then triggers the activation of IRF3 and NF-\u03baB transcription proteins through the IKK-related serine kinases TBK1 and IKK\u03b5 [10], [21]\u2013[23], leading to the primary activation of the antiviral program, involving production of type I interferons (IFN\u03b2 and IFN\u03b1), as well as pro-inflammatory cytokines and antiviral factors [5], [24], [25].", [["serine", "CHEMICAL", 99, 105], ["MAVS", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF3", "GENE_OR_GENE_PRODUCT", 37, 41], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 46, 51], ["IKK", "GENE_OR_GENE_PRODUCT", 87, 90], ["TBK1", "GENE_OR_GENE_PRODUCT", 114, 118], ["IKK", "GENE_OR_GENE_PRODUCT", 123, 126], ["[21]\u2013[23]", "SIMPLE_CHEMICAL", 134, 143], ["type I interferons", "GENE_OR_GENE_PRODUCT", 229, 247], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 249, 253], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 258, 262], ["[24]", "SIMPLE_CHEMICAL", 330, 334], ["[25]", "SIMPLE_CHEMICAL", 336, 340], ["MAVS", "PROTEIN", 0, 4], ["IRF3", "PROTEIN", 37, 41], ["NF-\u03baB", "PROTEIN", 46, 51], ["transcription proteins", "PROTEIN", 52, 74], ["IKK", "PROTEIN", 87, 90], ["serine kinases", "PROTEIN", 99, 113], ["TBK1", "PROTEIN", 114, 118], ["IKK", "PROTEIN", 123, 126], ["type I interferons", "PROTEIN", 229, 247], ["IFN\u03b2", "PROTEIN", 249, 253], ["IFN\u03b1", "PROTEIN", 258, 262], ["pro-inflammatory cytokines", "PROTEIN", 276, 302], ["antiviral factors", "PROTEIN", 307, 324], ["MAVS", "PROBLEM", 0, 4], ["IRF3", "TEST", 37, 41], ["NF", "TEST", 46, 48], ["the IKK", "TEST", 83, 90], ["serine kinases", "TEST", 99, 113], ["TBK1", "TEST", 114, 118], ["IKK\u03b5", "TEST", 123, 127], ["type I interferons (IFN\u03b2 and IFN\u03b1)", "PROBLEM", 229, 263], ["pro-inflammatory cytokines", "TEST", 276, 302], ["antiviral factors", "TEST", 307, 324]]], ["A secondary response involving the induction of IFN stimulated genes (ISGs) is induced by the binding of IFN to its cognate receptor (IFN\u03b1/\u03b2R), which triggers the JAK-STAT pathway to amplify the antiviral immune response [6], [26]\u2013[29].IntroductionThe nature of the ligand recognized by RIG-I has been the subject of intense study given that these PAMPs are the initial triggers of the antiviral immune response.", [["IFN stimulated genes", "GENE_OR_GENE_PRODUCT", 48, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 105, 108], ["IFN\u03b1/\u03b2R", "GENE_OR_GENE_PRODUCT", 134, 141], ["JAK", "GENE_OR_GENE_PRODUCT", 163, 166], ["STAT", "GENE_OR_GENE_PRODUCT", 167, 171], ["[26]\u2013[29]", "SIMPLE_CHEMICAL", 226, 235], ["RIG-I", "GENE_OR_GENE_PRODUCT", 287, 292], ["PAMPs", "GENE_OR_GENE_PRODUCT", 348, 353], ["IFN stimulated genes", "DNA", 48, 68], ["ISGs", "DNA", 70, 74], ["IFN", "PROTEIN", 105, 108], ["cognate receptor", "PROTEIN", 116, 132], ["IFN\u03b1", "PROTEIN", 134, 138], ["\u03b2R", "PROTEIN", 139, 141], ["JAK", "PROTEIN", 163, 166], ["STAT", "PROTEIN", 167, 171], ["RIG-I", "PROTEIN", 287, 292], ["PAMPs", "PROTEIN", 348, 353], ["A secondary response", "PROBLEM", 0, 20], ["IFN stimulated genes", "TREATMENT", 48, 68], ["the antiviral immune response", "TEST", 191, 220], ["intense study", "TEST", 317, 330], ["these PAMPs", "PROBLEM", 342, 353], ["the antiviral immune response", "TREATMENT", 382, 411], ["secondary response", "OBSERVATION", 2, 20], ["antiviral immune", "OBSERVATION", 386, 402]]], ["In vitro synthesized RNA carrying an exposed 5\u2032 terminal triphosphate (5\u2032ppp) moiety was first identified as RIG-I agonists [30]\u2013[32].", [["5\u2032 terminal triphosphate", "CHEMICAL", 45, 69], ["5\u2032ppp", "CHEMICAL", 71, 76], ["5\u2032 terminal triphosphate", "CHEMICAL", 45, 69], ["5\u2032ppp", "CHEMICAL", 71, 76], ["5\u2032 terminal triphosphate", "SIMPLE_CHEMICAL", 45, 69], ["5\u2032ppp", "SIMPLE_CHEMICAL", 71, 76], ["RIG-I", "GENE_OR_GENE_PRODUCT", 109, 114], ["[30]\u2013[32]", "SIMPLE_CHEMICAL", 124, 133], ["an exposed 5\u2032 terminal triphosphate (5\u2032ppp) moiety", "TREATMENT", 34, 84]]], ["The 5\u2032ppp moiety is present at the end of viral and self RNA molecules generated by RNA polymerization; however, in eukaryotic cells, RNA processing in the nucleus cleaves the 5\u2032ppp end and the RNA is capped prior to release into the cytoplasm.", [["cells", "ANATOMY", 127, 132], ["nucleus", "ANATOMY", 156, 163], ["cytoplasm", "ANATOMY", 234, 243], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 5, 9], ["cells", "CELL", 127, 132], ["nucleus", "CELLULAR_COMPONENT", 156, 163], ["5\u2032ppp", "GENE_OR_GENE_PRODUCT", 176, 181], ["cytoplasm", "ORGANISM_SUBSTANCE", 234, 243], ["5\u2032ppp moiety", "PROTEIN", 4, 16], ["viral and self RNA molecules", "RNA", 42, 70], ["eukaryotic cells", "CELL_TYPE", 116, 132], ["5\u2032ppp end", "RNA", 176, 185], ["RNA", "RNA", 194, 197], ["The 5\u2032ppp moiety", "TREATMENT", 0, 16], ["viral and self RNA molecules", "TREATMENT", 42, 70], ["RNA polymerization", "PROBLEM", 84, 102], ["the RNA", "TREATMENT", 190, 197], ["RNA polymerization", "OBSERVATION", 84, 102], ["eukaryotic cells", "OBSERVATION", 116, 132], ["nucleus", "ANATOMY_MODIFIER", 156, 163], ["cytoplasm", "OBSERVATION", 234, 243]]], ["This mechanism distinguishes viral \u2018non-self\u2019 5\u2032pppRNA from cellular \u2018self\u2019 RNA, and renders it recognizable to the innate RIG-I sensor [30], [31], [33].", [["cellular", "ANATOMY", 60, 68], ["cellular", "CELL", 60, 68], ["RIG-I", "GENE_OR_GENE_PRODUCT", 123, 128], ["[31]", "SIMPLE_CHEMICAL", 142, 146], ["viral \u2018non-self\u2019 5\u2032pppRNA", "RNA", 29, 54], ["cellular \u2018self\u2019 RNA", "RNA", 60, 79], ["cellular \u2018self\u2019 RNA", "TREATMENT", 60, 79]]], ["Further characterization of the RNA structure demonstrated that blunt base pairing at the 5\u2032 end of the RNA, with a minimum double strand (ds) length of 20 nucleotides was also important for RIG-I signaling [17], [33], [34].", [["nucleotides", "CHEMICAL", 156, 167], ["RIG-I", "GENE_OR_GENE_PRODUCT", 191, 196], ["5\u2032 end", "DNA", 90, 96], ["RNA", "RNA", 104, 107], ["RIG", "PROTEIN", 191, 194], ["Further characterization", "TEST", 0, 24], ["the RNA structure", "TEST", 28, 45], ["blunt base pairing", "PROBLEM", 64, 82], ["a minimum double strand (ds) length of 20 nucleotides", "TREATMENT", 114, 167], ["RIG-I signaling", "TEST", 191, 206], ["blunt", "OBSERVATION_MODIFIER", 64, 69], ["base", "OBSERVATION_MODIFIER", 70, 74], ["RNA", "ANATOMY", 104, 107]]], ["Furthermore, short dsRNA (<300 bp) triggered RIG-I, whereas long dsRNA (>2000 bp) such as poly I:C and lacking 5\u2032ppp failed to trigger RIG-I, but was recognized by Mda5 [35].IntroductionNatural RNA extracted from virally infected cells, specifically the viral RNA genome or viral replicative intermediates, were also shown to activate RIG-I [30], [31], [36]\u2013[38].", [["cells", "ANATOMY", 230, 235], ["RIG-I", "GENE_OR_GENE_PRODUCT", 45, 50], ["poly I:C", "GENE_OR_GENE_PRODUCT", 90, 98], ["5", "ORGANISM", 111, 112], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 112, 116], ["RIG-I", "GENE_OR_GENE_PRODUCT", 135, 140], ["Mda5", "GENE_OR_GENE_PRODUCT", 164, 168], ["cells", "CELL", 230, 235], ["RIG-I", "GENE_OR_GENE_PRODUCT", 335, 340], ["[31]", "SIMPLE_CHEMICAL", 347, 351], ["[36]\u2013[38]", "SIMPLE_CHEMICAL", 353, 362], ["short dsRNA", "DNA", 13, 24], ["RIG-I", "DNA", 45, 50], ["long dsRNA", "DNA", 60, 70], ["poly I:C", "DNA", 90, 98], ["5\u2032ppp", "DNA", 111, 116], ["RIG-I", "DNA", 135, 140], ["virally infected cells", "CELL_TYPE", 213, 235], ["viral RNA genome", "DNA", 254, 270], ["RIG", "PROTEIN", 335, 338], ["short dsRNA", "PROBLEM", 13, 24], ["bp", "TEST", 31, 33], ["long dsRNA", "PROBLEM", 60, 70], ["IntroductionNatural RNA", "TREATMENT", 174, 197], ["virally infected cells", "PROBLEM", 213, 235], ["the viral RNA genome", "PROBLEM", 250, 270], ["viral replicative intermediates", "PROBLEM", 274, 305], ["short dsRNA", "OBSERVATION_MODIFIER", 13, 24], ["infected cells", "OBSERVATION", 221, 235]]], ["Interestingly, the highly conserved 5\u2032 and 3\u2032 untranslated regions (UTRs) of negative single strand RNA virus genomes display high base pair complementarity and the panhandle structure theoretically formed by the viral genome meets the requirements for RIG-I recognition [17].", [["5\u2032", "GENE_OR_GENE_PRODUCT", 36, 38], ["RIG-I", "GENE_OR_GENE_PRODUCT", 253, 258], ["5\u2032 and 3\u2032 untranslated regions", "DNA", 36, 66], ["UTRs", "DNA", 68, 72], ["viral genome", "DNA", 213, 225], ["RIG", "PROTEIN", 253, 256], ["the highly conserved 5\u2032 and 3\u2032 untranslated regions (UTRs", "PROBLEM", 15, 72], ["single strand RNA virus genomes", "PROBLEM", 86, 117], ["high base pair complementarity", "PROBLEM", 126, 156], ["viral genome", "OBSERVATION", 213, 225]]], ["The elucidation of the crystal structure of RIG-I highlighted the molecular interactions between RIG-I and 5\u2032ppp dsRNA [18], [39], providing a structural basis for the conformational changes involved in exposing the CARD domain for effective downstream signaling [18].IntroductionGiven the level of molecular understanding of the RIG-I ligand and subsequent signaling leading to induction of antiviral immune response, we sought to investigate the range of the protective innate immune response triggered by RIG-I agonists against viral infections.", [["viral infections", "DISEASE", 531, 547], ["RIG-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["RIG-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["5\u2032ppp", "GENE_OR_GENE_PRODUCT", 107, 112], ["RIG-I ligand", "GENE_OR_GENE_PRODUCT", 330, 342], ["RIG-I", "GENE_OR_GENE_PRODUCT", 508, 513], ["RIG-I", "PROTEIN", 44, 49], ["RIG", "PROTEIN", 97, 100], ["CARD domain", "PROTEIN", 216, 227], ["RIG-I ligand", "PROTEIN", 330, 342], ["the conformational changes", "PROBLEM", 164, 190], ["effective downstream signaling", "PROBLEM", 232, 262], ["antiviral immune response", "TREATMENT", 392, 417], ["RIG-I agonists", "TREATMENT", 508, 522], ["viral infections", "PROBLEM", 531, 547], ["infections", "OBSERVATION", 537, 547]]], ["A short in vitro-synthesized 5\u2032pppRNA derived from the 5\u2032 and 3\u2032 UTRs of the VSV genome activated the RIG-I signaling pathway and triggered a robust antiviral response that interfered with infection by several pathogenic viruses, including Dengue, HCV, H1N1 Influenza A/PR/8/34 and HIV-1.", [["infection", "DISEASE", 189, 198], ["Dengue", "DISEASE", 240, 246], ["VSV", "ORGANISM", 77, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 102, 107], ["Dengue", "ORGANISM", 240, 246], ["HCV", "ORGANISM", 248, 251], ["H1N1", "ORGANISM", 253, 257], ["Influenza A/PR/8/34", "ORGANISM", 258, 277], ["HIV-1", "ORGANISM", 282, 287], ["UTRs", "DNA", 65, 69], ["VSV genome", "DNA", 77, 87], ["RIG", "PROTEIN", 102, 105], ["H1N1 Influenza", "SPECIES", 253, 267], ["HIV-1", "SPECIES", 282, 287], ["VSV", "SPECIES", 77, 80], ["HCV", "SPECIES", 248, 251], ["H1N1 Influenza A/PR/8/34", "SPECIES", 253, 277], ["HIV-1", "SPECIES", 282, 287], ["a robust antiviral response", "PROBLEM", 140, 167], ["infection", "PROBLEM", 189, 198], ["several pathogenic viruses", "PROBLEM", 202, 228], ["Dengue", "PROBLEM", 240, 246], ["HCV", "PROBLEM", 248, 251], ["H1N1", "PROBLEM", 253, 257], ["HIV", "PROBLEM", 282, 285], ["VSV genome", "OBSERVATION", 77, 87], ["antiviral response", "OBSERVATION", 149, 167]]], ["Furthermore, intravenous delivery of the RNA agonist stimulated an antiviral state in vivo that protected mice from lethal influenza virus challenge.", [["intravenous", "ANATOMY", 13, 24], ["influenza virus", "DISEASE", 123, 138], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["mice", "ORGANISM", 106, 110], ["lethal influenza virus", "ORGANISM", 116, 138], ["mice", "SPECIES", 106, 110], ["influenza virus", "SPECIES", 123, 138], ["mice", "SPECIES", 106, 110], ["intravenous delivery of the RNA agonist", "TREATMENT", 13, 52], ["an antiviral state", "TREATMENT", 64, 82], ["lethal influenza virus challenge", "TREATMENT", 116, 148]]], ["This report highlights the therapeutic potential of naturally derived RIG-I agonists as potent stimulators of the innate antiviral response, with the capacity to mobilize genes essential for the generation of efficient immunity against multiple infections.5\u2032pppRNA stimulates an antiviral response in lung epithelial A549 cells ::: ResultsA 5\u2032 triphosphate containing RNA derived from the 5\u2032 and 3\u2032 UTRs of the negative-strand RNA virus Vesicular Stomatitis Virus (VSV) [17] was generated by in vitro transcription using T7 polymerase, an enzymatic reaction that synthesizes RNA molecules with a 5\u2032ppp terminus [17].", [["lung epithelial A549 cells", "ANATOMY", 301, 327], ["infections", "DISEASE", 245, 255], ["5\u2032 triphosphate", "CHEMICAL", 341, 356], ["ResultsA 5\u2032 triphosphate", "CHEMICAL", 332, 356], ["RIG-I", "GENE_OR_GENE_PRODUCT", 70, 75], ["5", "ORGANISM", 256, 257], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 257, 264], ["lung epithelial A549 cells", "CELL", 301, 327], ["ResultsA 5\u2032 triphosphate", "SIMPLE_CHEMICAL", 332, 356], ["Vesicular Stomatitis Virus", "ORGANISM", 437, 463], ["VSV", "ORGANISM", 465, 468], ["\u2032pppRNA", "PROTEIN", 257, 264], ["lung epithelial A549 cells", "CELL_LINE", 301, 327], ["UTRs", "DNA", 399, 403], ["T7 polymerase", "PROTEIN", 521, 534], ["RNA molecules", "PROTEIN", 575, 588], ["5\u2032ppp terminus", "PROTEIN", 596, 610], ["Vesicular Stomatitis Virus", "SPECIES", 437, 463], ["Vesicular Stomatitis Virus", "SPECIES", 437, 463], ["VSV", "SPECIES", 465, 468], ["RIG-I agonists", "TREATMENT", 70, 84], ["potent stimulators", "TREATMENT", 88, 106], ["the innate antiviral response", "TREATMENT", 110, 139], ["the capacity", "PROBLEM", 146, 158], ["multiple infections", "PROBLEM", 236, 255], ["an antiviral response in lung epithelial A549 cells", "TEST", 276, 327], ["ResultsA", "TEST", 332, 340], ["triphosphate containing RNA", "TEST", 344, 371], ["UTRs", "TEST", 399, 403], ["strand RNA virus Vesicular Stomatitis Virus (VSV)", "PROBLEM", 420, 469], ["T7 polymerase", "PROBLEM", 521, 534], ["an enzymatic reaction", "PROBLEM", 536, 557], ["synthesizes RNA molecules", "PROBLEM", 563, 588], ["a 5\u2032ppp terminus", "TREATMENT", 594, 610], ["antiviral response", "OBSERVATION", 121, 139], ["infections", "OBSERVATION", 245, 255], ["lung", "ANATOMY", 301, 305], ["epithelial", "ANATOMY_MODIFIER", 306, 316], ["A549 cells", "OBSERVATION", 317, 327], ["negative", "OBSERVATION", 411, 419], ["strand RNA", "OBSERVATION_MODIFIER", 420, 430], ["virus", "OBSERVATION", 431, 436], ["Vesicular Stomatitis Virus", "OBSERVATION", 437, 463]]], ["Predicted panhandle secondary structure of the 5\u2032pppRNA is depicted in Fig. 1A; gel analysis and nuclease sensitivity confirmed the generation of a single RNA product of the expected size (67 nucleotides).", [["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 47, 55], ["5\u2032pppRNA", "DNA", 47, 55], ["nuclease", "PROTEIN", 97, 105], ["gel analysis", "TEST", 80, 92], ["nuclease sensitivity", "TEST", 97, 117], ["secondary structure", "OBSERVATION", 20, 39], ["Fig", "OBSERVATION_MODIFIER", 71, 74], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["Transfection of increasing amounts of 5\u2032pppRNA resulted in Ser396 phosphorylation of IRF3 at 8 h \u2013 a hallmark of immediate early activation of the antiviral response (Fig. 1B, lane 2 to 6).", [["Ser396", "CHEMICAL", 59, 65], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 38, 46], ["Ser396", "GENE_OR_GENE_PRODUCT", 59, 65], ["IRF3", "GENE_OR_GENE_PRODUCT", 85, 89], ["5\u2032pppRNA", "PROTEIN", 38, 46], ["IRF3", "PROTEIN", 85, 89], ["increasing amounts of 5\u2032pppRNA", "PROBLEM", 16, 46], ["IRF3", "TREATMENT", 85, 89], ["the antiviral response", "TREATMENT", 143, 165], ["antiviral response", "OBSERVATION", 147, 165]]], ["Induction of apoptosis was detected following treatment with higher concentrations of 5\u2032pppRNA; the pro-apoptotic BH3-only protein NOXA \u2013 a direct transcriptional target of IRF3 [40] \u2013 as well as cleavage products of caspase 3 and PARP were up-regulated in a dose dependent manner (Fig. 1B, lane 2\u20136).", [["5\u2032pppRNA", "SIMPLE_CHEMICAL", 86, 94], ["NOXA", "GENE_OR_GENE_PRODUCT", 131, 135], ["IRF3 [40", "GENE_OR_GENE_PRODUCT", 173, 181], ["caspase 3", "GENE_OR_GENE_PRODUCT", 217, 226], ["PARP", "GENE_OR_GENE_PRODUCT", 231, 235], ["5\u2032pppRNA", "PROTEIN", 86, 94], ["BH3", "PROTEIN", 114, 117], ["NOXA", "PROTEIN", 131, 135], ["IRF3", "PROTEIN", 173, 177], ["caspase 3", "PROTEIN", 217, 226], ["PARP", "PROTEIN", 231, 235], ["apoptosis", "PROBLEM", 13, 22], ["treatment", "TREATMENT", 46, 55], ["higher concentrations of 5\u2032pppRNA", "TREATMENT", 61, 94], ["the pro-apoptotic BH3", "TREATMENT", 96, 117], ["protein NOXA", "TREATMENT", 123, 135], ["IRF3", "TEST", 173, 177], ["caspase", "TREATMENT", 217, 224], ["PARP", "TEST", 231, 235]]], ["Optimal induction of antiviral signaling with limited cytotoxicity was achieved at a concentration of 10 ng/ml (\u223c500 pM) (Fig. 1B; lane 4).", [["antiviral signaling", "TREATMENT", 21, 40], ["limited cytotoxicity", "PROBLEM", 46, 66]]], ["Importantly, the stimulation of immune signaling and apoptosis was dependent on the 5\u2032ppp moiety; a homologous RNA without a 5\u2032ppp terminus abrogated stimulation over a range of RNA concentrations (Fig. 1B, lane 8\u201312).5\u2032pppRNA stimulates an antiviral response in lung epithelial A549 cells ::: ResultsTo characterize the antiviral response triggered by 5\u2032pppRNA, the kinetics of downstream RIG-I signaling were measured at different times (0\u201348 h) after stimulation of A549 cells (Fig. 1C).", [["lung epithelial A549 cells", "ANATOMY", 263, 289], ["A549 cells", "ANATOMY", 469, 479], ["5\u2032ppp", "GENE_OR_GENE_PRODUCT", 84, 89], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 219, 226], ["lung epithelial A549 cells", "CELL", 263, 289], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 353, 361], ["RIG-I", "GENE_OR_GENE_PRODUCT", 390, 395], ["A549 cells", "CELL", 469, 479], ["Fig. 1C", "CELL", 481, 488], ["5\u2032ppp moiety", "PROTEIN", 84, 96], ["5\u2032ppp terminus", "PROTEIN", 125, 139], ["\u2032pppRNA", "PROTEIN", 219, 226], ["lung epithelial A549 cells", "CELL_LINE", 263, 289], ["5\u2032pppRNA", "PROTEIN", 353, 361], ["RIG", "PROTEIN", 390, 393], ["A549 cells", "CELL_LINE", 469, 479], ["immune signaling", "PROBLEM", 32, 48], ["apoptosis", "PROBLEM", 53, 62], ["the 5\u2032ppp moiety", "TREATMENT", 80, 96], ["a homologous RNA", "TREATMENT", 98, 114], ["a 5\u2032ppp terminus abrogated stimulation", "TREATMENT", 123, 161], ["RNA concentrations", "TREATMENT", 178, 196], ["stimulation of A549 cells", "PROBLEM", 454, 479], ["antiviral response", "OBSERVATION", 241, 259], ["lung", "ANATOMY", 263, 267], ["epithelial", "ANATOMY_MODIFIER", 268, 278], ["A549 cells", "OBSERVATION", 279, 289], ["antiviral response", "OBSERVATION", 321, 339], ["A549 cells", "OBSERVATION", 469, 479]]], ["IRF3 homodimerization (1st panel) and IRF3 phosphorylation at Ser396 (2nd panel) were detected as early as 2 h post treatment with 5\u2032pppRNA, and sustained until 24 h.", [["IRF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF3", "GENE_OR_GENE_PRODUCT", 38, 42], ["Ser396", "AMINO_ACID", 62, 68], ["IRF3", "PROTEIN", 0, 4], ["IRF3", "PROTEIN", 38, 42], ["5\u2032pppRNA", "PROTEIN", 131, 139], ["IRF3 homodimerization", "TREATMENT", 0, 21], ["1st panel", "TEST", 23, 32], ["IRF3 phosphorylation", "TEST", 38, 58], ["treatment", "TREATMENT", 116, 125], ["5\u2032pppRNA", "TREATMENT", 131, 139]]], ["Using a newly characterized anti-IRF7 antibody, induction of endogenous IRF7 was detected with kinetics that was delayed compared to IRF3 activation (4th vs. 3rd panel).", [["anti-IRF7", "GENE_OR_GENE_PRODUCT", 28, 37], ["IRF7", "GENE_OR_GENE_PRODUCT", 72, 76], ["IRF3", "GENE_OR_GENE_PRODUCT", 133, 137], ["anti-IRF7 antibody", "PROTEIN", 28, 46], ["endogenous IRF7", "PROTEIN", 61, 76], ["IRF3", "PROTEIN", 133, 137], ["a newly characterized anti-IRF7 antibody", "TREATMENT", 6, 46], ["endogenous IRF7", "PROBLEM", 61, 76], ["3rd panel", "TEST", 158, 167], ["endogenous IRF7", "OBSERVATION", 61, 76]]], ["I\u03baB\u03b1 phosphorylation was likewise detected as early as 2 h post-treatment and was sustained in A549 cells (6th panel).", [["A549 cells", "ANATOMY", 95, 105], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["A549 cells", "CELL", 95, 105], ["I\u03baB\u03b1", "PROTEIN", 0, 4], ["A549 cells", "CELL_LINE", 95, 105], ["I\u03baB\u03b1 phosphorylation", "TEST", 0, 20], ["treatment", "TREATMENT", 64, 73], ["A549 cells", "OBSERVATION", 95, 105]]], ["Altogether, IRF3, IRF7 and NF-\u03baB are required for optimal induction of the IFN\u03b2 promoter [27].", [["IRF3", "GENE_OR_GENE_PRODUCT", 12, 16], ["IRF7", "GENE_OR_GENE_PRODUCT", 18, 22], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 27, 32], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 75, 79], ["IRF3", "PROTEIN", 12, 16], ["IRF7", "PROTEIN", 18, 22], ["NF-\u03baB", "PROTEIN", 27, 32], ["IFN\u03b2 promoter", "DNA", 75, 88], ["IRF7", "TEST", 18, 22], ["the IFN\u03b2 promoter", "TREATMENT", 71, 88]]], ["JAK-STAT signaling was detected at 4 h with Tyr701 phosphorylation of STAT1 (9th panel), as well as later accumulation at 24 h (10th panel).", [["Tyr701", "CHEMICAL", 44, 50], ["JAK", "GENE_OR_GENE_PRODUCT", 0, 3], ["STAT", "GENE_OR_GENE_PRODUCT", 4, 8], ["Tyr701", "SIMPLE_CHEMICAL", 44, 50], ["STAT1", "GENE_OR_GENE_PRODUCT", 70, 75], ["JAK", "PROTEIN", 0, 3], ["STAT", "PROTEIN", 4, 8], ["STAT1", "PROTEIN", 70, 75], ["9th panel", "PROTEIN", 77, 86]]], ["IFIT1 and RIG-I itself, were up-regulated 4 h post-treatment (11th and 12th panel) whereas a second group of ISGs (STAT1 and IRF7; 4th and 10th panel) was induced between 6 h and 8 h after agonist treatment.", [["IFIT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["RIG-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["STAT1", "GENE_OR_GENE_PRODUCT", 115, 120], ["IRF7", "GENE_OR_GENE_PRODUCT", 125, 129], ["IFIT1", "PROTEIN", 0, 5], ["RIG-I", "DNA", 10, 15], ["ISGs", "PROTEIN", 109, 113], ["STAT1", "PROTEIN", 115, 120], ["IRF7", "PROTEIN", 125, 129], ["4th", "PROTEIN", 131, 134], ["treatment", "TREATMENT", 51, 60], ["IRF7", "TEST", 125, 129], ["agonist treatment", "TREATMENT", 189, 206]]], ["IFN\u03b2 was detectable in cell culture supernatant as early as 6 h after 5\u2032pppRNA treatment with a substantial release (4000 pg/ml) that peaked at 12\u201324 h (Fig. 1D, top panel).", [["cell culture supernatant", "ANATOMY", 23, 47], ["5\u2032pppRNA", "CHEMICAL", 70, 78], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 23, 27], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 70, 78], ["IFN\u03b2", "PROTEIN", 0, 4], ["cell culture", "TEST", 23, 35], ["5\u2032pppRNA treatment", "TREATMENT", 70, 88], ["a substantial release", "TREATMENT", 94, 115], ["top panel", "TEST", 162, 171]]], ["IFN\u03b1 release was detected later at 12 h, and remained high thereafter (400 pg/ml) (Figure 1D).", [["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFN\u03b1", "PROTEIN", 0, 4]]], ["Thus 5\u2032pppRNA triggers a full antiviral response as demonstrated by the activation of transcription factors IRF3, IRF7 and NF-\u03baB, release of interferons, JAK/STAT pathway activation and induction of ISGs.5\u2032pppRNA induction of the antiviral response requires an intact RIG-I pathway ::: ResultsTo address whether 5\u2032pppRNA exclusively activated the RIG-I sensor, wild type mouse embryonic fibroblasts (wt MEF) and RIG-I\u2212/\u2212 MEF were co-transfected with 5\u2032pppRNA and type 1 IFN reporter constructs to measure promoter activity.", [["embryonic fibroblasts", "ANATOMY", 377, 398], ["MEF", "ANATOMY", 403, 406], ["RIG-I\u2212/\u2212 MEF", "ANATOMY", 412, 424], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 5, 13], ["IRF3", "GENE_OR_GENE_PRODUCT", 108, 112], ["IRF7", "GENE_OR_GENE_PRODUCT", 114, 118], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 123, 128], ["interferons", "GENE_OR_GENE_PRODUCT", 141, 152], ["JAK", "GENE_OR_GENE_PRODUCT", 154, 157], ["STAT", "GENE_OR_GENE_PRODUCT", 158, 162], ["5", "ORGANISM", 204, 205], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 205, 212], ["RIG-I", "GENE_OR_GENE_PRODUCT", 268, 273], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 312, 320], ["RIG-I", "GENE_OR_GENE_PRODUCT", 347, 352], ["mouse", "ORGANISM", 371, 376], ["embryonic fibroblasts", "CELL", 377, 398], ["wt MEF", "CELL", 400, 406], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 412, 418], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 450, 458], ["5\u2032pppRNA", "PROTEIN", 5, 13], ["transcription factors", "PROTEIN", 86, 107], ["IRF3", "PROTEIN", 108, 112], ["IRF7", "PROTEIN", 114, 118], ["NF-\u03baB", "PROTEIN", 123, 128], ["interferons", "PROTEIN", 141, 152], ["JAK", "PROTEIN", 154, 157], ["STAT", "PROTEIN", 158, 162], ["ISGs", "DNA", 199, 203], ["RIG-I", "PROTEIN", 268, 273], ["5\u2032pppRNA", "PROTEIN", 312, 320], ["RIG-I", "PROTEIN", 347, 352], ["wild type mouse embryonic fibroblasts", "CELL_LINE", 361, 398], ["wt MEF", "CELL_LINE", 400, 406], ["RIG-I\u2212/\u2212 MEF", "CELL_LINE", 412, 424], ["5\u2032pppRNA and type 1 IFN reporter constructs", "DNA", 450, 493], ["mouse", "SPECIES", 371, 376], ["mouse", "SPECIES", 371, 376], ["IRF7", "TEST", 114, 118], ["NF", "TEST", 123, 125], ["interferons", "TREATMENT", 141, 152], ["JAK", "TREATMENT", 154, 157], ["STAT pathway activation", "TREATMENT", 158, 181], ["induction of ISGs", "TREATMENT", 186, 203], ["wild type mouse embryonic fibroblasts", "PROBLEM", 361, 398], ["RIG", "TEST", 412, 415], ["I\u2212/\u2212 MEF", "TREATMENT", 416, 424], ["5\u2032pppRNA", "TREATMENT", 450, 458], ["type 1 IFN reporter constructs", "TREATMENT", 463, 493]]], ["5\u2032pppRNA activated the IFN\u03b2 promoter 60-fold and the IFN\u03b1 promoter 450-fold in wt MEF; promoter activity was dependent on RIG-I since these promoters were not stimulated in RIG-I\u2212/\u2212 MEF.", [["MEF", "ANATOMY", 82, 85], ["RIG-I\u2212/\u2212 MEF", "ANATOMY", 173, 185], ["5", "ORGANISM", 0, 1], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 1, 8], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 23, 27], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 53, 57], ["MEF", "CELL", 82, 85], ["RIG-I", "GENE_OR_GENE_PRODUCT", 122, 127], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 173, 179], ["\u2032pppRNA", "PROTEIN", 1, 8], ["IFN\u03b2 promoter", "DNA", 23, 36], ["IFN\u03b1 promoter", "DNA", 53, 66], ["RIG-I", "DNA", 122, 127], ["RIG-I\u2212/\u2212 MEF", "CELL_LINE", 173, 185], ["the IFN\u03b2 promoter", "TREATMENT", 19, 36], ["the IFN\u03b1 promoter", "TREATMENT", 49, 66]]], ["As positive control, a constitutively active, CARD domain-containing RIG-I mutant [41] was used to bypass the requirement for RIG-I (Figure 2A).", [["CARD", "GENE_OR_GENE_PRODUCT", 46, 50], ["RIG-I", "GENE_OR_GENE_PRODUCT", 69, 74], ["RIG-I", "GENE_OR_GENE_PRODUCT", 126, 131], ["Figure 2A", "GENE_OR_GENE_PRODUCT", 133, 142], ["CARD domain", "PROTEIN", 46, 57], ["RIG-I mutant", "PROTEIN", 69, 81], ["RIG-I", "PROTEIN", 126, 131], ["Figure 2A", "PROTEIN", 133, 142], ["CARD domain", "TEST", 46, 57], ["RIG-I mutant", "TREATMENT", 69, 81], ["bypass", "TREATMENT", 99, 105], ["active", "OBSERVATION_MODIFIER", 38, 44]]], ["Furthermore, induction of the IFN response was exclusively dependent on intact RIG-I signaling, since IFN\u03b2 promoter activity was not decreased in Mda5\u2212/\u2212, TLR3\u2212/\u2212 or TLR7\u2212/\u2212 MEFs (Figure 2B).", [["Mda5\u2212/\u2212", "ANATOMY", 146, 153], ["TLR7\u2212/\u2212 MEFs", "ANATOMY", 166, 178], ["IFN", "GENE_OR_GENE_PRODUCT", 30, 33], ["RIG-I", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 102, 106], ["Mda5", "GENE_OR_GENE_PRODUCT", 146, 150], ["TLR3\u2212", "GENE_OR_GENE_PRODUCT", 155, 160], ["TLR7", "GENE_OR_GENE_PRODUCT", 166, 170], ["IFN", "PROTEIN", 30, 33], ["RIG-I", "PROTEIN", 79, 84], ["IFN\u03b2 promoter", "DNA", 102, 115], ["Mda5", "PROTEIN", 146, 150], ["TLR7\u2212/\u2212 MEFs", "CELL_LINE", 166, 178], ["the IFN response", "PROBLEM", 26, 42], ["Mda5", "TEST", 146, 150], ["TLR3\u2212", "TEST", 155, 160], ["TLR7", "TEST", 166, 170]]], ["In A549 cells treated with 5\u2032pppRNA, knocking down RIG-I abolished IRF3 and STAT1 phosphorylation, as well as IFIT1 and RIG-I upregulation compared to control siRNA-treated cells (Fig. 2C; lane 6 vs. 4).", [["A549 cells", "ANATOMY", 3, 13], ["cells", "ANATOMY", 173, 178], ["A549 cells", "CELL", 3, 13], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 27, 35], ["RIG-I", "GENE_OR_GENE_PRODUCT", 51, 56], ["IRF3", "GENE_OR_GENE_PRODUCT", 67, 71], ["STAT1", "GENE_OR_GENE_PRODUCT", 76, 81], ["IFIT1", "GENE_OR_GENE_PRODUCT", 110, 115], ["RIG-I", "GENE_OR_GENE_PRODUCT", 120, 125], ["cells", "CELL", 173, 178], ["A549 cells", "CELL_LINE", 3, 13], ["5\u2032pppRNA", "PROTEIN", 27, 35], ["RIG-I", "PROTEIN", 51, 56], ["IRF3", "PROTEIN", 67, 71], ["STAT1", "PROTEIN", 76, 81], ["treated cells", "CELL_LINE", 165, 178], ["5\u2032pppRNA", "TREATMENT", 27, 35], ["IRF3", "PROBLEM", 67, 71], ["STAT1 phosphorylation", "TEST", 76, 97], ["IFIT1", "TEST", 110, 115], ["RIG-I upregulation", "TREATMENT", 120, 138], ["A549 cells", "OBSERVATION", 3, 13], ["IRF3", "OBSERVATION", 67, 71], ["STAT1 phosphorylation", "OBSERVATION", 76, 97]]], ["Of note, generation of the knock down by transient transfection of short RNA did not activate immune signaling (Fig. 2C; lane 3 vs. 1).", [["transient transfection of short RNA", "PROBLEM", 41, 76]]], ["Hence, this 5\u2032pppRNA signals specifically via RIG-I.Kinetics of the host response to 5\u2032pppRNA ::: ResultsTo evaluate the breadth of the host intrinsic response resulting from RNA agonist stimulation of RIG-I, modulation of the transcriptome of A549 cells stimulated with 5\u2032pppRNA from 1 to 48 h was analysed by gene array using the Illumina platform.", [["A549 cells", "ANATOMY", 244, 254], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 12, 20], ["RIG-I.", "GENE_OR_GENE_PRODUCT", 46, 52], ["RIG-I", "GENE_OR_GENE_PRODUCT", 202, 207], ["A549 cells", "CELL", 244, 254], ["5\u2032pppRNA", "PROTEIN", 12, 20], ["RIG", "PROTEIN", 46, 49], ["RIG-I", "PROTEIN", 202, 207], ["A549 cells", "CELL_LINE", 244, 254], ["5\u2032pppRNA", "PROTEIN", 271, 279], ["this 5\u2032pppRNA signals", "TEST", 7, 28], ["RNA agonist stimulation", "TREATMENT", 175, 198], ["A549 cells", "TREATMENT", 244, 254], ["5\u2032pppRNA", "TREATMENT", 271, 279], ["the Illumina platform", "TREATMENT", 328, 349], ["RNA agonist", "OBSERVATION", 175, 186], ["A549 cells", "OBSERVATION", 244, 254]]], ["Figure 3A shows a waterfall plot of differentially expressed genes (DEG; selected based on fold change \u2265\u00b12, p-value \u22640.001) after 5\u2032pppRNA stimulation.", [["differentially expressed genes", "DNA", 36, 66], ["DEG", "DNA", 68, 71], ["5\u2032pppRNA", "PROTEIN", 130, 138], ["fold change", "TEST", 91, 102], ["p-value", "TEST", 108, 115], ["5\u2032pppRNA stimulation", "TREATMENT", 130, 150]]], ["The number of genes up-regulated by 5\u2032pppRNA administration steadily increased with time, while the majority of down-regulation occurred at 24\u201348 h (Fig. 3A).", [["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 36, 44], ["5\u2032pppRNA", "PROTEIN", 36, 44]]], ["The heatmap presents DEG with emphasis on the most highly deregulated genes over time (Fig. 3B).", [["DEG", "DNA", 21, 24]]], ["Canonical pathway analysis using Ingenuity Pathway Analysis software identified IFN signaling, activation of IRFs by cytosolic PRRs, TNFR2 signaling and antigen presentation as the main up-regulated functional categories, while functions related to cell metabolism and cell cycle were down-regulated by RIG-I agonist treatment (Fig. 3C).", [["cytosolic", "ANATOMY", 117, 126], ["cell", "ANATOMY", 249, 253], ["cell", "ANATOMY", 269, 273], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["PRRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["TNFR2", "GENE_OR_GENE_PRODUCT", 133, 138], ["antigen", "GENE_OR_GENE_PRODUCT", 153, 160], ["cell", "CELL", 249, 253], ["cell", "CELL", 269, 273], ["RIG-I", "GENE_OR_GENE_PRODUCT", 303, 308], ["IFN", "PROTEIN", 80, 83], ["IRFs", "PROTEIN", 109, 113], ["cytosolic PRRs", "PROTEIN", 117, 131], ["TNFR2", "PROTEIN", 133, 138], ["Canonical pathway analysis", "TEST", 0, 26], ["Analysis software", "TEST", 51, 68], ["IFN signaling", "PROBLEM", 80, 93], ["IRFs", "PROBLEM", 109, 113], ["cytosolic PRRs", "TEST", 117, 131], ["TNFR2 signaling", "PROBLEM", 133, 148], ["antigen presentation", "TEST", 153, 173], ["cell metabolism", "PROBLEM", 249, 264], ["cell cycle", "TEST", 269, 279], ["RIG-I agonist treatment", "TREATMENT", 303, 326], ["functional categories", "OBSERVATION", 199, 220]]], ["Subsequent kinetic analysis revealed that RIG-I agonist induced distinct temporal patterns of gene expression (Fig. 3D, S1 and S2A).", [["RIG-I", "GENE_OR_GENE_PRODUCT", 42, 47], ["S2A", "GENE_OR_GENE_PRODUCT", 127, 130], ["S1", "PROTEIN", 120, 122], ["S2A", "PROTEIN", 127, 130], ["Subsequent kinetic analysis", "TEST", 0, 27], ["RIG-I agonist", "TREATMENT", 42, 55], ["gene expression", "PROBLEM", 94, 109], ["distinct", "OBSERVATION_MODIFIER", 64, 72], ["temporal", "OBSERVATION_MODIFIER", 73, 81], ["gene expression", "OBSERVATION", 94, 109]]], ["For example, some genes were highly expressed early at 6\u201312 h, including IFNB1 and the IFN\u03bb family (IL29, IL-28A, IL28B), but the expression of these genes was not sustained throughout the time course and decreased at 24\u201348 h (Fig. 3D; lest panel).", [["IFNB1", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN\u03bb", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL29", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-28A", "GENE_OR_GENE_PRODUCT", 106, 112], ["IL28B", "GENE_OR_GENE_PRODUCT", 114, 119], ["IFNB1", "PROTEIN", 73, 78], ["IFN\u03bb family", "PROTEIN", 87, 98], ["IL29", "PROTEIN", 100, 104], ["IL", "PROTEIN", 106, 108], ["IL28B", "DNA", 114, 119]]], ["A second subset of genes associated with the antiviral response were induced early at 6\u20138 h, but expression was sustained and markedly augmented at 24\u201348 h, as exemplified by IFI family members, IRF7, and other ISGs (Fig. 3D; middle panel).", [["IFI", "GENE_OR_GENE_PRODUCT", 175, 178], ["IRF7", "GENE_OR_GENE_PRODUCT", 195, 199], ["IFI family members", "PROTEIN", 175, 193], ["IRF7", "PROTEIN", 195, 199], ["ISGs", "PROTEIN", 211, 215], ["Fig. 3D; middle panel", "PROTEIN", 217, 238], ["middle panel", "TEST", 226, 238]]], ["A third subset of genes was induced primarily at later time points, as part of the secondary response to 5\u2032pppRNA treatment, and included HLA and CCL3 families (Fig. 3D; right panel).", [["5\u2032pppRNA", "CHEMICAL", 105, 113], ["5\u2032pppRNA", "CHEMICAL", 105, 113], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 105, 113], ["CCL3", "GENE_OR_GENE_PRODUCT", 146, 150], ["5\u2032pppRNA", "PROTEIN", 105, 113], ["CCL3 families", "PROTEIN", 146, 159], ["5\u2032pppRNA treatment", "TREATMENT", 105, 123], ["right panel", "TEST", 170, 181], ["genes", "OBSERVATION", 18, 23], ["right", "ANATOMY_MODIFIER", 170, 175]]], ["Representative genes from different subsets were validated by quantitative real-time RT-PCR (Fig. S1).", [["S1", "GENE_OR_GENE_PRODUCT", 98, 100], ["S1", "PROTEIN", 98, 100]]], ["Overall, 5\u2032pppRNA induced a robust bi-phasic transcriptional response, characterized by strong activation of antiviral and inflammatory gene signatures; the kinetics of the transcriptional profile mirrored the biochemical activation events detected in Figures 1.Kinetics of the host response to 5\u2032pppRNA ::: ResultsIn order to gain systems-wide insight into the RIG-I transcriptome, a functional clustering of 5\u2032pppRNA-induced DEGs was performed.", [["5\u2032pppRNA", "CHEMICAL", 9, 17], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 9, 17], ["RIG-I", "GENE_OR_GENE_PRODUCT", 362, 367], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 410, 418], ["5\u2032pppRNA", "PROTEIN", 9, 17], ["antiviral and inflammatory gene signatures", "DNA", 109, 151], ["5\u2032pppRNA", "PROTEIN", 410, 418], ["DEGs", "DNA", 427, 431], ["a robust bi-phasic transcriptional response", "PROBLEM", 26, 69], ["strong activation of antiviral and inflammatory gene signatures", "PROBLEM", 88, 151], ["the biochemical activation events", "PROBLEM", 206, 239], ["induced DEGs", "PROBLEM", 419, 431], ["transcriptional response", "OBSERVATION", 45, 69], ["antiviral", "OBSERVATION", 109, 118], ["biochemical activation", "OBSERVATION", 210, 232]]], ["This functional clustering identified a variety of transcriptional sub-networks and biological processes regulated by RIG-I (Fig. 4).", [["RIG-I", "GENE_OR_GENE_PRODUCT", 118, 123], ["RIG-I", "PROTEIN", 118, 123], ["transcriptional sub-networks", "TREATMENT", 51, 79], ["variety", "OBSERVATION_MODIFIER", 40, 47]]], ["As expected, at 6 h (Fig. 4A), induction of antiviral and inflammatory response programs downstream of IRF, NF-\u03baB, STAT signaling were identified (Fig. 4A and S2B); expression of several cytokine and chemokine genes were also up-regulated.", [["IRF", "GENE_OR_GENE_PRODUCT", 103, 106], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 108, 113], ["STAT", "GENE_OR_GENE_PRODUCT", 115, 119], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 147, 154], ["S2B", "GENE_OR_GENE_PRODUCT", 159, 162], ["IRF", "PROTEIN", 103, 106], ["NF-\u03baB", "PROTEIN", 108, 113], ["STAT", "PROTEIN", 115, 119], ["S2B", "PROTEIN", 159, 162], ["cytokine and chemokine genes", "DNA", 187, 215], ["antiviral and inflammatory response programs", "TREATMENT", 44, 88], ["IRF", "PROBLEM", 103, 106], ["NF", "TEST", 108, 110], ["several cytokine and chemokine genes", "PROBLEM", 179, 215]]], ["Concomitantly, genes related to Fos and TGF-\u03b2 signaling, as well as hypoxic signaling via HIF-1\u03b1 were down-regulated.", [["Fos", "GENE_OR_GENE_PRODUCT", 32, 35], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["HIF-1\u03b1", "GENE_OR_GENE_PRODUCT", 90, 96], ["Fos", "PROTEIN", 32, 35], ["TGF-\u03b2", "PROTEIN", 40, 45], ["HIF-1\u03b1", "PROTEIN", 90, 96], ["Fos", "TEST", 32, 35], ["TGF", "TEST", 40, 43], ["hypoxic signaling", "PROBLEM", 68, 85], ["HIF", "TEST", 90, 93]]], ["At 24 h (Fig. 4B), genes associated with pathogen recognition receptor signaling, the ubiquitin pathway, inflammation and apoptosis were also induced by RIG-I activation; interestingly, profiling of down-regulated genes identified functional clusters involved in cell cycle regulation, MYC signaling, and the heat shock response.Comparative analysis of the gene expression profile in response to 5\u2032pppRNA and IFN\u03b1-2b ::: ResultsAlthough the contribution of type I IFN to the antiviral response stimulated by 5\u2032pppRNA is unquestionable, other factors may also augment the antiviral state established by 5\u2032pppRNA.", [["cell", "ANATOMY", 263, 267], ["inflammation", "DISEASE", 105, 117], ["shock", "DISEASE", 314, 319], ["pathogen recognition receptor", "GENE_OR_GENE_PRODUCT", 41, 70], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 86, 95], ["RIG-I", "GENE_OR_GENE_PRODUCT", 153, 158], ["cell", "CELL", 263, 267], ["MYC", "GENE_OR_GENE_PRODUCT", 286, 289], ["type I IFN", "GENE_OR_GENE_PRODUCT", 457, 467], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 508, 516], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 602, 610], ["RIG", "PROTEIN", 153, 156], ["down-regulated genes", "DNA", 199, 219], ["MYC", "PROTEIN", 286, 289], ["5\u2032pppRNA", "PROTEIN", 396, 404], ["IFN", "PROTEIN", 409, 412], ["type I IFN", "PROTEIN", 457, 467], ["5\u2032pppRNA", "PROTEIN", 508, 516], ["5\u2032pppRNA", "PROTEIN", 602, 610], ["the ubiquitin pathway", "PROBLEM", 82, 103], ["inflammation", "PROBLEM", 105, 117], ["apoptosis", "PROBLEM", 122, 131], ["functional clusters", "PROBLEM", 231, 250], ["cell cycle regulation", "TREATMENT", 263, 284], ["MYC signaling", "PROBLEM", 286, 299], ["the heat shock response", "PROBLEM", 305, 328], ["Comparative analysis", "TEST", 329, 349], ["5\u2032pppRNA", "TEST", 396, 404], ["type I IFN", "PROBLEM", 457, 467], ["the antiviral response", "TREATMENT", 471, 493], ["inflammation", "OBSERVATION", 105, 117]]], ["To define gene uniquely induced by 5\u2032pppRNA, gene expression profiles of A549 cells stimulated with 5\u2032pppRNA or with IFN\u03b1-2b for 6 and 24 h were compared.", [["A549 cells", "ANATOMY", 73, 83], ["IFN\u03b1-2b", "CHEMICAL", 117, 124], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 35, 43], ["A549 cells", "CELL", 73, 83], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 100, 108], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 117, 124], ["5\u2032pppRNA", "PROTEIN", 35, 43], ["A549 cells", "CELL_LINE", 73, 83], ["5\u2032pppRNA", "PROTEIN", 100, 108], ["IFN\u03b1", "PROTEIN", 117, 121], ["A549 cells", "TEST", 73, 83], ["5\u2032pppRNA", "TREATMENT", 100, 108], ["IFN", "TEST", 117, 120]]], ["The heatmap in Figure 5A displays the expression profile of genes differentially up- and down-regulated (fold change \u22652; p-value \u22640.001) by 5\u2032pppRNA and IFN (black and blue genes) or exclusively by 5\u2032pppRNA (red and green genes).", [["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 140, 148], ["IFN (black and blue genes", "GENE_OR_GENE_PRODUCT", 153, 178], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 198, 206], ["IFN (black and blue genes", "DNA", 153, 178], ["5\u2032pppRNA", "DNA", 198, 206], ["red and green genes", "DNA", 208, 227], ["p-value", "TEST", 121, 128], ["5\u2032pppRNA", "TEST", 140, 148], ["IFN (black and blue genes)", "PROBLEM", 153, 179]]], ["Interestingly, 5\u2032pppRNA induced a significantly broader gene expression program compared to IFN\u03b1-2b, especially at 24 h.", [["IFN\u03b1-2b", "CHEMICAL", 92, 99], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 15, 23], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 92, 99], ["5\u2032pppRNA", "PROTEIN", 15, 23], ["IFN\u03b1", "PROTEIN", 92, 96], ["IFN\u03b1", "TEST", 92, 96]]], ["To determine whether differences in gene expression observed between 5\u2032pppRNA and IFN\u03b1-2b were due to sub-optimal stimulation by IFN\u03b1-2b, higher concentrations of IFN\u03b1-2b within the range reported for in vitro applications were tested.", [["IFN\u03b1-2b", "CHEMICAL", 129, 136], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 69, 77], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 82, 89], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 129, 136], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 163, 170], ["5\u2032pppRNA", "PROTEIN", 69, 77], ["IFN\u03b1", "PROTEIN", 82, 86], ["IFN\u03b1", "PROTEIN", 129, 133], ["IFN", "PROTEIN", 163, 166], ["gene expression", "TEST", 36, 51], ["5\u2032pppRNA", "TEST", 69, 77], ["IFN", "TEST", 82, 85], ["IFN\u03b1", "TEST", 129, 133], ["IFN", "TEST", 163, 166]]], ["Treatment with 5\u2032pppRNA at 10 ng/ml was equivalent to treatment with IFN\u03b1-2b at 100 IU/ml in terms of IFN\u03b1 levels released into cell culture supernatant.", [["cell", "ANATOMY", 128, 132], ["supernatant", "ANATOMY", 141, 152], ["5\u2032pppRNA", "CHEMICAL", 15, 23], ["IFN\u03b1-2b", "CHEMICAL", 69, 76], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 15, 23], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 69, 76], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 102, 106], ["cell", "CELL", 128, 132], ["5\u2032pppRNA", "PROTEIN", 15, 23], ["IFN", "PROTEIN", 69, 72], ["IFN\u03b1", "PROTEIN", 102, 106], ["5\u2032pppRNA", "TREATMENT", 15, 23], ["treatment", "TREATMENT", 54, 63], ["IFN", "TREATMENT", 69, 72], ["IFN\u03b1 levels", "TEST", 102, 113], ["cell culture", "TEST", 128, 140]]], ["Increasing the concentration of IFN\u03b1-2b to 1000 IU/ml corresponded to levels of IFN\u03b1 that were 8-times greater than physiological secretion following 10 ng/ml 5\u2032pppRNA treatment (2500 pg/ml vs 480 pg/ml; Fig. 5B).", [["5\u2032pppRNA", "CHEMICAL", 159, 167], ["5\u2032pppRNA", "CHEMICAL", 159, 167], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 32, 39], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 80, 84], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 159, 167], ["IFN\u03b1", "PROTEIN", 32, 36], ["IFN\u03b1", "PROTEIN", 80, 84], ["IFN", "TEST", 32, 35], ["levels of IFN\u03b1", "TEST", 70, 84], ["5\u2032pppRNA treatment", "TREATMENT", 159, 177]]], ["Regardless of the amount of IFN\u03b1-2b used to activate cells, gene expression levels remained relatively unchanged (Fig. 5A; IFN\u03b1-2b 100 IU/ml vs 1000 IU/ml), indicating that IFN\u03b1-2b treatment was saturating.Comparative analysis of the gene expression profile in response to 5\u2032pppRNA and IFN\u03b1-2b ::: ResultsRemarkably, the spectrum of genes differentially expressed by IFN\u03b1-2b treatment were virtually all contained within the transcriptome induced by 5\u2032pppRNA treatment - 57 at 6 h and 134 at 24 h, out of 139 genes (Fig. 5C) - demonstrating that 5\u2032pppRNA induced a complete IFN response by 24 h.", [["cells", "ANATOMY", 53, 58], ["IFN\u03b1-2b", "CHEMICAL", 28, 35], ["IFN\u03b1-2b", "CHEMICAL", 173, 180], ["IFN\u03b1-2b", "CHEMICAL", 367, 374], ["5\u2032pppRNA", "CHEMICAL", 450, 458], ["\u03b1-2b", "GENE_OR_GENE_PRODUCT", 31, 35], ["cells", "CELL", 53, 58], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 123, 130], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 173, 180], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 367, 374], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 546, 554], ["IFN", "PROTEIN", 28, 31], ["\u03b1", "PROTEIN", 31, 32], ["IFN", "PROTEIN", 123, 126], ["IFN", "PROTEIN", 173, 176], ["5\u2032pppRNA", "PROTEIN", 273, 281], ["IFN", "PROTEIN", 286, 289], ["IFN\u03b1", "PROTEIN", 367, 371], ["5\u2032pppRNA", "DNA", 546, 554], ["IFN", "PROTEIN", 574, 577], ["IFN\u03b1-2b", "TREATMENT", 28, 35], ["gene expression levels", "TEST", 60, 82], ["IFN", "TEST", 123, 126], ["IFN", "TEST", 173, 176], ["2b treatment", "TREATMENT", 178, 190], ["Comparative analysis", "TEST", 206, 226], ["5\u2032pppRNA", "TEST", 273, 281], ["IFN\u03b1-2b treatment", "TREATMENT", 367, 384], ["5\u2032pppRNA treatment", "TREATMENT", 450, 468], ["unchanged", "OBSERVATION_MODIFIER", 103, 112]]], ["Some of the genes characteristically activated as part of the IFN signature and maximally induced by 5\u2032pppRNA are MX1, IFIT1, ISG15 (Fig. 5A, black portion).", [["IFN", "GENE_OR_GENE_PRODUCT", 62, 65], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 101, 109], ["MX1", "GENE_OR_GENE_PRODUCT", 114, 117], ["IFIT1", "GENE_OR_GENE_PRODUCT", 119, 124], ["ISG15", "GENE_OR_GENE_PRODUCT", 126, 131], ["IFN", "PROTEIN", 62, 65], ["5\u2032pppRNA", "PROTEIN", 101, 109], ["MX1", "PROTEIN", 114, 117], ["IFIT1", "PROTEIN", 119, 124], ["ISG15", "PROTEIN", 126, 131], ["Fig. 5A", "PROTEIN", 133, 140], ["the IFN signature", "TEST", 58, 75], ["MX1", "TEST", 114, 117], ["IFIT1", "TEST", 119, 124], ["ISG15", "TEST", 126, 131]]], ["This comparison also highlighted the fact that a surprisingly large number of genes are uniquely regulated by 5\u2032pppRNA - 38 genes at 6 h and 730 genes at 24 h (Fig. 5C).", [["5\u2032pppRNA - 38", "GENE_OR_GENE_PRODUCT", 110, 123], ["5\u2032pppRNA - 38 genes", "DNA", 110, 129], ["730 genes", "DNA", 141, 150], ["5\u2032pppRNA", "TEST", 110, 118], ["large", "OBSERVATION_MODIFIER", 62, 67]]], ["Most notably, IFNB1 and all three members of the IFN\u03bb family, as well as the cytokines CCL5, CXCL10, IL-6, and CCL3, were highly induced by 5\u2032pppRNA but not IFN\u03b1-2b treatment (Fig. 5A; red genes).", [["IFN\u03b1-2b", "CHEMICAL", 157, 164], ["IFNB1", "GENE_OR_GENE_PRODUCT", 14, 19], ["IFN\u03bb", "GENE_OR_GENE_PRODUCT", 49, 53], ["CCL5", "GENE_OR_GENE_PRODUCT", 87, 91], ["CXCL10", "GENE_OR_GENE_PRODUCT", 93, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 101, 105], ["CCL3", "GENE_OR_GENE_PRODUCT", 111, 115], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 140, 148], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 157, 164], ["IFNB1", "PROTEIN", 14, 19], ["IFN\u03bb family", "PROTEIN", 49, 60], ["cytokines", "PROTEIN", 77, 86], ["CCL5", "PROTEIN", 87, 91], ["CXCL10", "PROTEIN", 93, 99], ["IL-6", "PROTEIN", 101, 105], ["CCL3", "PROTEIN", 111, 115], ["5\u2032pppRNA", "PROTEIN", 140, 148], ["IFN", "PROTEIN", 157, 160], ["red genes", "DNA", 185, 194], ["the cytokines CCL5", "TEST", 73, 91], ["CXCL10", "TEST", 93, 99], ["IL", "TEST", 101, 103], ["CCL3", "TEST", 111, 115], ["IFN", "TEST", 157, 160], ["2b treatment", "TREATMENT", 162, 174]]], ["While IFN signaling was highly induced by both treatments, IFN\u03b1-2b strongly activated antigen presentation machinery, and 5\u2032pppRNA preferentially stimulated dendritic cell maturation and crosstalk, linking innate and adaptive immunity as well as induction of a wider range of signaling pathways (Fig. 5D).", [["dendritic cell", "ANATOMY", 157, 171], ["IFN", "GENE_OR_GENE_PRODUCT", 6, 9], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 59, 66], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 122, 130], ["dendritic cell", "CELL", 157, 171], ["IFN", "PROTEIN", 6, 9], ["IFN", "PROTEIN", 59, 62], ["\u03b1", "PROTEIN", 62, 63], ["5\u2032pppRNA", "PROTEIN", 122, 130], ["IFN", "TEST", 59, 62], ["dendritic cell maturation", "OBSERVATION", 157, 182]]], ["Significantly, 5\u2032pppRNA preferentially stimulated a more extensive induction of IRF7 and NF-\u03baB signaling nodes compared to IFN\u03b1-2b treatment (Fig. S2C).", [["IFN\u03b1-2b", "CHEMICAL", 123, 130], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 15, 23], ["IRF7", "GENE_OR_GENE_PRODUCT", 80, 84], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 123, 130], ["5\u2032pppRNA", "PROTEIN", 15, 23], ["IRF7", "PROTEIN", 80, 84], ["NF-\u03baB", "PROTEIN", 89, 94], ["IFN", "PROTEIN", 123, 126], ["\u03b1", "PROTEIN", 126, 127], ["IRF7", "TEST", 80, 84], ["NF", "TEST", 89, 91], ["B signaling nodes", "PROBLEM", 93, 110], ["IFN", "TEST", 123, 126], ["2b treatment", "TREATMENT", 128, 140], ["signaling nodes", "OBSERVATION", 95, 110]]], ["Thus, 5\u2032pppRNA treatment, besides inducing a complete IFN response, additionally stimulated the transcription of a large and unique set of inflammatory and antiviral genes.5\u2032pppRNA acts as a broad-spectrum antiviral agent ::: ResultsTo determine if the RIG-I agonist was capable of inducing a functional antiviral response, A549 cells were treated with 5\u2032pppRNA, and 24 h later, challenged with VSV, Dengue (DENV), or Vaccinia viruses.", [["A549 cells", "ANATOMY", 324, 334], ["5\u2032pppRNA", "CHEMICAL", 6, 14], ["Dengue", "DISEASE", 400, 406], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 6, 14], ["IFN", "GENE_OR_GENE_PRODUCT", 54, 57], ["5", "ORGANISM", 172, 173], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 173, 180], ["RIG-I", "GENE_OR_GENE_PRODUCT", 253, 258], ["A549 cells", "CELL", 324, 334], ["VSV", "ORGANISM", 395, 398], ["Dengue (DENV", "ORGANISM", 400, 412], ["Vaccinia viruses", "ORGANISM", 418, 434], ["5\u2032pppRNA", "PROTEIN", 6, 14], ["IFN", "PROTEIN", 54, 57], ["inflammatory and antiviral genes", "DNA", 139, 171], ["\u2032pppRNA", "PROTEIN", 173, 180], ["A549 cells", "CELL_LINE", 324, 334], ["VSV", "SPECIES", 395, 398], ["DENV", "SPECIES", 408, 412], ["Vaccinia viruses", "SPECIES", 418, 434], ["5\u2032pppRNA treatment", "TREATMENT", 6, 24], ["inflammatory and antiviral genes", "PROBLEM", 139, 171], ["a broad-spectrum antiviral agent", "TREATMENT", 189, 221], ["A549 cells", "PROBLEM", 324, 334], ["5\u2032pppRNA", "TREATMENT", 353, 361], ["VSV", "TREATMENT", 395, 398], ["Dengue (DENV)", "PROBLEM", 400, 413], ["Vaccinia viruses", "PROBLEM", 418, 434], ["large", "OBSERVATION_MODIFIER", 115, 120], ["inflammatory", "OBSERVATION", 139, 151], ["antiviral genes", "OBSERVATION", 156, 171], ["Vaccinia viruses", "OBSERVATION", 418, 434]]], ["All viruses established infection in untreated cells as assessed by flow cytometry (60%, 20% and 80%, respectively) but in 5\u2032pppRNA-treated cells, VSV and DENV infectivity was reduced to <0.5%, while infection with vaccinia was reduced to 10% (Fig. 6A).", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 140, 145], ["infection", "DISEASE", 24, 33], ["infection", "DISEASE", 200, 209], ["cells", "CELL", 47, 52], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 123, 131], ["cells", "CELL", 140, 145], ["VSV", "ORGANISM", 147, 150], ["DENV", "ORGANISM", 155, 159], ["vaccinia", "ORGANISM", 215, 223], ["untreated cells", "CELL_TYPE", 37, 52], ["5\u2032pppRNA-treated cells", "CELL_LINE", 123, 145], ["VSV", "SPECIES", 147, 150], ["DENV", "SPECIES", 155, 159], ["vaccinia", "SPECIES", 215, 223], ["All viruses established infection in untreated cells", "PROBLEM", 0, 52], ["flow cytometry", "TEST", 68, 82], ["5\u2032pppRNA", "TEST", 123, 131], ["VSV", "PROBLEM", 147, 150], ["DENV infectivity", "PROBLEM", 155, 171], ["infection", "PROBLEM", 200, 209], ["vaccinia", "TREATMENT", 215, 223], ["viruses", "OBSERVATION", 4, 11], ["infection", "OBSERVATION", 24, 33], ["untreated cells", "OBSERVATION", 37, 52], ["DENV infectivity", "OBSERVATION", 155, 171]]], ["Release of infectious VSV and DENV virus was completely blocked by 5\u2032pppRNA treatment (1.7\u00d7109 and 4.3\u00d7106 PFU/mL in untreated cells, respectively vs. undetectable in treated cells; Fig. S3).", [["cells", "ANATOMY", 127, 132], ["cells", "ANATOMY", 175, 180], ["5\u2032pppRNA", "CHEMICAL", 67, 75], ["infectious VSV", "ORGANISM", 11, 25], ["DENV virus", "ORGANISM", 30, 40], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 67, 75], ["cells", "CELL", 127, 132], ["cells", "CELL", 175, 180], ["treated cells", "CELL_LINE", 167, 180], ["VSV", "SPECIES", 22, 25], ["VSV", "SPECIES", 22, 25], ["DENV virus", "SPECIES", 30, 40], ["infectious VSV", "PROBLEM", 11, 25], ["DENV virus", "PROBLEM", 30, 40], ["5\u2032pppRNA treatment", "TREATMENT", 67, 85], ["untreated cells", "PROBLEM", 117, 132], ["undetectable in treated cells", "PROBLEM", 151, 180], ["infectious VSV", "OBSERVATION", 11, 25], ["DENV virus", "OBSERVATION", 30, 40]]], ["Similarly, in primary human CD14+ monocytes, DENV infection decreased from 53.7% to 2.6% in the presence of 5\u2032pppRNA; in the CD14\u2212 fraction, DENV infectivity was lower (3%), but was likewise inhibited by RNA agonist treatment (0.4%; Fig. 6B).", [["CD14+ monocytes", "ANATOMY", 28, 43], ["infection", "DISEASE", 50, 59], ["human", "ORGANISM", 22, 27], ["CD14", "GENE_OR_GENE_PRODUCT", 28, 32], ["DENV", "ORGANISM", 45, 49], ["5\u2032ppp", "GENE_OR_GENE_PRODUCT", 108, 113], ["CD14", "GENE_OR_GENE_PRODUCT", 125, 129], ["DENV", "ORGANISM", 141, 145], ["CD14", "PROTEIN", 28, 32], ["monocytes", "CELL_TYPE", 34, 43], ["5\u2032pppRNA", "RNA", 108, 116], ["CD14", "PROTEIN", 125, 129], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["DENV", "SPECIES", 45, 49], ["DENV", "SPECIES", 141, 145], ["monocytes", "TEST", 34, 43], ["DENV infection", "PROBLEM", 45, 59], ["5\u2032pppRNA", "PROBLEM", 108, 116], ["DENV infectivity", "PROBLEM", 141, 157], ["RNA agonist treatment", "TREATMENT", 204, 225], ["monocytes", "OBSERVATION_MODIFIER", 34, 43], ["DENV", "OBSERVATION_MODIFIER", 45, 49], ["infection", "OBSERVATION_MODIFIER", 50, 59], ["decreased", "OBSERVATION_MODIFIER", 60, 69], ["DENV infectivity", "OBSERVATION", 141, 157]]], ["To demonstrate the requirement for intracellular delivery of 5\u2032pppRNA, primary CD14+ cells from three patients were treated with 5\u2032pppRNA alone, transfection reagent alone or the combination; DENV infectivity was reduced from \u223c30% to \u223c0.5% only upon transfection of the RNA agonist (Fig. 6C).", [["intracellular", "ANATOMY", 35, 48], ["primary CD14+ cells", "ANATOMY", 71, 90], ["5\u2032pppRNA", "CHEMICAL", 129, 137], ["5\u2032pppRNA", "CHEMICAL", 129, 137], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 61, 69], ["CD14", "GENE_OR_GENE_PRODUCT", 79, 83], ["patients", "ORGANISM", 102, 110], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 129, 137], ["DENV", "ORGANISM", 192, 196], ["5\u2032pppRNA", "PROTEIN", 61, 69], ["CD14", "PROTEIN", 79, 83], ["patients", "SPECIES", 102, 110], ["DENV", "SPECIES", 192, 196], ["intracellular delivery of 5\u2032pppRNA", "TREATMENT", 35, 69], ["primary CD14+ cells", "PROBLEM", 71, 90], ["5\u2032pppRNA", "TREATMENT", 129, 137], ["transfection reagent", "TREATMENT", 145, 165], ["DENV infectivity", "PROBLEM", 192, 208], ["the RNA agonist", "TREATMENT", 266, 281]]], ["To evaluate the antiviral effect of 5\u2032pppRNA against HIV infection, activated CD4+ T cells were pre-treated with supernatant isolated from 5\u2032pppRNA-treated monocytes and then infected with HIV-GFP.", [["CD4+ T cells", "ANATOMY", 78, 90], ["supernatant", "ANATOMY", 113, 124], ["monocytes", "ANATOMY", 156, 165], ["5\u2032pppRNA", "CHEMICAL", 36, 44], ["HIV infection", "DISEASE", 53, 66], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 36, 44], ["HIV", "ORGANISM", 53, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 78, 81], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 139, 147], ["monocytes", "CELL", 156, 165], ["HIV-GFP", "ORGANISM", 189, 196], ["5\u2032pppRNA", "PROTEIN", 36, 44], ["activated CD4+ T cells", "CELL_TYPE", 68, 90], ["5\u2032pppRNA-treated monocytes", "CELL_LINE", 139, 165], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 189, 192], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 189, 192], ["5\u2032pppRNA", "TREATMENT", 36, 44], ["HIV infection", "PROBLEM", 53, 66], ["activated CD4+ T cells", "PROBLEM", 68, 90], ["supernatant", "TEST", 113, 124], ["5\u2032pppRNA", "TEST", 139, 147], ["monocytes", "PROBLEM", 156, 165], ["HIV-GFP", "PROBLEM", 189, 196]]], ["In the absence of treatment, 24% of the activated CD4+ T cells were actively infected by HIV as determined by GFP expression by flow cytometry, whereas infection of CD4+ T cells treated with 5\u2032pppRNA supernatants was reduced to 11% (Fig. 6D).", [["CD4+ T cells", "ANATOMY", 50, 62], ["CD4+ T cells", "ANATOMY", 165, 177], ["supernatants", "ANATOMY", 200, 212], ["infection", "DISEASE", 152, 161], ["CD4", "GENE_OR_GENE_PRODUCT", 50, 53], ["HIV", "ORGANISM", 89, 92], ["GFP", "GENE_OR_GENE_PRODUCT", 110, 113], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["activated CD4+ T cells", "CELL_TYPE", 40, 62], ["GFP", "PROTEIN", 110, 113], ["CD4", "PROTEIN", 165, 168], ["T cells", "CELL_TYPE", 170, 177], ["HIV", "SPECIES", 89, 92], ["HIV", "SPECIES", 89, 92], ["treatment", "TREATMENT", 18, 27], ["the activated CD4+ T cells", "PROBLEM", 36, 62], ["HIV", "PROBLEM", 89, 92], ["flow cytometry", "TEST", 128, 142], ["infection", "PROBLEM", 152, 161], ["CD4", "TEST", 165, 168], ["T cells", "PROBLEM", 170, 177], ["5\u2032pppRNA supernatants", "TREATMENT", 191, 212], ["flow cytometry", "OBSERVATION", 128, 142]]], ["5\u2032pppRNA also had an antiviral effect against HCV in hepatocellular carcinoma cell line Huh7; HCV NS3 expression was inhibited by 5\u2032pppRNA treatment (Fig. 6E; lane 4 vs. 2 and 6).", [["hepatocellular carcinoma cell line Huh7", "ANATOMY", 53, 92], ["HCV in hepatocellular carcinoma", "DISEASE", 46, 77], ["5\u2032pppRNA", "CHEMICAL", 130, 138], ["5\u2032pppRNA", "CHEMICAL", 130, 138], ["5", "ORGANISM", 0, 1], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 1, 8], ["HCV", "ORGANISM", 46, 49], ["hepatocellular carcinoma cell line Huh7", "CELL", 53, 92], ["HCV", "ORGANISM", 94, 97], ["NS3", "ORGANISM", 98, 101], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 130, 138], ["\u2032pppRNA", "PROTEIN", 1, 8], ["hepatocellular carcinoma cell line Huh7", "CELL_LINE", 53, 92], ["HCV NS3", "PROTEIN", 94, 101], ["HCV", "SPECIES", 46, 49], ["HCV", "SPECIES", 94, 97], ["an antiviral effect", "TREATMENT", 18, 37], ["HCV", "PROBLEM", 46, 49], ["hepatocellular carcinoma cell line Huh7", "TREATMENT", 53, 92], ["HCV NS3 expression", "TREATMENT", 94, 112], ["5\u2032pppRNA treatment", "TREATMENT", 130, 148], ["antiviral", "OBSERVATION", 21, 30], ["hepatocellular", "ANATOMY", 53, 67], ["carcinoma cell line", "OBSERVATION", 68, 87], ["Huh7", "OBSERVATION_MODIFIER", 88, 92]]], ["The antiviral effect was fully dependent on RIG-I, as demonstrated in Huh7.5 cells (that express a mutated inactive RIG-I) by the absence of IFIT1 up-regulation following 5\u2032pppRNA treatment (Fig. 6E; lane 9) and NS3 expression comparable to untreated HCV-infected cells (Fig. 6E; lane 10 vs. 8 and 12).", [["Huh7.5 cells", "ANATOMY", 70, 82], ["cells", "ANATOMY", 264, 269], ["HCV-infected", "DISEASE", 251, 263], ["5\u2032pppRNA", "CHEMICAL", 171, 179], ["RIG-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["Huh7.5 cells", "CELL", 70, 82], ["RIG-I", "GENE_OR_GENE_PRODUCT", 116, 121], ["IFIT1", "GENE_OR_GENE_PRODUCT", 141, 146], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 171, 179], ["NS3", "GENE_OR_GENE_PRODUCT", 212, 215], ["HCV", "ORGANISM", 251, 254], ["cells", "CELL", 264, 269], ["RIG-I", "PROTEIN", 44, 49], ["Huh7.5 cells", "CELL_LINE", 70, 82], ["mutated inactive RIG-I", "PROTEIN", 99, 121], ["IFIT1", "PROTEIN", 141, 146], ["5\u2032pppRNA", "PROTEIN", 171, 179], ["NS3", "PROTEIN", 212, 215], ["untreated HCV-infected cells", "CELL_TYPE", 241, 269], ["HCV", "SPECIES", 251, 254], ["The antiviral effect", "PROBLEM", 0, 20], ["5\u2032pppRNA treatment", "TREATMENT", 171, 189], ["NS3 expression", "TREATMENT", 212, 226], ["untreated HCV", "PROBLEM", 241, 254], ["infected cells", "PROBLEM", 255, 269], ["antiviral effect", "OBSERVATION", 4, 20], ["infected cells", "OBSERVATION", 255, 269]]], ["Thus, 5\u2032pppRNA is a broad-spectrum antiviral agent able to trigger an efficient innate immune response in different cell types and prevent infection by RNA and DNA viruses.5\u2032pppRNA inhibits H1N1 Influenza infection in vitro::: ResultsTo further explore the inhibitory potential of 5\u2032pppRNA, A549 cells were pre-treated with 5\u2032pppRNA for 24 h and then infected with H1N1 A/PR/8/34 Influenza virus at increasing MOI (0.02, 0.2, 2); influenza replication was monitored by NS1 protein expression (Fig. 7A) and plaque assay (Fig. 7B).", [["cell", "ANATOMY", 116, 120], ["A549 cells", "ANATOMY", 291, 301], ["plaque", "ANATOMY", 506, 512], ["5\u2032pppRNA", "CHEMICAL", 6, 14], ["infection", "DISEASE", 139, 148], ["Influenza infection", "DISEASE", 195, 214], ["5\u2032pppRNA", "CHEMICAL", 324, 332], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 6, 14], ["cell", "CELL", 116, 120], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["5", "ORGANISM", 172, 173], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 173, 180], ["H1N1 Influenza", "ORGANISM", 190, 204], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 281, 289], ["A549 cells", "CELL", 291, 301], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 324, 332], ["H1N1 A/PR/8/34 Influenza virus", "ORGANISM", 365, 395], ["influenza", "ORGANISM", 430, 439], ["NS1", "GENE_OR_GENE_PRODUCT", 469, 472], ["5\u2032pppRNA", "PROTEIN", 6, 14], ["5\u2032pppRNA", "PROTEIN", 281, 289], ["A549 cells", "CELL_LINE", 291, 301], ["5\u2032pppRNA", "PROTEIN", 324, 332], ["PR", "PROTEIN", 372, 374], ["NS1", "PROTEIN", 469, 472], ["H1N1 Influenza", "SPECIES", 190, 204], ["8/34 Influenza virus", "SPECIES", 375, 395], ["H1N1 A/PR/8/34 Influenza virus", "SPECIES", 365, 395], ["5\u2032pppRNA", "TREATMENT", 6, 14], ["a broad-spectrum antiviral agent", "TREATMENT", 18, 50], ["different cell types", "TREATMENT", 106, 126], ["infection", "PROBLEM", 139, 148], ["DNA viruses", "PROBLEM", 160, 171], ["H1N1 Influenza infection", "PROBLEM", 190, 214], ["A549 cells", "PROBLEM", 291, 301], ["5\u2032pppRNA", "TREATMENT", 324, 332], ["H1N1", "PROBLEM", 365, 369], ["Influenza virus", "PROBLEM", 380, 395], ["increasing MOI", "PROBLEM", 399, 413], ["influenza replication", "TREATMENT", 430, 451], ["plaque assay", "TEST", 506, 518], ["different cell types", "OBSERVATION", 106, 126], ["infection", "OBSERVATION", 139, 148]]], ["Viral replication was blocked by 5\u2032pppRNA pre-treatment, even at the highest MOI, as demonstrated by complete loss of NS1 expression and 40-fold decrease in viral titer at MOI 2.", [["5\u2032pppRNA", "CHEMICAL", 33, 41], ["Viral", "ORGANISM", 0, 5], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 33, 41], ["NS1", "GENE_OR_GENE_PRODUCT", 118, 121], ["5\u2032pppRNA", "PROTEIN", 33, 41], ["NS1", "PROTEIN", 118, 121], ["Viral replication", "TREATMENT", 0, 17], ["complete loss of NS1 expression", "PROBLEM", 101, 132], ["viral titer at MOI", "PROBLEM", 157, 175], ["NS1 expression", "OBSERVATION", 118, 132], ["decrease", "OBSERVATION_MODIFIER", 145, 153], ["viral titer", "OBSERVATION", 157, 168]]], ["In A549 cells pre-treated with decreasing concentrations of 5\u2032pppRNA (10\u20130.1 ng/ml) prior to influenza virus challenge (0.2 MOI), 5\u2032pppRNA significantly blocked influenza replication at a concentration of 1 ng/ml, as demonstrated by a 3-fold reduction in NS1 protein expression (Fig. 7C; lane 7) and a 7-fold reduction in virus titer by plaque assay (Fig. 7D).5\u2032pppRNA inhibits H1N1 Influenza infection in vitro::: ResultsTo demonstrate that the antiviral activity of 5\u2032pppRNA against influenza relies on RIG-I signaling, A549 cells were knocked down for RIG-I and infected with influenza; in the knockdown, ISGs were not induced (Fig. 7E, lanes 3 vs. 6) and 5\u2032pppRNA treatment failed to inhibit NS1 expression (Fig. 7E; lanes 5 vs. 6), indicating that the antiviral effect of 5\u2032pppRNA is exclusively dependent on RIG-I.", [["A549 cells", "ANATOMY", 3, 13], ["plaque", "ANATOMY", 337, 343], ["A549 cells", "ANATOMY", 522, 532], ["5\u2032pppRNA", "CHEMICAL", 60, 68], ["\u2032pppRNA", "CHEMICAL", 131, 138], ["Influenza infection", "DISEASE", 383, 402], ["5\u2032pppRNA", "CHEMICAL", 468, 476], ["influenza", "DISEASE", 485, 494], ["influenza", "DISEASE", 579, 588], ["5\u2032pppRNA", "CHEMICAL", 659, 667], ["5\u2032pppRNA", "CHEMICAL", 777, 785], ["5\u2032pppRNA", "CHEMICAL", 60, 68], ["A549 cells", "CELL", 3, 13], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 60, 68], ["influenza virus", "ORGANISM", 93, 108], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 131, 138], ["NS1", "GENE_OR_GENE_PRODUCT", 255, 258], ["5", "ORGANISM", 360, 361], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 361, 368], ["H1N1 Influenza", "ORGANISM", 378, 392], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 468, 476], ["RIG-I", "GENE_OR_GENE_PRODUCT", 505, 510], ["A549 cells", "CELL", 522, 532], ["RIG-I", "GENE_OR_GENE_PRODUCT", 555, 560], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 659, 667], ["NS1", "GENE_OR_GENE_PRODUCT", 696, 699], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 777, 785], ["RIG-I.", "GENE_OR_GENE_PRODUCT", 814, 820], ["A549 cells", "CELL_LINE", 3, 13], ["NS1", "PROTEIN", 255, 258], ["5\u2032pppRNA", "PROTEIN", 468, 476], ["A549 cells", "CELL_LINE", 522, 532], ["RIG-I", "PROTEIN", 555, 560], ["ISGs", "DNA", 608, 612], ["5\u2032pppRNA", "PROTEIN", 659, 667], ["NS1", "PROTEIN", 696, 699], ["5\u2032pppRNA", "PROTEIN", 777, 785], ["H1N1 Influenza", "SPECIES", 378, 392], ["influenza virus", "SPECIES", 93, 108], ["decreasing concentrations of 5\u2032pppRNA", "TREATMENT", 31, 68], ["influenza virus challenge", "TREATMENT", 93, 118], ["5\u2032pppRNA", "TREATMENT", 130, 138], ["blocked influenza replication", "TREATMENT", 153, 182], ["a 3-fold reduction", "TREATMENT", 233, 251], ["NS1 protein expression", "TREATMENT", 255, 277], ["a 7-fold reduction in virus titer", "TREATMENT", 300, 333], ["H1N1 Influenza infection", "PROBLEM", 378, 402], ["the antiviral activity of 5\u2032pppRNA", "TREATMENT", 442, 476], ["influenza", "PROBLEM", 485, 494], ["A549 cells", "PROBLEM", 522, 532], ["influenza", "PROBLEM", 579, 588], ["5\u2032pppRNA treatment", "TREATMENT", 659, 677], ["the antiviral effect of 5\u2032pppRNA", "TREATMENT", 753, 785], ["A549 cells", "OBSERVATION", 3, 13], ["NS1 protein expression", "OBSERVATION", 255, 277], ["virus", "OBSERVATION", 322, 327], ["infected", "OBSERVATION", 565, 573], ["influenza", "OBSERVATION", 579, 588]]], ["Next, to determine whether the RIG-I \u2018unique\u2019 gene expression profile characterized in Figure 5 could compensate for the IFN response, A549 cells were knocked down for the IFN\u03b1/\u03b2R; the knock down was efficient, as demonstrated by the absence of IFIT1 and RIG-I induction following IFN\u03b1-2b stimulation (Fig. 7F; lane 6).", [["A549 cells", "ANATOMY", 135, 145], ["RIG-I", "GENE_OR_GENE_PRODUCT", 31, 36], ["IFN", "GENE_OR_GENE_PRODUCT", 121, 124], ["A549 cells", "CELL", 135, 145], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 172, 176], ["\u03b2R", "GENE_OR_GENE_PRODUCT", 177, 179], ["IFIT1", "GENE_OR_GENE_PRODUCT", 245, 250], ["RIG-I", "GENE_OR_GENE_PRODUCT", 255, 260], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 281, 288], ["IFN", "PROTEIN", 121, 124], ["A549 cells", "CELL_LINE", 135, 145], ["IFN\u03b1", "PROTEIN", 172, 176], ["\u03b2R", "PROTEIN", 177, 179], ["IFIT1", "PROTEIN", 245, 250], ["RIG-I", "PROTEIN", 255, 260], ["IFN", "PROTEIN", 281, 284], ["gene expression profile", "TEST", 46, 69], ["the IFN response", "PROBLEM", 117, 133], ["A549 cells", "TEST", 135, 145], ["RIG-I induction", "TREATMENT", 255, 270], ["IFN", "TREATMENT", 281, 284]]], ["Interestingly, induction of ISGs was only partially reduced following 5\u2032pppRNA treatment (2.2-fold reduction of IFIT1 vs. siCtrl; Fig. 7F; lane 5 vs. 2); this IFN-independent activation of innate signaling was sufficient to reduce viral NS1 expression by 2.4-fold (Fig. 7E; lane 9 vs. 8).", [["5\u2032pppRNA", "CHEMICAL", 70, 78], ["5\u2032pppRNA", "CHEMICAL", 70, 78], ["ISGs", "GENE_OR_GENE_PRODUCT", 28, 32], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 70, 78], ["IFN", "GENE_OR_GENE_PRODUCT", 159, 162], ["NS1", "GENE_OR_GENE_PRODUCT", 237, 240], ["ISGs", "DNA", 28, 32], ["IFIT1", "PROTEIN", 112, 117], ["siCtrl", "PROTEIN", 122, 128], ["IFN", "PROTEIN", 159, 162], ["NS1", "PROTEIN", 237, 240], ["ISGs", "TREATMENT", 28, 32], ["5\u2032pppRNA treatment", "TREATMENT", 70, 88], ["IFIT1", "PROBLEM", 112, 117], ["siCtrl", "PROBLEM", 122, 128], ["this IFN", "TREATMENT", 154, 162], ["innate signaling", "TREATMENT", 189, 205], ["viral NS1 expression", "TEST", 231, 251]]], ["Thus, in lung epithelial A549 cells, 5\u2032pppRNA treatment can efficiently inhibit influenza H1N1 replication in a RIG-I-dependent manner and stimulate an antiviral and inflammatory response independently of IFN signaling to limit influenza infection in vitro.5\u2032pppRNA activates innate immunity and protects mice from lethal influenza infection ::: ResultsTo determine the potential of 5\u2032pppRNA in vivo, C57Bl/6 mice were inoculated intravenously with 5\u2032pppRNA (25 \u00b5g) in complex with the in vivo-jetPEI transfection reagent.", [["lung epithelial A549 cells", "ANATOMY", 9, 35], ["intravenously", "ANATOMY", 430, 443], ["5\u2032pppRNA", "CHEMICAL", 37, 45], ["influenza infection", "DISEASE", 228, 247], ["influenza infection", "DISEASE", 322, 341], ["5\u2032pppRNA", "CHEMICAL", 449, 457], ["PEI", "CHEMICAL", 497, 500], ["5\u2032pppRNA", "CHEMICAL", 449, 457], ["PEI", "CHEMICAL", 497, 500], ["lung epithelial A549 cells", "CELL", 9, 35], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 37, 45], ["influenza H1N1", "ORGANISM", 80, 94], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 112, 118], ["IFN", "GENE_OR_GENE_PRODUCT", 205, 208], ["5", "ORGANISM", 257, 258], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 258, 265], ["mice", "ORGANISM", 305, 309], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 383, 391], ["C57Bl/6 mice", "ORGANISM", 401, 413], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 449, 457], ["lung epithelial A549 cells", "CELL_LINE", 9, 35], ["IFN", "PROTEIN", 205, 208], ["\u2032pppRNA", "PROTEIN", 258, 265], ["5\u2032pppRNA", "PROTEIN", 383, 391], ["influenza H1N1", "SPECIES", 80, 94], ["mice", "SPECIES", 305, 309], ["mice", "SPECIES", 409, 413], ["influenza H1N1", "SPECIES", 80, 94], ["mice", "SPECIES", 305, 309], ["mice", "SPECIES", 409, 413], ["5\u2032pppRNA treatment", "TREATMENT", 37, 55], ["influenza H1N1 replication", "TREATMENT", 80, 106], ["a RIG-I-dependent manner", "TREATMENT", 110, 134], ["an antiviral", "TREATMENT", 149, 161], ["inflammatory response", "PROBLEM", 166, 187], ["IFN signaling", "PROBLEM", 205, 218], ["influenza infection", "PROBLEM", 228, 247], ["lethal influenza infection", "PROBLEM", 315, 341], ["5\u2032pppRNA", "TREATMENT", 383, 391], ["C57Bl/6 mice", "TREATMENT", 401, 413], ["5\u2032pppRNA", "TREATMENT", 449, 457], ["the in vivo-jetPEI transfection reagent", "TREATMENT", 482, 521], ["lung", "ANATOMY", 9, 13], ["epithelial", "ANATOMY_MODIFIER", 14, 24], ["A549 cells", "OBSERVATION", 25, 35], ["I-dependent", "OBSERVATION_MODIFIER", 116, 127], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178], ["transfection reagent", "OBSERVATION", 501, 521]]], ["5\u2032pppRNA stimulated a potent immune response in vivo characterized by IFN\u03b1 and IFN\u03b2 secretion in the serum and lungs (Fig. S4A) as well as antiviral gene up-regulation (Fig. S4B).", [["serum", "ANATOMY", 101, 106], ["lungs", "ANATOMY", 111, 116], ["5", "ORGANISM", 0, 1], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 1, 8], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 79, 83], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["lungs", "ORGAN", 111, 116], ["S4A", "GENE_OR_GENE_PRODUCT", 123, 126], ["\u2032pppRNA", "PROTEIN", 1, 8], ["IFN\u03b1", "PROTEIN", 70, 74], ["IFN\u03b2", "PROTEIN", 79, 83], ["S4A", "PROTEIN", 123, 126], ["antiviral gene", "DNA", 139, 153], ["IFN\u03b2 secretion in the serum and lungs (Fig", "PROBLEM", 79, 121], ["antiviral gene", "TREATMENT", 139, 153], ["serum", "ANATOMY", 101, 106], ["lungs", "ANATOMY", 111, 116]]], ["The response was potent and rapid with serum IFN\u03b2 levels increased \u223c20-fold compared to basal levels, as early as 6 h post administration (Fig. S4A; top left panel).", [["serum", "ANATOMY", 39, 44], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 45, 49], ["S4A", "GENE_OR_GENE_PRODUCT", 144, 147], ["IFN\u03b2", "PROTEIN", 45, 49], ["S4A", "PROTEIN", 144, 147], ["serum IFN\u03b2 levels", "TEST", 39, 56], ["basal levels", "TEST", 88, 100], ["top left panel", "TEST", 149, 163], ["potent", "OBSERVATION_MODIFIER", 17, 23], ["left", "ANATOMY_MODIFIER", 153, 157]]], ["The immune activation observed in vivo correlated with an early and transient recruitment of neutrophils to the lungs along with a more sustained increase in macrophages and dendritic cells populations (Fig. S4C).5\u2032pppRNA activates innate immunity and protects mice from lethal influenza infection ::: ResultsNext, to determine the antiviral potential of 5\u2032pppRNA in vivo, mice were treated with 5\u2032pppRNA 24 h before (day \u22121), and on the day of infection (day 0) with a lethal inoculum of H1N1 A/PR/8/34 Influenza.", [["neutrophils", "ANATOMY", 93, 104], ["lungs", "ANATOMY", 112, 117], ["macrophages", "ANATOMY", 158, 169], ["dendritic cells", "ANATOMY", 174, 189], ["influenza infection", "DISEASE", 278, 297], ["5\u2032pppRNA", "CHEMICAL", 396, 404], ["infection", "DISEASE", 445, 454], ["Influenza", "DISEASE", 504, 513], ["neutrophils", "CELL", 93, 104], ["lungs", "ORGAN", 112, 117], ["macrophages", "CELL", 158, 169], ["dendritic cells populations", "CELL", 174, 201], ["S4C", "GENE_OR_GENE_PRODUCT", 208, 211], ["5", "ORGANISM", 213, 214], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 214, 221], ["mice", "ORGANISM", 261, 265], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 355, 363], ["mice", "ORGANISM", 373, 377], ["PR/8/34 Influenza", "ORGANISM", 496, 513], ["neutrophils", "CELL_TYPE", 93, 104], ["macrophages", "CELL_TYPE", 158, 169], ["dendritic cells populations", "CELL_TYPE", 174, 201], ["S4C", "PROTEIN", 208, 211], ["\u2032pppRNA", "PROTEIN", 214, 221], ["5\u2032pppRNA", "PROTEIN", 355, 363], ["PR", "PROTEIN", 496, 498], ["mice", "SPECIES", 261, 265], ["mice", "SPECIES", 373, 377], ["mice", "SPECIES", 261, 265], ["mice", "SPECIES", 373, 377], ["H1N1 A/PR/8/34 Influenza", "SPECIES", 489, 513], ["The immune activation", "PROBLEM", 0, 21], ["a more sustained increase in macrophages", "PROBLEM", 129, 169], ["dendritic cells populations", "PROBLEM", 174, 201], ["lethal influenza infection", "PROBLEM", 271, 297], ["5\u2032pppRNA", "TREATMENT", 355, 363], ["5\u2032pppRNA", "TREATMENT", 396, 404], ["infection", "PROBLEM", 445, 454], ["a lethal inoculum", "PROBLEM", 468, 485], ["H1N1", "PROBLEM", 489, 493], ["Influenza", "PROBLEM", 504, 513], ["immune activation", "OBSERVATION", 4, 21], ["transient", "OBSERVATION_MODIFIER", 68, 77], ["recruitment", "OBSERVATION_MODIFIER", 78, 89], ["lungs", "ANATOMY", 112, 117], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["macrophages", "OBSERVATION", 158, 169], ["dendritic cells populations", "OBSERVATION", 174, 201], ["infection", "OBSERVATION", 445, 454], ["H1N1", "OBSERVATION", 489, 493]]], ["Whereas all untreated, infected mice succumbed to infection by day 11, all 5\u2032pppRNA-treated mice fully recovered (100% survival) (Fig. 8A).", [["infection", "DISEASE", 50, 59], ["5\u2032pppRNA", "CHEMICAL", 75, 83], ["mice", "ORGANISM", 32, 36], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 75, 83], ["mice", "ORGANISM", 92, 96], ["5\u2032pppRNA", "PROTEIN", 75, 83], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 92, 96], ["infection", "PROBLEM", 50, 59], ["all 5\u2032pppRNA", "TREATMENT", 71, 83], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["infection", "OBSERVATION", 50, 59]]], ["Overall, weight loss was similar between the two groups (Fig. 8B), although a noticeable delay of 2\u20133 days in the onset of weight loss was observed in 5\u2032pppRNA-treated animals; treated mice then fully recovered within 12\u201314 days (Fig. 8B).", [["weight loss", "DISEASE", 9, 20], ["weight loss", "DISEASE", 123, 134], ["5\u2032pppRNA", "CHEMICAL", 151, 159], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 151, 159], ["mice", "ORGANISM", 185, 189], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 185, 189], ["weight loss", "PROBLEM", 9, 20], ["weight loss", "PROBLEM", 123, 134], ["weight loss", "OBSERVATION", 9, 20]]], ["Influenza replication in the lungs was monitored by plaque assay over the course of infection with virus titers in the lungs of untreated mice reaching a maximum at day 3 post-infection (Fig. 8C).", [["lungs", "ANATOMY", 29, 34], ["plaque", "ANATOMY", 52, 58], ["lungs", "ANATOMY", 119, 124], ["Influenza", "DISEASE", 0, 9], ["infection", "DISEASE", 84, 93], ["lungs", "ORGAN", 29, 34], ["lungs", "ORGAN", 119, 124], ["mice", "ORGANISM", 138, 142], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 138, 142], ["Influenza replication in the lungs", "PROBLEM", 0, 34], ["infection", "PROBLEM", 84, 93], ["virus titers", "TREATMENT", 99, 111], ["infection", "PROBLEM", 176, 185], ["lungs", "ANATOMY", 29, 34], ["plaque", "OBSERVATION", 52, 58], ["infection", "OBSERVATION", 84, 93], ["lungs", "ANATOMY", 119, 124], ["infection", "OBSERVATION", 176, 185]]], ["A decrease in virus titer was noted by day 9 post-infection, possibly correlating with the onset of adaptive immunity, and all animals succumbed to influenza infection by day 11 (Fig. 8A).", [["infection", "DISEASE", 50, 59], ["influenza infection", "DISEASE", 148, 167], ["A decrease in virus titer", "PROBLEM", 0, 25], ["infection", "PROBLEM", 50, 59], ["adaptive immunity", "PROBLEM", 100, 117], ["influenza infection", "PROBLEM", 148, 167], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["virus titer", "OBSERVATION", 14, 25], ["infection", "OBSERVATION", 50, 59]]], ["Interestingly, 5\u2032pppRNA treatment inhibited influenza virus replication in the lungs early after infection, within the first 24\u201348 h (Fig. 8C; Day 1); by day 3, virus titers in the lung had increased, although influenza titers were still \u223c10-fold lower compared to titers in untreated mice (Fig. 8C; Day 3).", [["lungs", "ANATOMY", 79, 84], ["lung", "ANATOMY", 181, 185], ["5\u2032pppRNA", "CHEMICAL", 15, 23], ["infection", "DISEASE", 97, 106], ["influenza", "DISEASE", 210, 219], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 15, 23], ["influenza virus", "ORGANISM", 44, 59], ["lungs", "ORGAN", 79, 84], ["lung", "ORGAN", 181, 185], ["mice", "ORGANISM", 285, 289], ["5\u2032pppRNA", "PROTEIN", 15, 23], ["influenza virus", "SPECIES", 44, 59], ["mice", "SPECIES", 285, 289], ["influenza virus", "SPECIES", 44, 59], ["mice", "SPECIES", 285, 289], ["5\u2032pppRNA treatment", "TREATMENT", 15, 33], ["influenza virus replication", "TREATMENT", 44, 71], ["infection", "PROBLEM", 97, 106], ["virus titers", "TEST", 161, 173], ["influenza titers", "TEST", 210, 226], ["lungs", "ANATOMY", 79, 84], ["infection", "OBSERVATION", 97, 106], ["lung", "ANATOMY", 181, 185], ["increased", "OBSERVATION_MODIFIER", 190, 199]]], ["By day 9, the 5\u2032pppRNA-treated animals had controlled the infection, as demonstrated by the decrease in viral titers.", [["5\u2032pppRNA", "CHEMICAL", 14, 22], ["infection", "DISEASE", 58, 67], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 14, 22], ["animals", "ORGANISM", 31, 38], ["5\u2032pppRNA", "PROTEIN", 14, 22], ["the 5\u2032pppRNA", "TREATMENT", 10, 22], ["the infection", "PROBLEM", 54, 67], ["the decrease in viral titers", "PROBLEM", 88, 116], ["infection", "OBSERVATION", 58, 67], ["decrease", "OBSERVATION_MODIFIER", 92, 100], ["viral titers", "OBSERVATION", 104, 116]]], ["Continuous administration of 5\u2032pppRNA at 24 h intervals post-infection had an additive therapeutic effect that further delayed viral replication (Fig. 8D; 3 versus 2 doses of 5\u2032pppRNA), indicating that antiviral immunity may be sustained with repetitive administration of 5\u2032pppRNA.", [["5\u2032pppRNA", "CHEMICAL", 29, 37], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 29, 37], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 175, 183], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 272, 280], ["5\u2032pppRNA", "PROTEIN", 175, 183], ["5\u2032pppRNA", "PROTEIN", 272, 280], ["5\u2032pppRNA", "TREATMENT", 29, 37], ["further delayed viral replication", "TREATMENT", 111, 144], ["5\u2032pppRNA", "TREATMENT", 175, 183], ["antiviral immunity", "TREATMENT", 202, 220], ["repetitive administration of 5\u2032pppRNA", "TREATMENT", 243, 280], ["viral replication", "OBSERVATION", 127, 144]]], ["Furthermore, therapeutic administration of 5\u2032pppRNA also controlled influenza viral replication; although prophylactic treatment was most effective at blocking influenza dissemination in the lung, administration of the RNA agonist on day 1 and day 2 after influenza infection also reduced viral lung titers by \u223c10-fold (Fig. 8E).5\u2032pppRNA activates innate immunity and protects mice from lethal influenza infection ::: ResultsThe antiviral response triggered by 5\u2032pppRNA in vivo was dependent on an intact RIG-I signaling; serum IFN\u03b2 release was abolished in MAVS\u2212/\u2212 mice, whereas the absence of TLR3 did not affect 5\u2032pppRNA-induced IFN\u03b2 release (Fig. 8F).", [["lung", "ANATOMY", 191, 195], ["lung", "ANATOMY", 295, 299], ["serum", "ANATOMY", 522, 527], ["5\u2032pppRNA", "CHEMICAL", 43, 51], ["influenza viral replication", "DISEASE", 68, 95], ["influenza", "DISEASE", 160, 169], ["influenza infection", "DISEASE", 256, 275], ["influenza infection", "DISEASE", 394, 413], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 43, 51], ["influenza viral", "ORGANISM", 68, 83], ["lung", "ORGAN", 191, 195], ["lung", "ORGAN", 295, 299], ["5", "ORGANISM", 329, 330], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 330, 337], ["mice", "ORGANISM", 377, 381], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 461, 469], ["RIG-I", "GENE_OR_GENE_PRODUCT", 505, 510], ["serum", "ORGANISM_SUBSTANCE", 522, 527], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 528, 532], ["MAVS", "GENE_OR_GENE_PRODUCT", 558, 562], ["TLR3", "GENE_OR_GENE_PRODUCT", 595, 599], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 615, 623], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 632, 636], ["\u2032pppRNA", "PROTEIN", 330, 337], ["5\u2032pppRNA", "PROTEIN", 461, 469], ["RIG-I", "PROTEIN", 505, 510], ["IFN\u03b2", "PROTEIN", 528, 532], ["MAVS", "PROTEIN", 558, 562], ["TLR3", "PROTEIN", 595, 599], ["5\u2032pppRNA", "PROTEIN", 615, 623], ["IFN\u03b2", "PROTEIN", 632, 636], ["mice", "SPECIES", 377, 381], ["mice", "SPECIES", 566, 570], ["mice", "SPECIES", 377, 381], ["mice", "SPECIES", 566, 570], ["5\u2032pppRNA", "TREATMENT", 43, 51], ["influenza viral replication", "TREATMENT", 68, 95], ["prophylactic treatment", "TREATMENT", 106, 128], ["blocking influenza dissemination in the lung", "PROBLEM", 151, 195], ["the RNA agonist", "TREATMENT", 215, 230], ["influenza infection", "PROBLEM", 256, 275], ["reduced viral lung titers", "PROBLEM", 281, 306], ["lethal influenza infection", "PROBLEM", 387, 413], ["serum IFN", "TEST", 522, 531], ["5\u2032pppRNA", "TEST", 615, 623], ["lung", "ANATOMY", 191, 195], ["infection", "OBSERVATION", 266, 275], ["lung", "ANATOMY", 295, 299]]], ["In agreement, MAVS\u2212/\u2212 mice treated with 5\u2032pppRNA did not control influenza lung titers (5-fold increase vs. wt mice) and the titer was comparable to untreated wt mice (Fig. 8G).", [["lung", "ANATOMY", 75, 79], ["influenza", "DISEASE", 65, 74], ["MAVS", "GENE_OR_GENE_PRODUCT", 14, 18], ["lung", "ORGAN", 75, 79], ["mice", "ORGANISM", 111, 115], ["mice", "ORGANISM", 162, 166], ["Fig. 8G", "ORGANISM", 168, 175], ["MAVS", "PROTEIN", 14, 18], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 162, 166], ["5\u2032pppRNA", "TREATMENT", 40, 48], ["influenza lung titers", "PROBLEM", 65, 86], ["lung", "ANATOMY", 75, 79], ["titers", "OBSERVATION", 80, 86]]], ["To determine whether 5\u2032pppRNA treatment was sufficient to protect against influenza in the absence of IFN signaling, IFN\u03b1/\u03b2R\u2212/\u2212 mice were treated or not with 5\u2032pppRNA and challenged with influenza H1N1 virus.", [["5\u2032pppRNA", "CHEMICAL", 21, 29], ["influenza", "DISEASE", 74, 83], ["5\u2032pppRNA", "CHEMICAL", 158, 166], ["influenza H1N1 virus", "DISEASE", 187, 207], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 21, 29], ["IFN", "GENE_OR_GENE_PRODUCT", 102, 105], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 117, 121], ["\u03b2", "GENE_OR_GENE_PRODUCT", 122, 123], ["\u2212", "GENE_OR_GENE_PRODUCT", 126, 127], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 158, 166], ["influenza H1N1 virus", "ORGANISM", 187, 207], ["5\u2032pppRNA", "PROTEIN", 21, 29], ["IFN", "PROTEIN", 102, 105], ["IFN\u03b1", "PROTEIN", 117, 121], ["\u03b2", "PROTEIN", 122, 123], ["5\u2032pppRNA", "PROTEIN", 158, 166], ["mice", "SPECIES", 128, 132], ["influenza H1N1 virus", "SPECIES", 187, 207], ["mice", "SPECIES", 128, 132], ["influenza H1N1 virus", "SPECIES", 187, 207], ["5\u2032pppRNA treatment", "TREATMENT", 21, 39], ["influenza", "PROBLEM", 74, 83], ["IFN signaling", "PROBLEM", 102, 115], ["5\u2032pppRNA", "TREATMENT", 158, 166], ["influenza H1N1 virus", "PROBLEM", 187, 207]]], ["While untreated IFN\u03b1/\u03b2R\u2212/\u2212 animals succumbed to infection, 40% of the animals that received 5\u2032pppRNA treatment survived, suggesting that an IFN-independent effect of 5\u2032pppRNA functioned in the absence of the IFN response.", [["infection", "DISEASE", 48, 57], ["5\u2032pppRNA", "CHEMICAL", 92, 100], ["5\u2032pppRNA", "CHEMICAL", 166, 174], ["5\u2032pppRNA", "CHEMICAL", 92, 100], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 16, 20], ["\u03b2R\u2212", "GENE_OR_GENE_PRODUCT", 21, 24], ["animals", "ORGANISM", 70, 77], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 92, 100], ["IFN", "GENE_OR_GENE_PRODUCT", 140, 143], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 166, 174], ["IFN", "GENE_OR_GENE_PRODUCT", 208, 211], ["IFN\u03b1", "PROTEIN", 16, 20], ["IFN", "PROTEIN", 140, 143], ["5\u2032pppRNA", "PROTEIN", 166, 174], ["IFN", "PROTEIN", 208, 211], ["infection", "PROBLEM", 48, 57], ["5\u2032pppRNA treatment", "TREATMENT", 92, 110], ["an IFN", "PROBLEM", 137, 143], ["5\u2032pppRNA", "TREATMENT", 166, 174], ["infection", "OBSERVATION", 48, 57]]], ["Thus, intravenous administration of 5\u2032pppRNA stimulated a potent and rapid immune response in vivo that delayed influenza H1N1 virus replication in the lungs of infected animals and rescued mice from a lethal inoculation of influenza H1N1.5\u2032pppRNA treatment limits influenza-mediated pneumonia ::: ResultsTo further evaluate the effect of RNA agonist administration on influenza-mediated pathology, histological sections of lungs from untreated and treated mice were prepared and analysed.", [["intravenous", "ANATOMY", 6, 17], ["lungs", "ANATOMY", 152, 157], ["sections", "ANATOMY", 412, 420], ["lungs", "ANATOMY", 424, 429], ["5\u2032pppRNA", "CHEMICAL", 36, 44], ["influenza H1N1.5\u2032pppRNA", "CHEMICAL", 224, 247], ["influenza", "DISEASE", 265, 274], ["pneumonia", "DISEASE", 284, 293], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 17], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 36, 44], ["influenza H1N1 virus", "ORGANISM", 112, 132], ["lungs", "ORGAN", 152, 157], ["mice", "ORGANISM", 190, 194], ["influenza H1N1.5\u2032pppRNA", "ORGANISM", 224, 247], ["histological sections", "MULTI-TISSUE_STRUCTURE", 399, 420], ["lungs", "ORGAN", 424, 429], ["mice", "ORGANISM", 457, 461], ["5\u2032pppRNA", "PROTEIN", 36, 44], ["influenza H1N1 virus", "SPECIES", 112, 132], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 457, 461], ["influenza H1N1 virus", "SPECIES", 112, 132], ["mice", "SPECIES", 190, 194], ["H1", "SPECIES", 234, 236], ["mice", "SPECIES", 457, 461], ["intravenous administration", "TREATMENT", 6, 32], ["5\u2032pppRNA", "TREATMENT", 36, 44], ["delayed influenza H1N1 virus replication", "TREATMENT", 104, 144], ["a lethal inoculation", "TREATMENT", 200, 220], ["influenza H1", "TREATMENT", 224, 236], ["\u2032pppRNA treatment", "TREATMENT", 240, 257], ["influenza", "PROBLEM", 265, 274], ["pneumonia", "PROBLEM", 284, 293], ["RNA agonist administration", "TREATMENT", 339, 365], ["influenza", "PROBLEM", 369, 378], ["lungs", "ANATOMY", 152, 157], ["infected", "OBSERVATION", 161, 169], ["pneumonia", "OBSERVATION", 284, 293], ["lungs", "ANATOMY", 424, 429]]], ["5\u2032pppRNA treatment alone was characterized by a modest and rare leukocyte-to-endothelium attachment; mixed leukocyte populations (mononuclear/polymorphonuclear) infiltrated the perivascular space at 24 h after injection (data not shown) but the infiltration resolved and was limited to endothelial cell attachment at 3 and 8 days after intravenous administration (Fig. 9A).", [["leukocyte", "ANATOMY", 64, 73], ["endothelium", "ANATOMY", 77, 88], ["leukocyte", "ANATOMY", 107, 116], ["mononuclear", "ANATOMY", 130, 141], ["polymorphonuclear", "ANATOMY", 142, 159], ["perivascular space", "ANATOMY", 177, 195], ["endothelial cell", "ANATOMY", 286, 302], ["intravenous", "ANATOMY", 336, 347], ["5", "ORGANISM", 0, 1], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 1, 8], ["leukocyte", "CELL", 64, 73], ["endothelium", "TISSUE", 77, 88], ["leukocyte populations", "CELL", 107, 128], ["mononuclear", "CELL", 130, 141], ["polymorphonuclear", "CELL", 142, 159], ["perivascular space", "MULTI-TISSUE_STRUCTURE", 177, 195], ["endothelial cell", "CELL", 286, 302], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 336, 347], ["\u2032pppRNA", "PROTEIN", 1, 8], ["mixed leukocyte populations", "CELL_TYPE", 101, 128], ["mononuclear/polymorphonuclear", "CELL_TYPE", 130, 159], ["5\u2032pppRNA treatment", "TREATMENT", 0, 18], ["a modest and rare leukocyte", "PROBLEM", 46, 73], ["endothelium attachment", "PROBLEM", 77, 99], ["mixed leukocyte populations", "PROBLEM", 101, 128], ["the infiltration", "PROBLEM", 241, 257], ["endothelial cell attachment", "TREATMENT", 286, 313], ["rare", "OBSERVATION_MODIFIER", 59, 63], ["leukocyte", "OBSERVATION", 64, 73], ["endothelium", "ANATOMY", 77, 88], ["mixed", "OBSERVATION_MODIFIER", 101, 106], ["leukocyte populations", "OBSERVATION", 107, 128], ["perivascular space", "ANATOMY", 177, 195], ["infiltration", "OBSERVATION", 245, 257], ["endothelial cell", "OBSERVATION", 286, 302]]], ["Influenza virus infection induced severe and extensive inflammation and oedema in the perivascular space and the bronchial lumen at day 3 post-infection.", [["perivascular space", "ANATOMY", 86, 104], ["bronchial lumen", "ANATOMY", 113, 128], ["Influenza virus infection", "DISEASE", 0, 25], ["inflammation", "DISEASE", 55, 67], ["oedema", "DISEASE", 72, 78], ["infection", "DISEASE", 143, 152], ["Influenza virus", "ORGANISM", 0, 15], ["perivascular space", "MULTI-TISSUE_STRUCTURE", 86, 104], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 113, 128], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus infection", "PROBLEM", 0, 25], ["extensive inflammation", "PROBLEM", 45, 67], ["oedema in the perivascular space", "PROBLEM", 72, 104], ["post-infection", "PROBLEM", 138, 152], ["virus infection", "OBSERVATION", 10, 25], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["extensive", "OBSERVATION_MODIFIER", 45, 54], ["inflammation", "OBSERVATION", 55, 67], ["oedema", "OBSERVATION", 72, 78], ["perivascular space", "ANATOMY", 86, 104], ["bronchial", "ANATOMY", 113, 122], ["lumen", "ANATOMY_MODIFIER", 123, 128], ["infection", "OBSERVATION", 143, 152]]], ["In animals receiving the RNA agonist, influenza triggered a mild and infrequent inflammation that did not extend to the bronchial lumen at day 3 post-infection.", [["bronchial lumen", "ANATOMY", 120, 135], ["influenza", "DISEASE", 38, 47], ["inflammation", "DISEASE", 80, 92], ["infection", "DISEASE", 150, 159], ["bronchial lumen", "MULTI-TISSUE_STRUCTURE", 120, 135], ["the RNA agonist", "TREATMENT", 21, 36], ["influenza", "PROBLEM", 38, 47], ["a mild and infrequent inflammation", "PROBLEM", 58, 92], ["post-infection", "PROBLEM", 145, 159], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["infrequent", "OBSERVATION_MODIFIER", 69, 79], ["inflammation", "OBSERVATION", 80, 92], ["bronchial", "ANATOMY", 120, 129], ["lumen", "ANATOMY_MODIFIER", 130, 135], ["infection", "OBSERVATION", 150, 159]]], ["Epithelial degeneration and loss of tissue integrity were more severe in the lungs of untreated, infected animals and correlated with epithelial hyperplasia observed at later times, compared to the lungs of animals treated with 5\u2032pppRNA.", [["Epithelial", "ANATOMY", 0, 10], ["tissue", "ANATOMY", 36, 42], ["lungs", "ANATOMY", 77, 82], ["epithelial", "ANATOMY", 134, 144], ["lungs", "ANATOMY", 198, 203], ["Epithelial degeneration", "DISEASE", 0, 23], ["5\u2032pppRNA", "CHEMICAL", 228, 236], ["Epithelial", "TISSUE", 0, 10], ["tissue", "TISSUE", 36, 42], ["lungs", "ORGAN", 77, 82], ["epithelial", "TISSUE", 134, 144], ["lungs", "ORGAN", 198, 203], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 228, 236], ["5\u2032pppRNA", "PROTEIN", 228, 236], ["Epithelial degeneration", "PROBLEM", 0, 23], ["loss of tissue integrity", "PROBLEM", 28, 52], ["epithelial hyperplasia", "PROBLEM", 134, 156], ["5\u2032pppRNA", "TREATMENT", 228, 236], ["degeneration", "OBSERVATION", 11, 23], ["loss", "OBSERVATION_MODIFIER", 28, 32], ["tissue", "OBSERVATION_MODIFIER", 36, 42], ["integrity", "OBSERVATION_MODIFIER", 43, 52], ["more", "OBSERVATION_MODIFIER", 58, 62], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["lungs", "ANATOMY", 77, 82], ["untreated", "OBSERVATION_MODIFIER", 86, 95], ["infected", "OBSERVATION_MODIFIER", 97, 105], ["epithelial", "ANATOMY_MODIFIER", 134, 144], ["hyperplasia", "OBSERVATION", 145, 156], ["later times", "OBSERVATION_MODIFIER", 169, 180], ["lungs", "ANATOMY", 198, 203]]], ["Inflammation and epithelial damage progressed in untreated mice by day 8 (Fig. 9E), and correlated with increased virus titer in the lungs (Fig. 8C); inflammation and epithelial damage was consistently less apparent in agonist-treated mice.", [["epithelial", "ANATOMY", 17, 27], ["lungs", "ANATOMY", 133, 138], ["epithelial", "ANATOMY", 167, 177], ["Inflammation", "DISEASE", 0, 12], ["epithelial damage", "DISEASE", 17, 34], ["inflammation", "DISEASE", 150, 162], ["epithelial", "TISSUE", 17, 27], ["mice", "ORGANISM", 59, 63], ["lungs", "ORGAN", 133, 138], ["epithelial", "TISSUE", 167, 177], ["mice", "ORGANISM", 235, 239], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 235, 239], ["Inflammation", "PROBLEM", 0, 12], ["epithelial damage", "PROBLEM", 17, 34], ["increased virus titer in the lungs", "PROBLEM", 104, 138], ["inflammation", "PROBLEM", 150, 162], ["epithelial damage", "PROBLEM", 167, 184], ["epithelial", "ANATOMY_MODIFIER", 17, 27], ["damage", "OBSERVATION", 28, 34], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["virus", "OBSERVATION", 114, 119], ["lungs", "ANATOMY", 133, 138], ["inflammation", "OBSERVATION", 150, 162], ["epithelial damage", "OBSERVATION", 167, 184]]], ["Strikingly, the surface area of the lungs affected by pneumonia was significantly reduced in 5\u2032pppRNA-treated mice compared to non-treated mice \u2013 on day 3, 16% vs 35%; day 8, 41% vs 73% (Fig. 9C; bottom panel).", [["surface area", "ANATOMY", 16, 28], ["lungs", "ANATOMY", 36, 41], ["pneumonia", "DISEASE", 54, 63], ["5\u2032pppRNA", "CHEMICAL", 93, 101], ["lungs", "ORGAN", 36, 41], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 93, 101], ["mice", "ORGANISM", 110, 114], ["mice", "ORGANISM", 139, 143], ["5\u2032pppRNA", "PROTEIN", 93, 101], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 139, 143], ["pneumonia", "PROBLEM", 54, 63], ["Fig", "TEST", 187, 190], ["bottom panel", "TEST", 196, 208], ["surface", "OBSERVATION_MODIFIER", 16, 23], ["area", "OBSERVATION_MODIFIER", 24, 28], ["lungs", "ANATOMY", 36, 41], ["pneumonia", "OBSERVATION", 54, 63], ["significantly", "OBSERVATION_MODIFIER", 68, 81], ["reduced", "OBSERVATION_MODIFIER", 82, 89]]], ["Overall, influenza-mediated pneumonia was less severe in animals administered 5\u2032pppRNA before influenza challenge, demonstrating that 5\u2032pppRNA possesses an antiviral effect in vivo that limits influenza replication in the lung, limits lung damage and prevents influenza-mediated pneumonia and mortality.DiscussionRIG-I agonists are attractive potential antiviral agents, as triggering the innate cytosolic RIG-I pathway mimics the earliest steps of immune recognition and response to viral pathogens.", [["lung", "ANATOMY", 222, 226], ["lung", "ANATOMY", 235, 239], ["cytosolic", "ANATOMY", 396, 405], ["influenza", "DISEASE", 9, 18], ["pneumonia", "DISEASE", 28, 37], ["5\u2032pppRNA", "CHEMICAL", 78, 86], ["5\u2032pppRNA", "CHEMICAL", 134, 142], ["lung damage", "DISEASE", 235, 246], ["influenza", "DISEASE", 260, 269], ["pneumonia", "DISEASE", 279, 288], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 79, 86], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 134, 142], ["lung", "ORGAN", 222, 226], ["lung", "ORGAN", 235, 239], ["DiscussionRIG-I", "GENE_OR_GENE_PRODUCT", 303, 318], ["RIG-I", "GENE_OR_GENE_PRODUCT", 406, 411], ["5\u2032pppRNA", "PROTEIN", 134, 142], ["RIG", "PROTEIN", 406, 409], ["influenza", "PROBLEM", 9, 18], ["pneumonia", "PROBLEM", 28, 37], ["influenza challenge", "TREATMENT", 94, 113], ["5\u2032pppRNA", "TREATMENT", 134, 142], ["an antiviral effect", "TREATMENT", 153, 172], ["influenza replication in the lung", "PROBLEM", 193, 226], ["lung damage", "PROBLEM", 235, 246], ["influenza", "PROBLEM", 260, 269], ["pneumonia", "PROBLEM", 279, 288], ["antiviral agents", "TREATMENT", 353, 369], ["immune recognition", "PROBLEM", 449, 467], ["viral pathogens", "PROBLEM", 484, 499], ["influenza", "OBSERVATION", 9, 18], ["pneumonia", "OBSERVATION", 28, 37], ["antiviral effect", "OBSERVATION", 156, 172], ["influenza replication", "OBSERVATION", 193, 214], ["lung", "ANATOMY", 222, 226], ["lung", "ANATOMY", 235, 239], ["damage", "OBSERVATION", 240, 246], ["influenza", "OBSERVATION", 260, 269], ["pneumonia", "OBSERVATION", 279, 288], ["viral pathogens", "OBSERVATION", 484, 499]]], ["In the present study, a short 5\u2032pppRNA agonist of RIG-I derived from the 5\u2032 and 3\u2032 UTRs of the VSV genome stimulated an antiviral response that protected human lung epithelial A549 cells or human PBMCs from challenge with several viruses, including DENV, Influenza, HIV, VSV, HCV and Vaccinia virus.", [["lung epithelial A549 cells", "ANATOMY", 160, 186], ["PBMCs", "ANATOMY", 196, 201], ["Influenza, HIV, VSV, HCV and Vaccinia virus", "DISEASE", 255, 298], ["RIG-I", "GENE_OR_GENE_PRODUCT", 50, 55], ["VSV", "ORGANISM", 95, 98], ["human", "ORGANISM", 154, 159], ["lung epithelial A549 cells", "CELL", 160, 186], ["human", "ORGANISM", 190, 195], ["PBMCs", "CELL", 196, 201], ["DENV", "ORGANISM", 249, 253], ["Influenza", "ORGANISM", 255, 264], ["HIV", "ORGANISM", 266, 269], ["VSV", "ORGANISM", 271, 274], ["HCV", "ORGANISM", 276, 279], ["Vaccinia virus", "ORGANISM", 284, 298], ["RIG-I", "PROTEIN", 50, 55], ["UTRs", "DNA", 83, 87], ["VSV genome", "DNA", 95, 105], ["human lung epithelial A549 cells", "CELL_LINE", 154, 186], ["human PBMCs", "CELL_TYPE", 190, 201], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 190, 195], ["Influenza", "SPECIES", 255, 264], ["HIV", "SPECIES", 266, 269], ["VSV", "SPECIES", 271, 274], ["Vaccinia virus", "SPECIES", 284, 298], ["VSV", "SPECIES", 95, 98], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 190, 195], ["DENV", "SPECIES", 249, 253], ["HIV", "SPECIES", 266, 269], ["VSV", "SPECIES", 271, 274], ["HCV", "SPECIES", 276, 279], ["Vaccinia virus", "SPECIES", 284, 298], ["the VSV genome", "PROBLEM", 91, 105], ["human lung epithelial A549 cells", "TREATMENT", 154, 186], ["human PBMCs", "TREATMENT", 190, 201], ["several viruses", "PROBLEM", 222, 237], ["DENV", "PROBLEM", 249, 253], ["Influenza", "PROBLEM", 255, 264], ["HIV", "PROBLEM", 266, 269], ["VSV", "PROBLEM", 271, 274], ["HCV", "PROBLEM", 276, 279], ["Vaccinia virus", "PROBLEM", 284, 298], ["VSV genome", "OBSERVATION", 95, 105], ["antiviral response", "OBSERVATION", 120, 138], ["lung", "ANATOMY", 160, 164], ["epithelial", "ANATOMY_MODIFIER", 165, 175], ["A549 cells", "OBSERVATION", 176, 186], ["viruses", "OBSERVATION", 230, 237], ["Vaccinia virus", "OBSERVATION", 284, 298]]], ["Intravenous administration of the 5\u2032pppRNA agonist in mice stimulated an antiviral state in vivo that protected animals from lethal influenza virus challenge and controlled influenza virus-mediated pneumonia.", [["Intravenous", "ANATOMY", 0, 11], ["influenza virus", "DISEASE", 132, 147], ["pneumonia", "DISEASE", 198, 207], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 34, 42], ["mice", "ORGANISM", 54, 58], ["lethal influenza virus", "ORGANISM", 125, 147], ["influenza virus", "ORGANISM", 173, 188], ["mice", "SPECIES", 54, 58], ["influenza virus", "SPECIES", 132, 147], ["influenza virus", "SPECIES", 173, 188], ["mice", "SPECIES", 54, 58], ["Intravenous administration", "TREATMENT", 0, 26], ["the 5\u2032pppRNA agonist", "TREATMENT", 30, 50], ["an antiviral state", "TREATMENT", 70, 88], ["lethal influenza virus challenge", "TREATMENT", 125, 157], ["controlled influenza virus-mediated pneumonia", "PROBLEM", 162, 207], ["pneumonia", "OBSERVATION", 198, 207]]], ["Analysis of the dynamics of the host transcriptome following 5\u2032pppRNA stimulation was characterized by antiviral and inflammation related gene expression patterns with transcriptional nodes of genes regulated by IRF, NF-\u03baB, and STAT families.", [["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 61, 69], ["IRF", "GENE_OR_GENE_PRODUCT", 212, 215], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 217, 222], ["STAT", "GENE_OR_GENE_PRODUCT", 228, 232], ["5\u2032pppRNA", "PROTEIN", 61, 69], ["IRF", "PROTEIN", 212, 215], ["NF-\u03baB", "PROTEIN", 217, 222], ["STAT families", "PROTEIN", 228, 241], ["5\u2032pppRNA stimulation", "TREATMENT", 61, 81], ["antiviral and inflammation", "PROBLEM", 103, 129], ["gene expression patterns", "PROBLEM", 138, 162], ["transcriptional nodes of genes", "PROBLEM", 168, 198], ["transcriptional nodes", "OBSERVATION", 168, 189]]], ["Virtually all of the genes activated by IFN\u03b1-2b were encompassed within the 5\u2032pppRNA transcriptome; bioinformatics analysis also identified distinct gene patterns and functional processes that were uniquely induced or inhibited by 5\u2032pppRNA.", [["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 40, 47], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 76, 84], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 231, 239], ["IFN\u03b1", "PROTEIN", 40, 44], ["5\u2032pppRNA", "DNA", 76, 84], ["5\u2032pppRNA", "PROTEIN", 231, 239], ["bioinformatics analysis", "TEST", 100, 123], ["distinct gene patterns and functional processes", "PROBLEM", 140, 187]]], ["Because of its potency both in vitro and in vivo, 5\u2032pppRNA represents a specific and powerful trigger of innate immunity and a novel approach to antiviral therapy.DiscussionFor the first time, an RNA-based agonist of RIG-I was shown to block the replication of multiple viruses; this broad-spectrum antiviral activity of 5\u2032pppRNA is attributable in part to a potent stimulation of the inflammatory and antiviral response driven by the early induction of IRF, NF-\u03baB, STAT, chemokines and pro-inflammatory cytokine genes.", [["5\u2032pppRNA", "CHEMICAL", 321, 329], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 50, 58], ["RIG-I", "GENE_OR_GENE_PRODUCT", 217, 222], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 321, 329], ["IRF", "GENE_OR_GENE_PRODUCT", 454, 457], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 459, 464], ["STAT", "GENE_OR_GENE_PRODUCT", 466, 470], ["5\u2032pppRNA", "PROTEIN", 50, 58], ["RIG-I", "PROTEIN", 217, 222], ["5\u2032pppRNA", "PROTEIN", 321, 329], ["IRF", "PROTEIN", 454, 457], ["NF-\u03baB", "PROTEIN", 459, 464], ["STAT", "PROTEIN", 466, 470], ["chemokines", "PROTEIN", 472, 482], ["pro-inflammatory cytokine genes", "DNA", 487, 518], ["5\u2032pppRNA", "TREATMENT", 50, 58], ["innate immunity", "TREATMENT", 105, 120], ["a novel approach", "TREATMENT", 125, 141], ["antiviral therapy", "TREATMENT", 145, 162], ["an RNA", "TEST", 193, 199], ["multiple viruses", "PROBLEM", 261, 277], ["this broad-spectrum antiviral activity of 5\u2032pppRNA", "TREATMENT", 279, 329], ["the inflammatory and antiviral response", "PROBLEM", 381, 420], ["IRF", "PROBLEM", 454, 457], ["NF", "TEST", 459, 461], ["pro-inflammatory cytokine genes", "TREATMENT", 487, 518], ["multiple", "OBSERVATION_MODIFIER", 261, 269], ["viruses", "OBSERVATION", 270, 277], ["antiviral activity", "OBSERVATION", 299, 317], ["inflammatory", "OBSERVATION", 385, 397], ["antiviral response", "OBSERVATION", 402, 420]]], ["In parallel, we also observed an inhibition of genes involved in TGF-\u03b2 signaling.", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["TGF-\u03b2", "PROTEIN", 65, 70]]], ["Because of the immunosuppressive nature of the TGF-\u03b2 pathway [42], inhibition of this transcriptional node could further potentiate immune activation in response to 5\u2032pppRNA agonist.", [["node", "ANATOMY", 102, 106], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 47, 52], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 165, 173], ["TGF-\u03b2", "PROTEIN", 47, 52], ["the TGF", "TEST", 43, 50], ["this transcriptional node", "PROBLEM", 81, 106], ["immune activation", "PROBLEM", 132, 149], ["5\u2032pppRNA agonist", "TREATMENT", 165, 181], ["node", "OBSERVATION", 102, 106]]], ["The emergence of apoptosis and ubiquitin signaling nodes at later times (24 h) suggests a role for cell death and ubiquitin-based signal modification in the antiviral response.Discussion5\u2032pppRNA stimulation of RIG-I triggered a complete IFN response.", [["cell", "ANATOMY", 99, 103], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 31, 40], ["cell", "CELL", 99, 103], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 114, 123], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 187, 194], ["RIG-I", "GENE_OR_GENE_PRODUCT", 210, 215], ["IFN", "GENE_OR_GENE_PRODUCT", 237, 240], ["ubiquitin", "PROTEIN", 114, 123], ["\u2032pppRNA", "PROTEIN", 187, 194], ["RIG-I", "PROTEIN", 210, 215], ["IFN", "PROTEIN", 237, 240], ["apoptosis and ubiquitin signaling nodes", "PROBLEM", 17, 56], ["cell death", "PROBLEM", 99, 109], ["ubiquitin-based signal modification", "PROBLEM", 114, 149], ["apoptosis", "OBSERVATION_MODIFIER", 17, 26], ["ubiquitin", "OBSERVATION_MODIFIER", 31, 40], ["signaling nodes", "OBSERVATION", 41, 56], ["antiviral response", "OBSERVATION", 157, 175]]], ["At 24 h post treatment, 5\u2032pppRNA induced the expression of 97% of the genes stimulated by IFN\u03b1-2b treatment and the magnitude of ISG induction by 5\u2032pppRNA was enhanced compared to IFN\u03b1-2b profile.", [["IFN\u03b1-2b", "CHEMICAL", 90, 97], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 24, 32], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 90, 97], ["ISG", "GENE_OR_GENE_PRODUCT", 129, 132], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 146, 154], ["\u03b1-2b", "GENE_OR_GENE_PRODUCT", 183, 187], ["5\u2032pppRNA", "PROTEIN", 24, 32], ["IFN", "PROTEIN", 90, 93], ["5\u2032pppRNA", "PROTEIN", 146, 154], ["IFN", "PROTEIN", 180, 183], ["\u03b1", "PROTEIN", 183, 184], ["treatment", "TREATMENT", 13, 22], ["5\u2032pppRNA", "TREATMENT", 24, 32], ["IFN\u03b1-2b treatment", "TREATMENT", 90, 107], ["ISG induction", "TREATMENT", 129, 142], ["IFN", "TEST", 180, 183]]], ["Among the ISGs, the tripartite motif containing (TRIM) proteins, the IFITM proteins, MX1 and viperin exemplify the range of ISGs induced by RIG-I and all have been implicated as inhibitors of HIV-1, Influenza, VSV, West Nile, Dengue, and HCV [43]\u2013[53].", [["Dengue", "DISEASE", 226, 232], ["TRIM", "GENE_OR_GENE_PRODUCT", 49, 53], ["IFITM", "GENE_OR_GENE_PRODUCT", 69, 74], ["MX1", "GENE_OR_GENE_PRODUCT", 85, 88], ["viperin", "GENE_OR_GENE_PRODUCT", 93, 100], ["RIG-I", "GENE_OR_GENE_PRODUCT", 140, 145], ["HIV-1", "ORGANISM", 192, 197], ["Influenza", "ORGANISM", 199, 208], ["VSV", "ORGANISM", 210, 213], ["West Nile", "ORGANISM", 215, 224], ["Dengue", "ORGANISM", 226, 232], ["HCV", "ORGANISM", 238, 241], ["ISGs", "DNA", 10, 14], ["tripartite motif containing (TRIM) proteins", "PROTEIN", 20, 63], ["IFITM proteins", "PROTEIN", 69, 83], ["MX1", "PROTEIN", 85, 88], ["viperin", "PROTEIN", 93, 100], ["ISGs", "PROTEIN", 124, 128], ["RIG-I", "PROTEIN", 140, 145], ["HIV-1", "SPECIES", 192, 197], ["Influenza", "SPECIES", 199, 208], ["VSV", "SPECIES", 210, 213], ["HIV-1", "SPECIES", 192, 197], ["VSV", "SPECIES", 210, 213], ["West Nile", "SPECIES", 215, 224], ["HCV", "SPECIES", 238, 241], ["the IFITM proteins", "TEST", 65, 83], ["viperin", "TREATMENT", 93, 100], ["HIV", "TEST", 192, 195], ["Influenza", "PROBLEM", 199, 208]]], ["In a recent study, high throughput screening of antiviral effectors identified a panel of broadly acting antiviral molecules, with the combined expression of multiple ISGs providing additive inhibitory effects against HCV replication [29].", [["HCV", "ORGANISM", 218, 221], ["antiviral effectors", "PROTEIN", 48, 67], ["antiviral molecules", "PROTEIN", 105, 124], ["ISGs", "DNA", 167, 171], ["HCV", "SPECIES", 218, 221], ["a recent study", "TEST", 3, 17], ["antiviral effectors", "TREATMENT", 48, 67], ["a panel", "TEST", 79, 86], ["broadly acting antiviral molecules", "PROBLEM", 90, 124], ["multiple ISGs", "TREATMENT", 158, 171], ["additive inhibitory effects", "TREATMENT", 182, 209], ["HCV replication", "TREATMENT", 218, 233]]], ["Of the 28 validated antiviral ISGs identified, 19 were induced by 5\u2032pppRNA in A549, including IRF1, RIG-I, Mda5, IFITM3.DiscussionThe transcriptome analysis also identified a distinct subset of 968 genes specifically induced by 5\u2032pppRNA - and not IFN\u03b1-2b - that additively or synergistically enhanced the antiviral response stimulated by 5\u2032pppRNA treatment.", [["A549", "ANATOMY", 78, 82], ["5\u2032pppRNA", "CHEMICAL", 338, 346], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 66, 74], ["A549", "CELL", 78, 82], ["IRF1", "GENE_OR_GENE_PRODUCT", 94, 98], ["RIG-I", "GENE_OR_GENE_PRODUCT", 100, 105], ["Mda5", "GENE_OR_GENE_PRODUCT", 107, 111], ["IFITM3", "GENE_OR_GENE_PRODUCT", 113, 119], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 228, 236], ["\u03b1-2b", "GENE_OR_GENE_PRODUCT", 250, 254], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 338, 346], ["antiviral ISGs", "DNA", 20, 34], ["5\u2032pppRNA", "PROTEIN", 66, 74], ["A549", "CELL_LINE", 78, 82], ["IRF1", "PROTEIN", 94, 98], ["RIG", "PROTEIN", 100, 103], ["Mda5", "DNA", 107, 111], ["IFITM3", "DNA", 113, 119], ["968 genes", "DNA", 194, 203], ["5\u2032pppRNA", "PROTEIN", 228, 236], ["IFN", "PROTEIN", 247, 250], ["5\u2032pppRNA", "PROTEIN", 338, 346], ["antiviral ISGs", "TEST", 20, 34], ["IRF1", "TEST", 94, 98], ["The transcriptome analysis", "TEST", 130, 156], ["5\u2032pppRNA", "TEST", 228, 236], ["IFN", "TEST", 247, 250], ["5\u2032pppRNA treatment", "TREATMENT", 338, 356], ["Mda5", "ANATOMY", 107, 111], ["antiviral response", "OBSERVATION", 305, 323]]], ["Bioinformatics analysis identified a unique functional signature with up-regulated genes involved in inducing a wider range of signaling pathways and bridging innate and adaptive immune responses.", [["Bioinformatics analysis", "TEST", 0, 23]]], ["The importance of genes uniquely induced by 5\u2032pppRNA is highlighted by the antiviral response that limited influenza infection in vitro and in vivo, even in the absence of functional type I IFN signaling.", [["influenza infection", "DISEASE", 107, 126], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 44, 52], ["type I IFN", "GENE_OR_GENE_PRODUCT", 183, 193], ["5\u2032pppRNA", "PROTEIN", 44, 52], ["IFN", "PROTEIN", 190, 193], ["limited influenza infection", "PROBLEM", 99, 126]]], ["We speculate that the extended range of genes induced by 5\u2032pppRNA, compared to IFN\u03b1-2b, reflect the activation of multiple signaling pathways downstream of RIG-I/MAVS [10], versus the more-limited transactivation potential of the IFN-regulated JAK-STAT axis [26].DiscussionType III IFNs (IL29, IL28A, IL28B) were among the most highly stimulated genes uniquely up-regulated in response to 5\u2032pppRNA.", [["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 57, 65], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 79, 86], ["RIG-I", "GENE_OR_GENE_PRODUCT", 156, 161], ["MAVS", "GENE_OR_GENE_PRODUCT", 162, 166], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 244, 252], ["DiscussionType III IFNs", "GENE_OR_GENE_PRODUCT", 263, 286], ["IL29", "GENE_OR_GENE_PRODUCT", 288, 292], ["IL28A", "GENE_OR_GENE_PRODUCT", 294, 299], ["IL28B", "GENE_OR_GENE_PRODUCT", 301, 306], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 389, 397], ["5\u2032pppRNA", "PROTEIN", 57, 65], ["IFN\u03b1", "PROTEIN", 79, 83], ["RIG-I", "PROTEIN", 156, 161], ["MAVS", "PROTEIN", 162, 166], ["IFN", "PROTEIN", 230, 233], ["JAK", "PROTEIN", 244, 247], ["STAT", "PROTEIN", 248, 252], ["DiscussionType III IFNs", "PROTEIN", 263, 286], ["IL29", "PROTEIN", 288, 292], ["IL28A", "PROTEIN", 294, 299], ["IL28B", "DNA", 301, 306], ["5\u2032pppRNA", "DNA", 389, 397], ["the IFN", "TEST", 226, 233], ["DiscussionType III IFNs (IL29, IL28A, IL28B)", "TREATMENT", 263, 307], ["5\u2032pppRNA", "TREATMENT", 389, 397]]], ["Recent studies have demonstrated that both type I and type III IFNs activate similar components of the JAK-STAT pathways, although type III IFNs were shown to prolong the activation of JAK-STAT signaling and induce a delayed and stronger induction of ISGs, compared to type I IFNs [54].", [["type I", "GENE_OR_GENE_PRODUCT", 43, 49], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 54, 67], ["JAK", "GENE_OR_GENE_PRODUCT", 103, 106], ["STAT", "GENE_OR_GENE_PRODUCT", 107, 111], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 131, 144], ["JAK", "GENE_OR_GENE_PRODUCT", 185, 188], ["STAT", "GENE_OR_GENE_PRODUCT", 189, 193], ["type I and type III IFNs", "PROTEIN", 43, 67], ["JAK", "PROTEIN", 103, 106], ["STAT", "PROTEIN", 107, 111], ["type III IFNs", "PROTEIN", 131, 144], ["JAK", "PROTEIN", 185, 188], ["STAT", "PROTEIN", 189, 193], ["ISGs", "PROTEIN", 251, 255], ["type I IFNs", "PROTEIN", 269, 280], ["Recent studies", "TEST", 0, 14], ["type I and type III IFNs activate", "PROBLEM", 43, 76], ["the JAK", "TEST", 99, 106], ["type III IFNs", "PROBLEM", 131, 144], ["a delayed and stronger induction of ISGs", "PROBLEM", 215, 255]]], ["IFN\u03bbs have been increasingly implicated in antiviral therapies: 1) IFN\u03bb administration in mice stimulated expression of Mx1 and protected IFN\u03b1R\u2212/\u2212 mice from lethal influenza challenge [55]; 2) IL29 blocked HIV-1 replication by inhibiting virus integration and post-transcriptional events [56]; and 3) the combination of IL29 and IFN\u03b1 or IL29 and IFN\u03b3 enhanced the induction of antiviral genes and effectively inhibited HCV and VSV replication [57].", [["IFN", "CHEMICAL", 67, 70], ["influenza", "DISEASE", 164, 173], ["IFN\u03bbs", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN\u03bb", "SIMPLE_CHEMICAL", 67, 71], ["mice", "ORGANISM", 90, 94], ["Mx1", "GENE_OR_GENE_PRODUCT", 120, 123], ["R", "GENE_OR_GENE_PRODUCT", 142, 143], ["IL29", "GENE_OR_GENE_PRODUCT", 193, 197], ["HIV-1", "ORGANISM", 206, 211], ["IL29", "GENE_OR_GENE_PRODUCT", 320, 324], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 329, 333], ["IL29", "GENE_OR_GENE_PRODUCT", 337, 341], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 346, 350], ["HCV", "ORGANISM", 419, 422], ["VSV", "ORGANISM", 427, 430], ["IFN\u03bbs", "PROTEIN", 0, 5], ["IFN\u03bb", "PROTEIN", 67, 71], ["Mx1", "PROTEIN", 120, 123], ["IFN", "PROTEIN", 138, 141], ["IL29", "PROTEIN", 320, 324], ["IFN\u03b1", "PROTEIN", 329, 333], ["IL29", "PROTEIN", 337, 341], ["IFN\u03b3", "PROTEIN", 346, 350], ["antiviral genes", "DNA", 377, 392], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 147, 151], ["HIV-1", "SPECIES", 206, 211], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 147, 151], ["HIV-1", "SPECIES", 206, 211], ["HCV", "SPECIES", 419, 422], ["VSV", "SPECIES", 427, 430], ["antiviral therapies", "TREATMENT", 43, 62], ["IFN\u03bb administration", "TREATMENT", 67, 86], ["lethal influenza challenge", "TREATMENT", 157, 183], ["IL29 blocked HIV", "TREATMENT", 193, 209], ["inhibiting virus integration", "PROBLEM", 227, 255], ["post-transcriptional events", "PROBLEM", 260, 287], ["IL29", "TREATMENT", 320, 324], ["IFN\u03b1", "TREATMENT", 329, 333], ["IL29", "TREATMENT", 337, 341], ["IFN", "TREATMENT", 346, 349], ["antiviral genes", "TREATMENT", 377, 392], ["effectively inhibited HCV", "PROBLEM", 397, 422], ["VSV replication", "TREATMENT", 427, 442]]], ["In addition, polymorphism in or near IFN\u03bb3 gene correlated with spontaneous or treatment-induced clearance of Hepatitis C infection and IFN\u03bb therapy is now actively investigated for the treatment of HCV [58].", [["Hepatitis C infection", "DISEASE", 110, 131], ["IFN", "CHEMICAL", 136, 139], ["HCV", "DISEASE", 199, 202], ["IFN\u03bb3", "GENE_OR_GENE_PRODUCT", 37, 42], ["Hepatitis C", "ORGANISM", 110, 121], ["IFN\u03bb", "GENE_OR_GENE_PRODUCT", 136, 140], ["HCV", "ORGANISM", 199, 202], ["IFN\u03bb3 gene", "DNA", 37, 47], ["IFN", "PROTEIN", 136, 139], ["Hepatitis C", "SPECIES", 110, 121], ["HCV", "SPECIES", 199, 202], ["polymorphism", "PROBLEM", 13, 25], ["treatment", "TREATMENT", 79, 88], ["Hepatitis C infection", "PROBLEM", 110, 131], ["IFN\u03bb therapy", "TREATMENT", 136, 148], ["HCV", "PROBLEM", 199, 202], ["Hepatitis", "OBSERVATION", 110, 119]]], ["Altogether these results indicate that specific induction of IFN\u03bb by 5\u2032pppRNA may contribute to immunity at the site of viral infection.DiscussionOf note, negative regulators of the innate immune response were also detected after 5\u2032pppRNA stimulation.", [["viral infection", "DISEASE", 120, 135], ["IFN\u03bb", "GENE_OR_GENE_PRODUCT", 61, 65], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 69, 77], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 230, 238], ["IFN\u03bb", "PROTEIN", 61, 65], ["5\u2032pppRNA", "PROTEIN", 69, 77], ["5\u2032pppRNA", "PROTEIN", 230, 238], ["IFN\u03bb", "TREATMENT", 61, 65], ["5\u2032pppRNA", "TREATMENT", 69, 77], ["viral infection", "PROBLEM", 120, 135], ["5\u2032pppRNA stimulation", "TREATMENT", 230, 250], ["viral", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["In addition to the induction of SOCS1, USP18, and IFIT1 by both 5\u2032pppRNA and IFN\u03b1-2b treatment, unique negative regulators activated exclusively by 5\u2032pppRNA were also identified: SOCS3 contributes to the inhibition of the JAK/STAT signaling [59], and hence limits the amplification of the IFN response; A20 and I\u03baB\u03b1 inhibit the activation of the NF\u03baB signaling complex [60], [61], which would prevent excessive inflammation.", [["inflammation", "DISEASE", 411, 423], ["SOCS1", "GENE_OR_GENE_PRODUCT", 32, 37], ["USP18", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFIT1", "GENE_OR_GENE_PRODUCT", 50, 55], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 65, 72], ["IFN\u03b1-2b", "GENE_OR_GENE_PRODUCT", 77, 84], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 148, 156], ["SOCS3", "GENE_OR_GENE_PRODUCT", 179, 184], ["JAK", "GENE_OR_GENE_PRODUCT", 222, 225], ["STAT", "GENE_OR_GENE_PRODUCT", 226, 230], ["IFN", "GENE_OR_GENE_PRODUCT", 289, 292], ["A20", "GENE_OR_GENE_PRODUCT", 303, 306], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 311, 315], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 346, 350], ["[61]", "SIMPLE_CHEMICAL", 375, 379], ["SOCS1", "PROTEIN", 32, 37], ["USP18", "PROTEIN", 39, 44], ["IFIT1", "PROTEIN", 50, 55], ["IFN", "PROTEIN", 77, 80], ["\u03b1", "PROTEIN", 80, 81], ["5\u2032pppRNA", "PROTEIN", 148, 156], ["SOCS3", "PROTEIN", 179, 184], ["JAK", "PROTEIN", 222, 225], ["STAT", "PROTEIN", 226, 230], ["IFN", "PROTEIN", 289, 292], ["A20", "PROTEIN", 303, 306], ["I\u03baB\u03b1", "PROTEIN", 311, 315], ["NF\u03baB signaling complex", "PROTEIN", 346, 368], ["SOCS1", "TEST", 32, 37], ["USP18", "TEST", 39, 44], ["IFIT1", "TEST", 50, 55], ["\u2032pppRNA", "TEST", 65, 72], ["IFN", "TEST", 77, 80], ["2b treatment", "TREATMENT", 82, 94], ["the IFN response", "PROBLEM", 285, 301], ["A20", "TREATMENT", 303, 306], ["excessive inflammation", "PROBLEM", 401, 423], ["excessive", "OBSERVATION_MODIFIER", 401, 410], ["inflammation", "OBSERVATION", 411, 423]]], ["This observation suggests that targeting an upstream viral sensor may provide activation as well as negative feed-back regulation to terminate the immune response and prevent uncontrolled inflammation; as such, this approach may offer an advantage over IFN therapy in terms of limiting potential toxic side-effects.DiscussionActivation of the RIG-I signaling pathway using 5\u2032pppRNA also induced an integrated set of genes and pathways that can efficiently bridge the innate and adaptive immune responses and utilize multiple arms of both systems.", [["inflammation", "DISEASE", 188, 200], ["IFN", "CHEMICAL", 253, 256], ["RIG-I", "GENE_OR_GENE_PRODUCT", 343, 348], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 373, 381], ["IFN", "PROTEIN", 253, 256], ["RIG", "PROTEIN", 343, 346], ["5\u2032pppRNA", "DNA", 373, 381], ["This observation", "TEST", 0, 16], ["an upstream viral sensor", "PROBLEM", 41, 65], ["uncontrolled inflammation", "PROBLEM", 175, 200], ["an advantage over IFN therapy", "TREATMENT", 235, 264], ["5\u2032pppRNA", "TREATMENT", 373, 381], ["multiple arms of both systems", "TREATMENT", 516, 545], ["uncontrolled", "OBSERVATION_MODIFIER", 175, 187], ["inflammation", "OBSERVATION", 188, 200]]], ["5\u2032pppRNA mobilized genes that enhance trafficking of immune cells such as neutrophils, monocytes, na\u00efve and memory T cells and B cells, including CCL17, CCL20, CXCL10, CCL3, CCL5 and many others.", [["immune cells", "ANATOMY", 53, 65], ["neutrophils", "ANATOMY", 74, 85], ["monocytes", "ANATOMY", 87, 96], ["na\u00efve", "ANATOMY", 98, 103], ["memory T cells", "ANATOMY", 108, 122], ["B cells", "ANATOMY", 127, 134], ["\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 1, 8], ["immune cells", "CELL", 53, 65], ["neutrophils", "CELL", 74, 85], ["monocytes", "CELL", 87, 96], ["na\u00efve", "CELL", 98, 103], ["memory T cells", "CELL", 108, 122], ["B cells", "CELL", 127, 134], ["CCL17", "GENE_OR_GENE_PRODUCT", 146, 151], ["CCL20", "GENE_OR_GENE_PRODUCT", 153, 158], ["CXCL10", "GENE_OR_GENE_PRODUCT", 160, 166], ["CCL3", "GENE_OR_GENE_PRODUCT", 168, 172], ["CCL5", "GENE_OR_GENE_PRODUCT", 174, 178], ["\u2032pppRNA mobilized genes", "DNA", 1, 24], ["immune cells", "CELL_TYPE", 53, 65], ["neutrophils", "CELL_TYPE", 74, 85], ["monocytes", "CELL_TYPE", 87, 96], ["na\u00efve and memory T cells", "CELL_TYPE", 98, 122], ["B cells", "CELL_TYPE", 127, 134], ["CCL17", "PROTEIN", 146, 151], ["CCL20", "PROTEIN", 153, 158], ["CXCL10", "PROTEIN", 160, 166], ["CCL3", "PROTEIN", 168, 172], ["CCL5", "PROTEIN", 174, 178], ["immune cells", "PROBLEM", 53, 65], ["neutrophils", "TEST", 74, 85], ["monocytes", "TEST", 87, 96], ["na\u00efve", "TEST", 98, 103], ["memory T cells", "TEST", 108, 122], ["B cells", "TEST", 127, 134], ["CCL17", "TEST", 146, 151], ["CCL20", "TEST", 153, 158], ["CXCL10", "TEST", 160, 166], ["CCL3", "TEST", 168, 172], ["CCL5", "TEST", 174, 178], ["immune cells", "OBSERVATION", 53, 65], ["CCL17", "ANATOMY", 146, 151]]], ["We also observed the induction of genes important for the activation of the effector arm of the adaptive immune system such as IL-6, which has been shown to enhance CD8+ T cell survival and killing potential [62].", [["immune system", "ANATOMY", 105, 118], ["CD8+ T cell", "ANATOMY", 165, 176], ["IL-6", "GENE_OR_GENE_PRODUCT", 127, 131], ["CD8", "GENE_OR_GENE_PRODUCT", 165, 168], ["IL-6", "PROTEIN", 127, 131], ["CD8", "PROTEIN", 165, 168]]], ["These cytokines and chemokines certainly play a role in initiating the innate and adaptive immune cell response, which is critical for the generation of efficient immunity against multiple viral infections in vivo.DiscussionIntravenous administration of the RIG-I agonist stimulated a potent immune response in vivo that reached the lungs and prevented mortality associated with virus challenge.", [["immune cell", "ANATOMY", 91, 102], ["lungs", "ANATOMY", 333, 338], ["viral infections", "DISEASE", 189, 205], ["immune cell", "CELL", 91, 102], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 224, 235], ["RIG-I", "GENE_OR_GENE_PRODUCT", 258, 263], ["lungs", "ORGAN", 333, 338], ["cytokines", "PROTEIN", 6, 15], ["chemokines", "PROTEIN", 20, 30], ["chemokines", "TREATMENT", 20, 30], ["the innate and adaptive immune cell response", "TREATMENT", 67, 111], ["multiple viral infections in vivo", "PROBLEM", 180, 213], ["the RIG-I agonist", "TREATMENT", 254, 271], ["virus challenge", "TREATMENT", 379, 394], ["viral", "OBSERVATION_MODIFIER", 189, 194], ["infections", "OBSERVATION", 195, 205], ["lungs", "ANATOMY", 333, 338]]], ["Histopathology analysis revealed diminished influenza-mediated lung damage and recruitment of inflammatory cells in infected lungs following 5\u2032pppRNA treatment.", [["lung", "ANATOMY", 63, 67], ["inflammatory cells", "ANATOMY", 94, 112], ["lungs", "ANATOMY", 125, 130], ["lung damage", "DISEASE", 63, 74], ["5\u2032pppRNA", "CHEMICAL", 141, 149], ["5\u2032pppRNA", "CHEMICAL", 141, 149], ["lung", "ORGAN", 63, 67], ["inflammatory cells", "CELL", 94, 112], ["lungs", "ORGAN", 125, 130], ["5\u2032pppRNA", "SIMPLE_CHEMICAL", 141, 149], ["inflammatory cells", "CELL_TYPE", 94, 112], ["Histopathology analysis", "TEST", 0, 23], ["diminished influenza", "PROBLEM", 33, 53], ["mediated lung damage", "PROBLEM", 54, 74], ["inflammatory cells", "PROBLEM", 94, 112], ["infected lungs", "PROBLEM", 116, 130], ["5\u2032pppRNA treatment", "TREATMENT", 141, 159], ["diminished", "OBSERVATION_MODIFIER", 33, 43], ["influenza", "OBSERVATION", 44, 53], ["lung", "ANATOMY", 63, 67], ["damage", "OBSERVATION", 68, 74], ["recruitment", "OBSERVATION_MODIFIER", 79, 90], ["inflammatory cells", "OBSERVATION", 94, 112], ["infected", "OBSERVATION_MODIFIER", 116, 124], ["lungs", "ANATOMY", 125, 130]]], ["The rapid control of virus replication, as demonstrated by significantly reduced virus titers in the lungs within 3 days of virus inoculation, may have prevented excessive immune cell recruitment early after infection.", [["lungs", "ANATOMY", 101, 106], ["immune cell", "ANATOMY", 172, 183], ["infection", "DISEASE", 208, 217], ["lungs", "ORGAN", 101, 106], ["immune cell", "CELL", 172, 183], ["virus replication", "TREATMENT", 21, 38], ["significantly reduced virus titers in the lungs", "PROBLEM", 59, 106], ["virus inoculation", "PROBLEM", 124, 141], ["excessive immune cell recruitment", "TREATMENT", 162, 195], ["infection", "PROBLEM", 208, 217], ["virus replication", "OBSERVATION", 21, 38], ["reduced", "OBSERVATION_MODIFIER", 73, 80], ["virus titers", "OBSERVATION", 81, 93], ["lungs", "ANATOMY", 101, 106], ["excessive", "OBSERVATION_MODIFIER", 162, 171], ["immune cell recruitment", "OBSERVATION", 172, 195], ["infection", "OBSERVATION", 208, 217]]], ["Influenza infection generates a complex pathogenesis mediated in part by viral- and immune-mediated damage [63]; therefore, the activation and recruitment of limited numbers of specific immune cell types, such as neutrophils, alveolar macrophages and dendritic cells may generate a beneficial antiviral microenvironment that additionally favor the initiation of adaptive immune response, which would eventually contribute to the in vivo efficacy of the agonist.DiscussionOther groups have recently reported that 5\u2032pppRNA induces a protective RIG-I mediated antiviral response that inhibits the replication of influenza virus [64]\u2013[66].", [["immune cell", "ANATOMY", 186, 197], ["neutrophils", "ANATOMY", 213, 224], ["alveolar macrophages", "ANATOMY", 226, 246], ["dendritic cells", "ANATOMY", 251, 266], ["Influenza infection", "DISEASE", 0, 19], ["5\u2032pppRNA", "CHEMICAL", 512, 520], ["immune cell", "CELL", 186, 197], ["neutrophils", "CELL", 213, 224], ["alveolar macrophages", "CELL", 226, 246], ["dendritic cells", "CELL", 251, 266], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 512, 520], ["RIG-I", "GENE_OR_GENE_PRODUCT", 542, 547], ["influenza virus", "ORGANISM", 609, 624], ["immune cell types", "CELL_TYPE", 186, 203], ["neutrophils", "CELL_TYPE", 213, 224], ["alveolar macrophages", "CELL_TYPE", 226, 246], ["dendritic cells", "CELL_TYPE", 251, 266], ["5\u2032pppRNA", "PROTEIN", 512, 520], ["RIG-I", "PROTEIN", 542, 547], ["influenza virus", "SPECIES", 609, 624], ["Influenza infection", "PROBLEM", 0, 19], ["a complex pathogenesis", "PROBLEM", 30, 52], ["viral", "TEST", 73, 78], ["immune-mediated damage", "PROBLEM", 84, 106], ["specific immune cell types", "PROBLEM", 177, 203], ["neutrophils", "TEST", 213, 224], ["alveolar macrophages", "PROBLEM", 226, 246], ["dendritic cells", "PROBLEM", 251, 266], ["a beneficial antiviral microenvironment", "TREATMENT", 280, 319], ["the agonist", "TREATMENT", 449, 460], ["a protective RIG-I mediated antiviral response", "TREATMENT", 529, 575], ["influenza virus", "PROBLEM", 609, 624], ["infection", "OBSERVATION", 10, 19], ["immune cell types", "OBSERVATION", 186, 203], ["alveolar macrophages", "OBSERVATION", 226, 246], ["dendritic cells", "OBSERVATION", 251, 266]]], ["The inhibition of influenza infection by 5\u2032pppRNA was dependent on the 5\u2032ppp moiety and the secondary IFN response was crucial for mounting an effective antiviral response [64], [65].", [["influenza infection", "DISEASE", 18, 37], ["5\u2032pppRNA", "CHEMICAL", 41, 49], ["influenza", "ORGANISM", 18, 27], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 41, 49], ["5\u2032ppp", "GENE_OR_GENE_PRODUCT", 71, 76], ["5\u2032pppRNA", "PROTEIN", 41, 49], ["5\u2032ppp moiety", "PROTEIN", 71, 83], ["IFN", "PROTEIN", 102, 105], ["influenza infection", "PROBLEM", 18, 37], ["5\u2032pppRNA", "TREATMENT", 41, 49], ["the 5\u2032ppp moiety", "TREATMENT", 67, 83], ["the secondary IFN response", "TREATMENT", 88, 114], ["influenza", "OBSERVATION_MODIFIER", 18, 27], ["infection", "OBSERVATION", 28, 37]]], ["Recently, a short RNA molecule with dual functionality was developed - a siRNA against influenza NP gene and an agonist of the RIG-I pathway [66].", [["influenza NP", "ORGANISM", 87, 99], ["RIG-I", "GENE_OR_GENE_PRODUCT", 127, 132], ["influenza NP gene", "DNA", 87, 104], ["RIG", "PROTEIN", 127, 130], ["a short RNA molecule", "PROBLEM", 10, 30], ["a siRNA", "TREATMENT", 71, 78], ["influenza NP gene", "TREATMENT", 87, 104]]], ["This 5\u2032pppRNA inhibited influenza infection in vitro and in vivo, but the contribution of RIG-I activation to the inhibition of influenza was not demonstrated.", [["5\u2032pppRNA", "CHEMICAL", 5, 13], ["influenza infection", "DISEASE", 24, 43], ["influenza", "DISEASE", 128, 137], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 5, 13], ["RIG-I", "GENE_OR_GENE_PRODUCT", 90, 95], ["5\u2032pppRNA", "PROTEIN", 5, 13], ["RIG-I", "PROTEIN", 90, 95], ["influenza infection", "PROBLEM", 24, 43], ["RIG-I activation", "PROBLEM", 90, 106], ["influenza", "PROBLEM", 128, 137], ["influenza", "OBSERVATION_MODIFIER", 24, 33], ["infection", "OBSERVATION", 34, 43], ["influenza", "OBSERVATION", 128, 137]]], ["The defective interfering RNA produced during Sendai virus life cycle is the best characterized natural RIG-I ligand and is known to induce strong inflammatory response [67].", [["Sendai virus", "ORGANISM", 46, 58], ["RIG-I ligand", "GENE_OR_GENE_PRODUCT", 104, 116], ["RIG-I ligand", "PROTEIN", 104, 116], ["Sendai virus", "SPECIES", 46, 58], ["Sendai virus", "SPECIES", 46, 58], ["The defective interfering RNA", "PROBLEM", 0, 29], ["Sendai virus life cycle", "TREATMENT", 46, 69], ["defective", "OBSERVATION_MODIFIER", 4, 13], ["interfering RNA", "OBSERVATION", 14, 29]]], ["Interestingly, this molecule has adjuvant potential and could stimulate an antibody-dependent response directed to influenza antigens.", [["influenza antigens", "PROTEIN", 115, 133], ["an antibody", "TEST", 72, 83], ["influenza antigens", "PROBLEM", 115, 133]]], ["Compared to these earlier studies, we adopted a systems approach to provide biochemical, transcriptional and biological mechanistic explanations for the antiviral efficacy observed in vitro and in vivo.DiscussionActivating natural host defense to prevent establishment and dissemination of viral infection is a valuable alternative strategy to antiviral drugs that specifically target viral processes.", [["viral infection", "DISEASE", 290, 305], ["these earlier studies", "TEST", 12, 33], ["the antiviral efficacy", "TREATMENT", 149, 171], ["viral infection", "PROBLEM", 290, 305], ["antiviral drugs", "TREATMENT", 344, 359], ["viral", "OBSERVATION_MODIFIER", 290, 295], ["infection", "OBSERVATION", 296, 305]]], ["Interferon therapy has been used in the clinic for over two decades and has proven effective in the treatment of certain viral infections, mainly Hepatitis B and Hepatitis C [58], as well as malignancies and autoimmune diseases [68], [69].", [["malignancies", "ANATOMY", 191, 203], ["Interferon", "CHEMICAL", 0, 10], ["viral infections", "DISEASE", 121, 137], ["Hepatitis B", "DISEASE", 146, 157], ["Hepatitis C", "DISEASE", 162, 173], ["malignancies", "DISEASE", 191, 203], ["autoimmune diseases", "DISEASE", 208, 227], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["Hepatitis B", "ORGANISM", 146, 157], ["Hepatitis C", "ORGANISM", 162, 173], ["malignancies", "CANCER", 191, 203], ["Hepatitis B", "SPECIES", 146, 157], ["Interferon therapy", "TREATMENT", 0, 18], ["certain viral infections", "PROBLEM", 113, 137], ["Hepatitis B", "PROBLEM", 146, 157], ["Hepatitis C", "PROBLEM", 162, 173], ["malignancies", "PROBLEM", 191, 203], ["autoimmune diseases", "PROBLEM", 208, 227], ["viral infections", "OBSERVATION", 121, 137], ["malignancies", "OBSERVATION", 191, 203]]], ["However, IFN therapy is also associated with significant side effects that limit its use [70].", [["IFN", "CHEMICAL", 9, 12], ["IFN", "PROTEIN", 9, 12], ["IFN therapy", "TREATMENT", 9, 20], ["significant side effects", "PROBLEM", 45, 69]]], ["PolyI:C, another dsRNA immune modulator, is also being tested in vitro and in vivo and has demonstrated efficacy against respiratory infections [71]\u2013[73].", [["respiratory", "ANATOMY", 121, 132], ["PolyI:C", "CHEMICAL", 0, 7], ["respiratory infections", "DISEASE", 121, 143], ["PolyI:C", "CHEMICAL", 0, 7], ["PolyI:C", "SIMPLE_CHEMICAL", 0, 7], ["PolyI:C", "PROTEIN", 0, 7], ["another dsRNA immune modulator", "TREATMENT", 9, 39], ["respiratory infections", "PROBLEM", 121, 143]]], ["Along with antiviral drugs, vaccination is the primary approach to reduce morbidity and mortality associated with viral infection.", [["viral infection", "DISEASE", 114, 129], ["antiviral drugs", "TREATMENT", 11, 26], ["vaccination", "TREATMENT", 28, 39], ["morbidity", "PROBLEM", 74, 83], ["viral infection", "PROBLEM", 114, 129], ["antiviral drugs", "OBSERVATION", 11, 26], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infection", "OBSERVATION", 120, 129]]], ["Increasing the immunogenicity of vaccines with molecular adjuvants eliciting cytokines, co-stimulatory molecules, or immunomodulatory factors enhance the vaccine-elicited immune responses.", [["cytokines", "PROTEIN", 77, 86], ["co-stimulatory molecules", "PROTEIN", 88, 112], ["immunomodulatory factors", "PROTEIN", 117, 141], ["vaccines", "TREATMENT", 33, 41], ["molecular adjuvants", "TREATMENT", 47, 66], ["co-stimulatory molecules", "PROBLEM", 88, 112], ["immunomodulatory factors", "PROBLEM", 117, 141], ["the vaccine", "TREATMENT", 150, 161]]], ["5\u2032pppRNA has the advantage of mimicking viral recognition to trigger an immune response analogous to natural viral infection.", [["5\u2032pppRNA", "CHEMICAL", 0, 8], ["viral infection", "DISEASE", 109, 124], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 0, 8], ["5\u2032pppRNA", "PROTEIN", 0, 8], ["5\u2032pppRNA", "TREATMENT", 0, 8], ["mimicking viral recognition", "PROBLEM", 30, 57], ["natural viral infection", "PROBLEM", 101, 124], ["viral infection", "OBSERVATION", 109, 124]]], ["Furthermore, the response stimulated by 5\u2032pppRNA was reminiscent of the integrated and multipotent response elicited early following immunization by the most protective vaccine identified so far, the yellow fever YD17 vaccine [74].", [["fever", "DISEASE", 207, 212], ["5\u2032pppRNA", "GENE_OR_GENE_PRODUCT", 40, 48], ["yellow fever YD17", "ORGANISM", 200, 217], ["5\u2032pppRNA", "PROTEIN", 40, 48], ["yellow fever YD17", "SPECIES", 200, 217], ["immunization", "TREATMENT", 133, 145], ["the most protective vaccine", "TREATMENT", 149, 176], ["the yellow fever YD17 vaccine", "TREATMENT", 196, 225]]], ["Therefore, an immune modulator such as a RIG-I agonist may not only function as an antiviral therapeutic, but may also serve as a vaccine adjuvant to increase the magnitude of the antiviral immune response elicited by vaccine epitopes.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 41, 46], ["vaccine epitopes", "PROTEIN", 218, 234], ["an immune modulator", "TREATMENT", 11, 30], ["a RIG-I agonist", "TREATMENT", 39, 54], ["a vaccine adjuvant", "TREATMENT", 128, 146], ["the antiviral immune response", "TREATMENT", 176, 205], ["vaccine epitopes", "TREATMENT", 218, 234]]], ["Thus, the present study not only demonstrated the prophylactic and therapeutic antiviral potential of 5\u2032pppRNA, but also opens the door to further investigation of the potential of RIG-I agonists as vaccine adjuvants.", [["5\u2032pppRNA", "SIMPLE_CHEMICAL", 102, 110], ["RIG-I", "GENE_OR_GENE_PRODUCT", 181, 186], ["5\u2032pppRNA", "PROTEIN", 102, 110], ["the present study", "TEST", 6, 23], ["the prophylactic", "TREATMENT", 46, 62], ["5\u2032pppRNA", "TREATMENT", 102, 110], ["RIG-I agonists", "TREATMENT", 181, 195], ["vaccine adjuvants", "TREATMENT", 199, 216]]]], "0efe71778fe4c67c5fc96fc8e5f006688fdf6b34": [["The recent emergence and rapid spread of COVID-19 in Wuhan, China pose an ongoing global challenge.", [["COVID-19", "CHEMICAL", 41, 49], ["COVID", "TEST", 41, 46], ["an ongoing global challenge", "TREATMENT", 71, 98], ["rapid", "OBSERVATION_MODIFIER", 25, 30], ["spread", "OBSERVATION_MODIFIER", 31, 37]]], ["An intriguing observation has been the near absence of children in initial disease reports, mild disease overall in child cases, no reported deaths in children aged <10 years of age and suggestions that minimally symptomatic children may facilitate disease transmission within communities.", [["deaths", "DISEASE", 141, 147], ["children", "ORGANISM", 55, 63], ["children", "ORGANISM", 151, 159], ["children", "ORGANISM", 225, 233], ["children", "SPECIES", 55, 63], ["children", "SPECIES", 151, 159], ["children", "SPECIES", 225, 233], ["mild disease", "PROBLEM", 92, 104], ["minimally symptomatic children", "PROBLEM", 203, 233], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["disease", "OBSERVATION", 97, 104]]], ["[1] [2] [3] [4] [5] [6] Li et al. report three child cases of confirmed COVID-19 infection 7 ; the report is notable for at least two reasons.", [["infection", "DISEASE", 81, 90], ["[1] [2] [3] [4] [5] [6] Li", "CHEMICAL", 0, 26], ["[1] [2] [3] [4] [5", "SIMPLE_CHEMICAL", 0, 18], ["COVID", "TEST", 72, 77], ["infection", "PROBLEM", 81, 90]]]], "PMC7436747": [["The pandemic of coronavirus disease 2019 (COVID\u201019), caused by the severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102), is a global public health emergency.", [["coronavirus disease", "DISEASE", 16, 35], ["acute respiratory syndrome coronavirus", "DISEASE", 74, 112], ["coronavirus", "ORGANISM", 16, 27], ["severe acute respiratory syndrome coronavirus", "SPECIES", 67, 112], ["SARS\u2010CoV", "SPECIES", 116, 124], ["coronavirus disease", "PROBLEM", 16, 35], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 63, 112], ["SARS\u2010CoV\u2010", "TEST", 116, 125], ["coronavirus disease", "OBSERVATION", 16, 35], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["respiratory syndrome", "OBSERVATION", 80, 100], ["global", "OBSERVATION_MODIFIER", 134, 140]]], ["Diagnostic testing is critical for detecting cases of COVID\u201019 and, ultimately, for reducing viral transmission.1, 2 However, the unprecedented surge in laboratory testing has placed extraordinary demands on health systems, causing global imbalances in supply and demand for laboratory consumables.3 Diagnostic testing for SARS\u2010CoV\u20102 chiefly employs the conventional paradigm of sample collection, nucleic acid extraction, and detection of viral RNA by reverse transcriptase polymerase chain reaction (RT\u2010PCR).4 The Australian Public Health Laboratory Network (PHLN) guidelines recommend combined deep nasal and oropharyngeal swabbing as the preferred method for collecting diagnostic specimens for SARS\u2010CoV\u20102 RT\u2010PCR.5 However, the shortage of appropriate swabs for diagnostic sampling is a major bottleneck that restricts testing capacity.6 In addition, international travel and transport restrictions in response to COVID\u201019 further reduce access by geographically remote countries such as Australia to swabs manufactured overseas.", [["sample", "ANATOMY", 379, 385], ["nasal", "ANATOMY", 602, 607], ["oropharyngeal", "ANATOMY", 612, 625], ["specimens", "ANATOMY", 685, 694], ["SARS", "DISEASE", 323, 327], ["nucleic acid", "CHEMICAL", 398, 410], ["SARS", "DISEASE", 699, 703], ["nasal", "ORGANISM_SUBDIVISION", 602, 607], ["oropharyngeal", "ORGANISM_SUBDIVISION", 612, 625], ["viral RNA", "RNA", 440, 449], ["reverse transcriptase", "PROTEIN", 453, 474], ["SARS\u2010CoV", "SPECIES", 323, 331], ["Diagnostic testing", "TEST", 0, 18], ["COVID", "TEST", 54, 59], ["reducing viral transmission", "PROBLEM", 84, 111], ["laboratory testing", "TEST", 153, 171], ["global imbalances in supply", "PROBLEM", 232, 259], ["laboratory consumables", "TEST", 275, 297], ["Diagnostic testing", "TEST", 300, 318], ["SARS", "PROBLEM", 323, 327], ["sample collection", "TEST", 379, 396], ["nucleic acid extraction", "TREATMENT", 398, 421], ["viral RNA", "PROBLEM", 440, 449], ["reverse transcriptase polymerase chain reaction", "TREATMENT", 453, 500], ["RT\u2010PCR", "TEST", 502, 508], ["combined deep nasal and oropharyngeal swabbing", "PROBLEM", 588, 634], ["collecting diagnostic specimens", "TEST", 663, 694], ["SARS", "PROBLEM", 699, 703], ["CoV", "TEST", 704, 707], ["RT\u2010PCR", "TEST", 710, 716], ["diagnostic sampling", "TEST", 766, 785], ["transport restrictions", "TREATMENT", 880, 902], ["COVID\u2010", "TREATMENT", 918, 924], ["viral transmission", "OBSERVATION", 93, 111], ["global", "OBSERVATION_MODIFIER", 232, 238], ["imbalances", "OBSERVATION", 239, 249], ["viral RNA", "OBSERVATION", 440, 449], ["deep", "ANATOMY_MODIFIER", 597, 601], ["nasal", "ANATOMY", 602, 607], ["oropharyngeal", "ANATOMY", 612, 625]]]], "ba2bcb73bf600d1adbceec46f8c2bc4096e792e5": [["AbstractThe outbreak of coronavirus disease 2019 (COVID-19) requires urgent need for effective treatment.", [["coronavirus disease", "DISEASE", 24, 43], ["COVID-19", "CHEMICAL", 50, 58], ["coronavirus", "ORGANISM", 24, 35], ["coronavirus disease", "PROBLEM", 24, 43], ["COVID", "TEST", 50, 55], ["effective treatment", "TREATMENT", 85, 104], ["coronavirus disease", "OBSERVATION", 24, 43]]], ["Severe COVID-19 is characterized by a cytokine storm syndrome with subsequent multiple organ failure (MOF) and acute respiratory distress syndrome (ARDS), which may lead to intensive care unit and increased risk of death.AbstractWhile awaiting a vaccine, targeting COVID-19-induced cytokine storm syndrome appears currently as the efficient strategy to reduce the mortality of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).AbstractThe stress-responsive enzyme, heme oxygenase-1 (HO-1) is largely known to protect against inflammatory response in animal models.", [["organ", "ANATOMY", 87, 92], ["respiratory", "ANATOMY", 117, 128], ["multiple organ failure", "DISEASE", 78, 100], ["MOF", "DISEASE", 102, 105], ["acute respiratory distress syndrome", "DISEASE", 111, 146], ["ARDS", "DISEASE", 148, 152], ["death", "DISEASE", 215, 220], ["COVID-19", "CHEMICAL", 265, 273], ["acute respiratory syndrome coronavirus", "DISEASE", 384, 422], ["organ", "ORGAN", 87, 92], ["COVID-19", "GENE_OR_GENE_PRODUCT", 265, 273], ["SARS-CoV-2", "ORGANISM", 426, 436], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 476, 492], ["HO-1", "GENE_OR_GENE_PRODUCT", 494, 498], ["cytokine", "PROTEIN", 38, 46], ["COVID-19", "DNA", 265, 273], ["cytokine", "PROTEIN", 282, 290], ["stress-responsive enzyme", "PROTEIN", 450, 474], ["heme oxygenase-1 (HO-1", "PROTEIN", 476, 498], ["severe acute respiratory syndrome coronavirus", "SPECIES", 377, 422], ["SARS-CoV-2", "SPECIES", 426, 436], ["Severe COVID", "PROBLEM", 0, 12], ["a cytokine storm syndrome", "PROBLEM", 36, 61], ["multiple organ failure", "PROBLEM", 78, 100], ["acute respiratory distress syndrome", "PROBLEM", 111, 146], ["ARDS", "PROBLEM", 148, 152], ["death", "PROBLEM", 215, 220], ["a vaccine", "TREATMENT", 244, 253], ["COVID", "TEST", 265, 270], ["cytokine storm syndrome", "PROBLEM", 282, 305], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 377, 422], ["CoV", "TEST", 431, 434], ["The stress", "TEST", 446, 456], ["responsive enzyme", "TEST", 457, 474], ["heme oxygenase", "TEST", 476, 490], ["HO", "TEST", 494, 496], ["inflammatory response in animal models", "PROBLEM", 536, 574], ["cytokine storm syndrome", "OBSERVATION", 38, 61], ["multiple", "OBSERVATION_MODIFIER", 78, 86], ["organ", "ANATOMY", 87, 92], ["failure", "OBSERVATION", 93, 100], ["MOF", "OBSERVATION_MODIFIER", 102, 105], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory distress syndrome", "OBSERVATION", 117, 146], ["ARDS", "OBSERVATION", 148, 152], ["severe", "OBSERVATION_MODIFIER", 377, 383], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["respiratory syndrome", "OBSERVATION", 390, 410]]], ["HO-1 is induced by hemin, a well-tolerated molecule, used for decades in the treatment of acute intermittent porphyria.", [["hemin", "CHEMICAL", 19, 24], ["porphyria", "DISEASE", 109, 118], ["hemin", "CHEMICAL", 19, 24], ["HO-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["hemin", "SIMPLE_CHEMICAL", 19, 24], ["HO", "PROTEIN", 0, 2], ["acute intermittent porphyria", "PROBLEM", 90, 118], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["intermittent", "OBSERVATION_MODIFIER", 96, 108], ["porphyria", "OBSERVATION", 109, 118]]], ["Experimental studies showed that hemin-induced HO-1 mitigates cytokine storm and lung injury in mouse models of sepsis and renal ischemia-reperfusion injury.", [["lung", "ANATOMY", 81, 85], ["renal", "ANATOMY", 123, 128], ["lung injury", "DISEASE", 81, 92], ["sepsis", "DISEASE", 112, 118], ["renal ischemia-reperfusion injury", "DISEASE", 123, 156], ["HO-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["lung", "ORGAN", 81, 85], ["mouse", "ORGANISM", 96, 101], ["renal", "ORGAN", 123, 128], ["HO", "PROTEIN", 47, 49], ["cytokine", "PROTEIN", 62, 70], ["mouse", "SPECIES", 96, 101], ["mouse", "SPECIES", 96, 101], ["Experimental studies", "TEST", 0, 20], ["hemin-induced HO", "PROBLEM", 33, 49], ["cytokine storm", "PROBLEM", 62, 76], ["lung injury", "PROBLEM", 81, 92], ["sepsis", "PROBLEM", 112, 118], ["renal ischemia-reperfusion injury", "PROBLEM", 123, 156], ["lung", "ANATOMY", 81, 85], ["injury", "OBSERVATION", 86, 92], ["sepsis", "OBSERVATION", 112, 118], ["renal", "ANATOMY", 123, 128], ["ischemia-reperfusion injury", "OBSERVATION", 129, 156]]], ["Furthermore, HO-1 may also control numerous viral infections by inhibiting virus replication.AbstractIn this context, we suggest the hypothesis that HO-1 cytoprotective pathway might be a promising target to control SARS-CoV-2 infection and mitigate COVID-19-induced cytokine storm and subsequent ARDS.AbstractKeywords: COVID-19; SARS-CoV-2; heme oxygenase-1 (HO-1); hemin; cytokine storm; acute respiratory distress syndrome (ARDS).COVID-19 and cytokine stormThe coronavirus disease 2019 (COVID-19) was first described in Wuhan, China, in December 2019 and the outbreak has rapidly spread across the world.", [["viral infections", "DISEASE", 44, 60], ["SARS", "DISEASE", 216, 220], ["infection", "DISEASE", 227, 236], ["COVID-19", "CHEMICAL", 250, 258], ["ARDS", "DISEASE", 297, 301], ["hemin", "CHEMICAL", 367, 372], ["acute respiratory distress syndrome", "DISEASE", 390, 425], ["ARDS", "DISEASE", 427, 431], ["coronavirus disease", "DISEASE", 464, 483], ["COVID-19", "CHEMICAL", 490, 498], ["COVID-19", "CHEMICAL", 250, 258], ["hemin", "CHEMICAL", 367, 372], ["HO-1", "GENE_OR_GENE_PRODUCT", 13, 17], ["HO-1", "GENE_OR_GENE_PRODUCT", 149, 153], ["SARS-CoV-2", "ORGANISM", 216, 226], ["COVID-19", "GENE_OR_GENE_PRODUCT", 250, 258], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 330, 340], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 342, 358], ["HO-1", "GENE_OR_GENE_PRODUCT", 360, 364], ["hemin", "SIMPLE_CHEMICAL", 367, 372], ["COVID-19", "GENE_OR_GENE_PRODUCT", 433, 441], ["coronavirus", "ORGANISM", 464, 475], ["COVID-19", "ORGANISM", 490, 498], ["HO", "PROTEIN", 13, 15], ["HO", "PROTEIN", 149, 151], ["cytokine", "PROTEIN", 267, 275], ["heme oxygenase-1 (HO-1", "PROTEIN", 342, 364], ["hemin", "PROTEIN", 367, 372], ["cytokine", "PROTEIN", 374, 382], ["COVID-19", "DNA", 433, 441], ["cytokine", "PROTEIN", 446, 454], ["SARS-CoV-2", "SPECIES", 216, 226], ["coronavirus disease 2019 (COVID-19", "SPECIES", 464, 498], ["numerous viral infections", "PROBLEM", 35, 60], ["inhibiting virus replication", "TREATMENT", 64, 92], ["SARS", "PROBLEM", 216, 220], ["CoV-2 infection", "PROBLEM", 221, 236], ["COVID", "TEST", 250, 255], ["cytokine storm", "PROBLEM", 267, 281], ["subsequent ARDS", "PROBLEM", 286, 301], ["COVID", "TEST", 320, 325], ["SARS", "TEST", 330, 334], ["CoV", "TEST", 335, 338], ["heme oxygenase", "TEST", 342, 356], ["cytokine storm", "PROBLEM", 374, 388], ["acute respiratory distress syndrome", "PROBLEM", 390, 425], ["ARDS", "PROBLEM", 427, 431], ["COVID", "TEST", 433, 438], ["The coronavirus disease", "PROBLEM", 460, 483], ["COVID", "TEST", 490, 495], ["numerous", "OBSERVATION_MODIFIER", 35, 43], ["viral infections", "OBSERVATION", 44, 60], ["ARDS", "OBSERVATION", 297, 301], ["cytokine storm", "OBSERVATION", 374, 388], ["acute", "OBSERVATION_MODIFIER", 390, 395], ["respiratory distress", "OBSERVATION", 396, 416], ["ARDS", "OBSERVATION", 427, 431], ["coronavirus disease", "OBSERVATION", 464, 483]]], ["COVID-19 is caused by a novel beta-coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2).", [["COVID-19", "CHEMICAL", 0, 8], ["acute respiratory syndrome coronavirus", "DISEASE", 60, 98], ["COVID-19", "SPECIES", 0, 8], ["severe acute respiratory syndrome coronavirus", "SPECIES", 53, 98], ["SARS-CoV-2", "SPECIES", 102, 112], ["COVID", "TEST", 0, 5], ["a novel beta-coronavirus", "PROBLEM", 22, 46], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 53, 98], ["SARS-CoV", "TEST", 102, 110], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86]]], ["Most of COVID-19 cases (about 80%) develop mild symptoms while 5% of infected patients have severe disease characterized by acute respiratory distress syndrome (ARDS) and multiorgan damage (1) .", [["respiratory", "ANATOMY", 130, 141], ["multiorgan", "ANATOMY", 171, 181], ["infected", "DISEASE", 69, 77], ["acute respiratory distress syndrome", "DISEASE", 124, 159], ["ARDS", "DISEASE", 161, 165], ["multiorgan damage", "DISEASE", 171, 188], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["COVID", "TEST", 8, 13], ["mild symptoms", "PROBLEM", 43, 56], ["severe disease", "PROBLEM", 92, 106], ["acute respiratory distress syndrome", "PROBLEM", 124, 159], ["ARDS", "PROBLEM", 161, 165], ["multiorgan damage", "PROBLEM", 171, 188], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["symptoms", "OBSERVATION", 48, 56], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["disease", "OBSERVATION", 99, 106], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory distress", "OBSERVATION", 130, 150]]], ["Through the binding of angiotensin-converting enzyme 2 (ACE2) receptor, SARS-CoV-2 targets lung and other organs (e.g., heart, kidney, intestine, brain, liver, and blood vessels), which may lead to subsequent multiple organ failure (MOF) and intensive care unit (ICU) requirement (1, 2) .", [["lung", "ANATOMY", 91, 95], ["organs", "ANATOMY", 106, 112], ["heart", "ANATOMY", 120, 125], ["kidney", "ANATOMY", 127, 133], ["intestine", "ANATOMY", 135, 144], ["brain", "ANATOMY", 146, 151], ["liver", "ANATOMY", 153, 158], ["blood vessels", "ANATOMY", 164, 177], ["organ", "ANATOMY", 218, 223], ["angiotensin", "CHEMICAL", 23, 34], ["multiple organ failure", "DISEASE", 209, 231], ["MOF", "DISEASE", 233, 236], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 23, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["lung", "ORGAN", 91, 95], ["organs", "ORGAN", 106, 112], ["heart", "ORGAN", 120, 125], ["kidney", "ORGAN", 127, 133], ["intestine", "ORGAN", 135, 144], ["brain", "ORGAN", 146, 151], ["liver", "ORGAN", 153, 158], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 164, 177], ["organ", "ORGAN", 218, 223], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 23, 70], ["angiotensin", "TEST", 23, 34], ["converting enzyme", "TEST", 35, 52], ["ACE2) receptor", "TEST", 56, 70], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["multiple organ failure", "PROBLEM", 209, 231], ["lung", "ANATOMY", 91, 95], ["heart", "ANATOMY", 120, 125], ["kidney", "ANATOMY", 127, 133], ["intestine", "ANATOMY", 135, 144], ["brain", "ANATOMY", 146, 151], ["liver", "ANATOMY", 153, 158], ["blood vessels", "ANATOMY", 164, 177], ["multiple", "OBSERVATION_MODIFIER", 209, 217], ["organ", "ANATOMY", 218, 223], ["failure", "OBSERVATION", 224, 231]]], ["The mortality of ICU patients is mainly due to ARDS and increases to 60% (3, 4) .COVID-19 and cytokine stormCompelling evidence suggest that cytokine storm syndrome plays a critical role in severe COVID-19 (5) .", [["ARDS", "DISEASE", 47, 51], ["COVID-19", "CHEMICAL", 197, 205], ["patients", "ORGANISM", 21, 29], ["COVID-19", "GENE_OR_GENE_PRODUCT", 81, 89], ["cytokine", "PROTEIN", 94, 102], ["cytokine", "PROTEIN", 141, 149], ["patients", "SPECIES", 21, 29], ["ARDS", "PROBLEM", 47, 51], ["COVID", "TEST", 81, 86], ["cytokine stormCompelling", "TEST", 94, 118], ["cytokine storm syndrome", "PROBLEM", 141, 164], ["severe COVID", "PROBLEM", 190, 202], ["ARDS", "OBSERVATION", 47, 51], ["increases", "OBSERVATION_MODIFIER", 56, 65], ["cytokine storm", "OBSERVATION", 141, 155]]], ["Indeed, proinflammatory cytokines/chemokines such as tumor necrosis factor (TNF)-\uf061, interleukin (IL)-1\uf062, IL-2, IL-6, IL-7, granulocyte-colony stimulating factor (G-CSF), interferon gamma-induced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-\uf061 (MIP-1\uf061) are elevated in plasma of COVID-19 patients, particularly in severe cases (4, 6, 7) .", [["plasma", "ANATOMY", 324, 330], ["tumor necrosis", "DISEASE", 53, 67], ["tumor necrosis factor (TNF)-\uf061", "GENE_OR_GENE_PRODUCT", 53, 82], ["interleukin (IL)-1\uf062", "GENE_OR_GENE_PRODUCT", 84, 103], ["IL-2", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["IL-7", "GENE_OR_GENE_PRODUCT", 117, 121], ["granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 123, 160], ["G-CSF", "GENE_OR_GENE_PRODUCT", 162, 167], ["interferon gamma-induced protein-10", "GENE_OR_GENE_PRODUCT", 170, 205], ["IP-10", "GENE_OR_GENE_PRODUCT", 207, 212], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 215, 249], ["MCP-1", "GENE_OR_GENE_PRODUCT", 251, 256], ["macrophage inflammatory protein 1-\uf061", "GENE_OR_GENE_PRODUCT", 263, 298], ["MIP-1\uf061", "GENE_OR_GENE_PRODUCT", 300, 306], ["plasma", "ORGANISM_SUBSTANCE", 324, 330], ["patients", "ORGANISM", 343, 351], ["proinflammatory cytokines", "PROTEIN", 8, 33], ["chemokines", "PROTEIN", 34, 44], ["tumor necrosis factor (TNF)-\uf061", "PROTEIN", 53, 82], ["interleukin (IL)-1\uf062", "PROTEIN", 84, 103], ["IL-7", "PROTEIN", 117, 121], ["granulocyte-colony stimulating factor", "PROTEIN", 123, 160], ["CSF", "PROTEIN", 164, 167], ["interferon gamma-induced protein-10 (IP-10", "PROTEIN", 170, 212], ["monocyte chemoattractant protein-1 (MCP-1", "PROTEIN", 215, 256], ["macrophage inflammatory protein 1-\uf061 (MIP-1\uf061", "PROTEIN", 263, 306], ["patients", "SPECIES", 343, 351], ["proinflammatory cytokines", "TEST", 8, 33], ["chemokines", "PROBLEM", 34, 44], ["tumor necrosis factor", "PROBLEM", 53, 74], ["TNF", "TEST", 76, 79], ["interleukin (IL)", "TEST", 84, 100], ["IL", "TEST", 105, 107], ["IL", "TEST", 111, 113], ["IL", "TEST", 117, 119], ["granulocyte", "TEST", 123, 134], ["colony stimulating factor", "TEST", 135, 160], ["G-CSF", "TEST", 162, 167], ["interferon gamma", "TEST", 170, 186], ["protein", "TEST", 195, 202], ["IP", "TEST", 207, 209], ["monocyte chemoattractant protein", "TEST", 215, 247], ["MCP", "TEST", 251, 254], ["macrophage inflammatory protein", "TEST", 263, 294], ["MIP", "TEST", 300, 303], ["COVID", "TEST", 334, 339], ["proinflammatory", "OBSERVATION_MODIFIER", 8, 23], ["tumor", "OBSERVATION", 53, 58], ["granulocyte", "ANATOMY", 123, 134], ["macrophage", "ANATOMY", 263, 273], ["inflammatory", "OBSERVATION", 274, 286], ["severe", "OBSERVATION_MODIFIER", 369, 375]]], ["This cytokine storm may trigger an uncontrolled systemic inflammatory response, which also contributes to ARDS and MOF leading to death (8) .COVID-19 and cytokine stormWhile awaiting a vaccine, targeting COVID-19-induced cytokine storm syndrome appears currently as the efficient strategy to reduce the mortality of SARS-CoV-2 and limit the overload of ICU.COVID-19 and cytokine stormIn this context, the use of glucocorticoids as an immunomodulatory therapy remains a current matter of debate.", [["ARDS", "DISEASE", 106, 110], ["MOF", "DISEASE", 115, 118], ["death", "DISEASE", 130, 135], ["COVID-19", "CHEMICAL", 204, 212], ["SARS", "DISEASE", 316, 320], ["glucocorticoids", "CHEMICAL", 412, 427], ["COVID-19", "GENE_OR_GENE_PRODUCT", 141, 149], ["COVID-19", "GENE_OR_GENE_PRODUCT", 204, 212], ["COVID-19", "GENE_OR_GENE_PRODUCT", 357, 365], ["cytokine", "PROTEIN", 5, 13], ["COVID", "PROTEIN", 141, 146], ["cytokine", "PROTEIN", 154, 162], ["cytokine", "PROTEIN", 221, 229], ["COVID-19", "PROTEIN", 357, 365], ["cytokine", "PROTEIN", 370, 378], ["SARS-CoV", "SPECIES", 316, 324], ["an uncontrolled systemic inflammatory response", "PROBLEM", 32, 78], ["ARDS", "PROBLEM", 106, 110], ["MOF", "PROBLEM", 115, 118], ["death", "PROBLEM", 130, 135], ["COVID", "TEST", 141, 146], ["a vaccine", "TREATMENT", 183, 192], ["COVID", "TEST", 204, 209], ["cytokine storm syndrome", "PROBLEM", 221, 244], ["SARS", "PROBLEM", 316, 320], ["CoV", "TEST", 321, 324], ["COVID", "TEST", 357, 362], ["cytokine stormIn", "TREATMENT", 370, 386], ["glucocorticoids", "TREATMENT", 412, 427], ["an immunomodulatory therapy", "TREATMENT", 431, 458], ["uncontrolled", "OBSERVATION_MODIFIER", 35, 47], ["systemic", "OBSERVATION_MODIFIER", 48, 56], ["inflammatory", "OBSERVATION", 57, 69], ["ARDS", "OBSERVATION", 106, 110], ["overload", "OBSERVATION", 341, 349]]], ["On the one hand, glucocorticoids might exacerbate COVID-19-associated lung injury, but on the other hand, short course of treatment is suggested for moderate-to-severe COVID-19-induced ARDS (5, 9) .COVID-19 and cytokine stormIL-6 has recently emerged as a key target due to its critical role in cytokine storm syndrome and subsequent disease severity (10) .", [["lung", "ANATOMY", 70, 74], ["glucocorticoids", "CHEMICAL", 17, 32], ["COVID-19", "CHEMICAL", 50, 58], ["lung injury", "DISEASE", 70, 81], ["COVID-19", "CHEMICAL", 168, 176], ["ARDS", "DISEASE", 185, 189], ["stormIL-6", "CHEMICAL", 220, 229], ["COVID-19", "CHEMICAL", 168, 176], ["glucocorticoids", "SIMPLE_CHEMICAL", 17, 32], ["COVID-19", "GENE_OR_GENE_PRODUCT", 50, 58], ["lung", "ORGAN", 70, 74], ["COVID-19", "SIMPLE_CHEMICAL", 168, 176], ["COVID-19", "GENE_OR_GENE_PRODUCT", 198, 206], ["stormIL-6", "GENE_OR_GENE_PRODUCT", 220, 229], ["COVID-19", "PROTEIN", 198, 206], ["cytokine", "PROTEIN", 211, 219], ["stormIL-6", "PROTEIN", 220, 229], ["cytokine", "PROTEIN", 295, 303], ["glucocorticoids", "TREATMENT", 17, 32], ["COVID", "TEST", 50, 55], ["lung injury", "PROBLEM", 70, 81], ["treatment", "TREATMENT", 122, 131], ["moderate-to-severe COVID", "PROBLEM", 149, 173], ["ARDS", "PROBLEM", 185, 189], ["COVID", "TEST", 198, 203], ["cytokine stormIL", "TREATMENT", 211, 227], ["cytokine storm syndrome", "PROBLEM", 295, 318], ["subsequent disease severity", "PROBLEM", 323, 350], ["lung", "ANATOMY", 70, 74], ["injury", "OBSERVATION", 75, 81], ["ARDS", "OBSERVATION", 185, 189], ["cytokine storm syndrome", "OBSERVATION", 295, 318]]], ["Hence, numbers of clinical trials using tocilizumab (IL-6 receptor blockade) have been approved and in progress (e.g., ChiCTR2000029765, NCT04317092, NCT04346355, NCT04335071).Heme oxygenase-1 (HO-1)Heme oxygenase-1 (HO-1, encoded by Hmox1) is a stress-induced enzyme that metabolizes free heme into carbon monoxide, biliverdin, and iron.", [["tocilizumab", "CHEMICAL", 40, 51], ["carbon monoxide", "CHEMICAL", 300, 315], ["biliverdin", "CHEMICAL", 317, 327], ["iron", "CHEMICAL", 333, 337], ["ChiCTR2000029765", "CHEMICAL", 119, 135], ["NCT04317092", "CHEMICAL", 137, 148], ["heme", "CHEMICAL", 290, 294], ["carbon monoxide", "CHEMICAL", 300, 315], ["biliverdin", "CHEMICAL", 317, 327], ["iron", "CHEMICAL", 333, 337], ["tocilizumab", "SIMPLE_CHEMICAL", 40, 51], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 53, 66], ["Heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 176, 192], ["HO-1", "GENE_OR_GENE_PRODUCT", 194, 198], ["Heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 199, 215], ["HO-1", "GENE_OR_GENE_PRODUCT", 217, 221], ["Hmox1", "GENE_OR_GENE_PRODUCT", 234, 239], ["carbon monoxide", "SIMPLE_CHEMICAL", 300, 315], ["biliverdin", "SIMPLE_CHEMICAL", 317, 327], ["iron", "SIMPLE_CHEMICAL", 333, 337], ["Heme oxygenase-1 (HO-1)Heme oxygenase-1", "PROTEIN", 176, 215], ["HO", "PROTEIN", 217, 219], ["Hmox1", "PROTEIN", 234, 239], ["clinical trials", "TREATMENT", 18, 33], ["tocilizumab (IL-6 receptor blockade", "TREATMENT", 40, 75], ["Heme oxygenase", "TEST", 176, 190], ["Heme oxygenase", "TEST", 199, 213], ["a stress-induced enzyme", "PROBLEM", 244, 267], ["carbon monoxide", "TREATMENT", 300, 315], ["biliverdin", "TREATMENT", 317, 327], ["iron", "TREATMENT", 333, 337]]], ["Through its byproducts, HO-1 exhibits cytoprotective, antiapoptotic, and immunomodulatory properties that may modulate diseases involving inflammation (11) .", [["inflammation", "DISEASE", 138, 150], ["HO-1", "GENE_OR_GENE_PRODUCT", 24, 28], ["HO", "PROTEIN", 24, 26], ["antiapoptotic", "TREATMENT", 54, 67], ["immunomodulatory properties", "TREATMENT", 73, 100], ["modulate diseases", "PROBLEM", 110, 127], ["inflammation", "PROBLEM", 138, 150], ["inflammation", "OBSERVATION", 138, 150]]], ["HO-1 controls the immune response, for instance, by stimulating the expression of IL-10, the well-known anti-inflammatory cytokine and by enhancing macrophage polarization toward an anti-inflammatory (i.e. M2) phenotype (12) (13) (14) (15) .", [["macrophage", "ANATOMY", 148, 158], ["HO-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-10", "GENE_OR_GENE_PRODUCT", 82, 87], ["macrophage", "CELL", 148, 158], ["HO", "PROTEIN", 0, 2], ["IL-10", "PROTEIN", 82, 87], ["anti-inflammatory cytokine", "PROTEIN", 104, 130], ["anti-inflammatory cytokine", "TREATMENT", 104, 130], ["enhancing macrophage polarization", "TREATMENT", 138, 171], ["anti-inflammatory cytokine", "OBSERVATION", 104, 130], ["enhancing", "OBSERVATION_MODIFIER", 138, 147], ["macrophage polarization", "OBSERVATION", 148, 171], ["anti-inflammatory", "OBSERVATION_MODIFIER", 182, 199]]], ["HO-1 also mediates immune response through IRF3 and subsequent IFN\uf061/\uf062 production, which may induce IL-10 and reduce the production of inflammatory cytokines (16) .", [["HO-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF3", "GENE_OR_GENE_PRODUCT", 43, 47], ["IFN\uf061", "GENE_OR_GENE_PRODUCT", 63, 67], ["\uf062", "GENE_OR_GENE_PRODUCT", 68, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 99, 104], ["HO", "PROTEIN", 0, 2], ["IRF3", "PROTEIN", 43, 47], ["IFN", "PROTEIN", 63, 66], ["IL-10", "PROTEIN", 99, 104], ["inflammatory cytokines", "PROTEIN", 134, 156], ["IRF3", "TEST", 43, 47], ["inflammatory cytokines", "PROBLEM", 134, 156], ["inflammatory", "OBSERVATION_MODIFIER", 134, 146]]], ["Interestingly, HO-1 is induced by hemin (i.e. synthetic heme), a molecule which is well tolerated with low rate of side effects and has been approved by the US Food and Drug Administration for the treatment of acute intermittent porphyria (17, 18) .HypothesisWe propose an approach to modulate SARS-CoV-2 infection and the subsequent cytokine storm by stimulating an anti-inflammatory pathway.", [["hemin", "CHEMICAL", 34, 39], ["acute intermittent porphyria", "DISEASE", 210, 238], ["infection", "DISEASE", 305, 314], ["hemin", "CHEMICAL", 34, 39], ["heme", "CHEMICAL", 56, 60], ["HO-1", "GENE_OR_GENE_PRODUCT", 15, 19], ["hemin", "SIMPLE_CHEMICAL", 34, 39], ["heme", "SIMPLE_CHEMICAL", 56, 60], ["SARS-CoV-2", "ORGANISM", 294, 304], ["HO", "PROTEIN", 15, 17], ["cytokine", "PROTEIN", 334, 342], ["SARS-CoV", "SPECIES", 294, 302], ["Drug Administration", "TREATMENT", 169, 188], ["acute intermittent porphyria", "PROBLEM", 210, 238], ["an approach", "TREATMENT", 270, 281], ["modulate SARS", "PROBLEM", 285, 298], ["CoV", "PROBLEM", 299, 302], ["2 infection", "PROBLEM", 303, 314], ["the subsequent cytokine storm", "TREATMENT", 319, 348], ["an anti-inflammatory pathway", "TREATMENT", 364, 392], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["intermittent", "OBSERVATION_MODIFIER", 216, 228], ["porphyria", "OBSERVATION", 229, 238], ["infection", "OBSERVATION", 305, 314], ["cytokine storm", "OBSERVATION", 334, 348]]], ["Based on current literature, hemin-induced HO-1 cytoprotective pathway appears as a consistent target to control COVID-19.Evidence supporting HO-1 as a potential target HO-1 as modulator of inflammatory response in animal modelsSepsis and ischemia-reperfusion injury (IRI) are interesting models to study inflammation.Evidence supporting HO-1 as a potential target HO-1 as modulator of inflammatory response in animal modelsThey combine major cell stress, significant burst of free radicals, and strong inflammatory responses comparable to COVID-19-induced cytokine storm, suggesting that findings about these models might be used as potential therapeutic strategy against SARS-CoV-2.Evidence supporting HO-1 as a potential target HO-1 as modulator of inflammatory response in animal modelsSepsis is characterized by a systemic inflammatory response syndrome with overexpression of proinflammatory cytokines, which may lead to lethal MOF (19) .", [["cell", "ANATOMY", 443, 447], ["hemin-", "CHEMICAL", 29, 35], ["Sepsis", "DISEASE", 228, 234], ["ischemia-reperfusion injury", "DISEASE", 239, 266], ["IRI", "DISEASE", 268, 271], ["inflammation", "DISEASE", 305, 317], ["COVID-19", "CHEMICAL", 540, 548], ["SARS", "DISEASE", 673, 677], ["Sepsis", "DISEASE", 790, 796], ["MOF", "DISEASE", 934, 937], ["COVID-19", "CHEMICAL", 113, 121], ["COVID-19", "CHEMICAL", 540, 548], ["hemin-", "SIMPLE_CHEMICAL", 29, 35], ["HO-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["HO-1", "GENE_OR_GENE_PRODUCT", 142, 146], ["HO-1", "GENE_OR_GENE_PRODUCT", 169, 173], ["HO-1", "GENE_OR_GENE_PRODUCT", 338, 342], ["HO-1", "GENE_OR_GENE_PRODUCT", 365, 369], ["cell", "CELL", 443, 447], ["COVID-19", "GENE_OR_GENE_PRODUCT", 540, 548], ["SARS-CoV-2", "ORGANISM", 673, 683], ["HO-1", "GENE_OR_GENE_PRODUCT", 704, 708], ["HO-1", "GENE_OR_GENE_PRODUCT", 731, 735], ["HO", "PROTEIN", 43, 45], ["COVID-19", "DNA", 113, 121], ["HO", "PROTEIN", 142, 144], ["HO", "PROTEIN", 169, 171], ["HO", "PROTEIN", 338, 340], ["HO", "PROTEIN", 365, 367], ["cytokine", "PROTEIN", 557, 565], ["HO", "PROTEIN", 704, 706], ["HO", "PROTEIN", 731, 733], ["proinflammatory cytokines", "PROTEIN", 882, 907], ["SARS-CoV", "SPECIES", 673, 681], ["COVID", "TEST", 113, 118], ["inflammatory response", "PROBLEM", 190, 211], ["Sepsis", "PROBLEM", 228, 234], ["ischemia-reperfusion injury", "PROBLEM", 239, 266], ["study inflammation", "PROBLEM", 299, 317], ["inflammatory response", "PROBLEM", 386, 407], ["significant burst of free radicals", "PROBLEM", 456, 490], ["strong inflammatory responses", "PROBLEM", 496, 525], ["COVID", "TEST", 540, 545], ["SARS", "PROBLEM", 673, 677], ["CoV", "TEST", 678, 681], ["inflammatory response", "PROBLEM", 752, 773], ["Sepsis", "PROBLEM", 790, 796], ["a systemic inflammatory response syndrome", "PROBLEM", 817, 858], ["proinflammatory cytokines", "PROBLEM", 882, 907], ["lethal MOF", "PROBLEM", 927, 937], ["inflammatory", "OBSERVATION", 190, 202], ["ischemia-reperfusion", "OBSERVATION_MODIFIER", 239, 259], ["injury", "OBSERVATION", 260, 266], ["inflammation", "OBSERVATION", 305, 317], ["inflammatory", "OBSERVATION", 386, 398], ["major cell stress", "OBSERVATION", 437, 454], ["significant", "OBSERVATION_MODIFIER", 456, 467], ["burst", "OBSERVATION_MODIFIER", 468, 473], ["free radicals", "OBSERVATION", 477, 490], ["strong", "OBSERVATION_MODIFIER", 496, 502], ["inflammatory", "OBSERVATION", 503, 515], ["cytokine storm", "OBSERVATION", 557, 571], ["inflammatory", "OBSERVATION_MODIFIER", 752, 764], ["animal models", "OBSERVATION_MODIFIER", 777, 790], ["Sepsis", "OBSERVATION", 790, 796], ["systemic", "OBSERVATION_MODIFIER", 819, 827], ["inflammatory response syndrome", "OBSERVATION", 828, 858], ["proinflammatory cytokines", "OBSERVATION", 882, 907]]], ["In this context, HO-1 has shown protective anti-inflammatory properties (11) .", [["HO-1", "GENE_OR_GENE_PRODUCT", 17, 21], ["HO", "PROTEIN", 17, 19], ["protective anti-inflammatory properties", "TREATMENT", 32, 71]]], ["Through down-regulation of proinflammatory cytokines (i.e., IL-1\uf062 and TNF-\uf061), HO-1 induction by using hemin protects mice from lethal endotoxemia and sepsis induced by liposaccharide (LPS) or cecal ligation and puncture (19) .", [["cecal", "ANATOMY", 192, 197], ["hemin", "CHEMICAL", 102, 107], ["endotoxemia", "DISEASE", 134, 145], ["sepsis", "DISEASE", 150, 156], ["liposaccharide", "CHEMICAL", 168, 182], ["LPS", "CHEMICAL", 184, 187], ["hemin", "CHEMICAL", 102, 107], ["liposaccharide", "CHEMICAL", 168, 182], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 60, 65], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 70, 75], ["HO-1", "GENE_OR_GENE_PRODUCT", 78, 82], ["hemin", "SIMPLE_CHEMICAL", 102, 107], ["mice", "ORGANISM", 117, 121], ["liposaccharide", "SIMPLE_CHEMICAL", 168, 182], ["LPS", "SIMPLE_CHEMICAL", 184, 187], ["proinflammatory cytokines", "PROTEIN", 27, 52], ["IL", "PROTEIN", 60, 62], ["TNF", "PROTEIN", 70, 73], ["HO", "PROTEIN", 78, 80], ["hemin", "PROTEIN", 102, 107], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 117, 121], ["proinflammatory cytokines", "TREATMENT", 27, 52], ["IL", "TEST", 60, 62], ["TNF", "TEST", 70, 73], ["lethal endotoxemia", "PROBLEM", 127, 145], ["sepsis", "PROBLEM", 150, 156], ["liposaccharide (LPS", "TREATMENT", 168, 187], ["cecal ligation", "TREATMENT", 192, 206], ["puncture", "TEST", 211, 219], ["proinflammatory cytokines", "OBSERVATION", 27, 52], ["sepsis", "OBSERVATION", 150, 156], ["cecal", "ANATOMY", 192, 197], ["ligation", "OBSERVATION", 198, 206]]], ["Furthermore, overexpression of HO-1 has also been demonstrated protective against LPS-induced lung injury (11) .Evidence supporting HO-1 as a potential target HO-1 as modulator of inflammatory response in animal modelsPreemptive induction of HO-1 by using hemin is largely known to be an efficient protective strategy against renal IRI in animal models (20, 21) .", [["lung", "ANATOMY", 94, 98], ["renal", "ANATOMY", 326, 331], ["LPS", "CHEMICAL", 82, 85], ["lung injury", "DISEASE", 94, 105], ["hemin", "CHEMICAL", 256, 261], ["renal IRI", "DISEASE", 326, 335], ["hemin", "CHEMICAL", 256, 261], ["HO-1", "GENE_OR_GENE_PRODUCT", 31, 35], ["LPS", "SIMPLE_CHEMICAL", 82, 85], ["lung", "ORGAN", 94, 98], ["HO-1", "GENE_OR_GENE_PRODUCT", 132, 136], ["HO-1", "GENE_OR_GENE_PRODUCT", 159, 163], ["HO-1", "GENE_OR_GENE_PRODUCT", 242, 246], ["hemin", "SIMPLE_CHEMICAL", 256, 261], ["renal", "ORGAN", 326, 331], ["HO-1", "PROTEIN", 31, 35], ["HO", "PROTEIN", 132, 134], ["HO", "PROTEIN", 159, 161], ["HO", "PROTEIN", 242, 244], ["LPS", "PROBLEM", 82, 85], ["lung injury", "PROBLEM", 94, 105], ["inflammatory response", "PROBLEM", 180, 201], ["lung", "ANATOMY", 94, 98], ["injury", "OBSERVATION", 99, 105], ["inflammatory", "OBSERVATION", 180, 192], ["renal", "ANATOMY", 326, 331], ["IRI", "OBSERVATION", 332, 335]]], ["Renal IRI also promotes systemic release of pro-inflammatory cytokines (e.g., IL-1\uf062, IL-6, and TNF-\uf061) that induces a systemic inflammatory response, resulting in proinflammatory cells recruitment and remote organ damage, particularly in lung (22) .Evidence supporting HO-1 as a potential target HO-1 as modulator of inflammatory response in animal modelsBasically, hemin-induced HO-1 improves renal outcomes after renal IRI by decreasing level of various renal proinflammatory cytokines, including IL-1\uf062, IL-6, TNF-\uf061, KC (keratinocyte chemoattractant also called CXCL1, a chemokine involved in neutrophils influx), and MCP-1 (20, 22) .", [["Renal", "ANATOMY", 0, 5], ["cells", "ANATOMY", 178, 183], ["organ", "ANATOMY", 207, 212], ["lung", "ANATOMY", 237, 241], ["renal", "ANATOMY", 393, 398], ["renal", "ANATOMY", 414, 419], ["renal", "ANATOMY", 455, 460], ["neutrophils", "ANATOMY", 594, 605], ["organ damage", "DISEASE", 207, 219], ["hemin-", "CHEMICAL", 365, 371], ["Renal", "ORGAN", 0, 5], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["TNF", "GENE_OR_GENE_PRODUCT", 95, 98], ["cells", "CELL", 178, 183], ["organ", "ORGAN", 207, 212], ["lung", "ORGAN", 237, 241], ["HO-1", "GENE_OR_GENE_PRODUCT", 268, 272], ["HO-1", "GENE_OR_GENE_PRODUCT", 295, 299], ["hemin-", "SIMPLE_CHEMICAL", 365, 371], ["HO-1", "GENE_OR_GENE_PRODUCT", 379, 383], ["renal", "ORGAN", 393, 398], ["renal", "ORGAN", 414, 419], ["renal", "ORGAN", 455, 460], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 498, 503], ["IL-6", "GENE_OR_GENE_PRODUCT", 505, 509], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 511, 516], ["KC", "GENE_OR_GENE_PRODUCT", 518, 520], ["keratinocyte chemoattractant", "GENE_OR_GENE_PRODUCT", 522, 550], ["CXCL1", "GENE_OR_GENE_PRODUCT", 563, 568], ["neutrophils", "CELL", 594, 605], ["MCP-1", "GENE_OR_GENE_PRODUCT", 619, 624], ["pro-inflammatory cytokines", "PROTEIN", 44, 70], ["IL", "PROTEIN", 78, 80], ["1\uf062", "PROTEIN", 81, 83], ["IL-6", "PROTEIN", 85, 89], ["TNF", "PROTEIN", 95, 98], ["proinflammatory cells", "CELL_TYPE", 162, 183], ["HO", "PROTEIN", 268, 270], ["HO", "PROTEIN", 295, 297], ["HO", "PROTEIN", 379, 381], ["renal proinflammatory cytokines", "PROTEIN", 455, 486], ["IL-1\uf062", "PROTEIN", 498, 503], ["IL-6", "PROTEIN", 505, 509], ["TNF", "PROTEIN", 511, 514], ["KC", "PROTEIN", 518, 520], ["keratinocyte chemoattractant", "PROTEIN", 522, 550], ["CXCL1", "PROTEIN", 563, 568], ["chemokine", "PROTEIN", 572, 581], ["neutrophils", "CELL_TYPE", 594, 605], ["MCP", "PROTEIN", 619, 622], ["pro-inflammatory cytokines", "TEST", 44, 70], ["IL", "TEST", 78, 80], ["IL", "TEST", 85, 87], ["TNF", "TREATMENT", 95, 98], ["a systemic inflammatory response", "PROBLEM", 115, 147], ["proinflammatory cells recruitment", "PROBLEM", 162, 195], ["remote organ damage", "PROBLEM", 200, 219], ["inflammatory response", "PROBLEM", 316, 337], ["renal IRI", "TREATMENT", 414, 423], ["various renal proinflammatory cytokines", "PROBLEM", 447, 486], ["IL", "TEST", 498, 500], ["IL", "TEST", 505, 507], ["TNF", "TEST", 511, 514], ["neutrophils influx", "TEST", 594, 612], ["MCP", "TEST", 619, 622], ["IRI", "OBSERVATION", 6, 9], ["systemic", "OBSERVATION_MODIFIER", 24, 32], ["systemic", "OBSERVATION_MODIFIER", 117, 125], ["inflammatory response", "OBSERVATION", 126, 147], ["proinflammatory cells", "OBSERVATION", 162, 183], ["organ", "ANATOMY", 207, 212], ["damage", "OBSERVATION", 213, 219], ["lung", "ANATOMY", 237, 241], ["inflammatory", "OBSERVATION", 316, 328], ["renal", "ANATOMY", 393, 398], ["renal", "ANATOMY", 414, 419], ["IRI", "OBSERVATION", 420, 423], ["renal", "ANATOMY", 455, 460], ["proinflammatory cytokines", "OBSERVATION", 461, 486]]], ["Moreover, it has been shown that hemin-induced HO-1 reduces IRI-induced cytokine storm and subsequent lung injury by decreasing plasma level of IL-6 and KC, and lung inflammation (neutrophils influx and lung KC) (22) .Resident-and circulating-macrophages are critical for HO-1 anti-inflammatory propertiesHemin-mediated protection against renal IRI requires specific expression of HO-1 within myeloid cells (i.e., CD11b + F4/80 lo macrophages) (20) .", [["lung", "ANATOMY", 102, 106], ["plasma", "ANATOMY", 128, 134], ["lung", "ANATOMY", 161, 165], ["neutrophils", "ANATOMY", 180, 191], ["lung", "ANATOMY", 203, 207], ["macrophages", "ANATOMY", 243, 254], ["renal", "ANATOMY", 339, 344], ["myeloid cells", "ANATOMY", 393, 406], ["CD11b + F4/80 lo macrophages", "ANATOMY", 414, 442], ["lung injury", "DISEASE", 102, 113], ["lung inflammation", "DISEASE", 161, 178], ["Hemin", "CHEMICAL", 305, 310], ["HO-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["IRI", "GENE_OR_GENE_PRODUCT", 60, 63], ["lung", "ORGAN", 102, 106], ["plasma", "ORGANISM_SUBSTANCE", 128, 134], ["IL-6", "GENE_OR_GENE_PRODUCT", 144, 148], ["KC", "GENE_OR_GENE_PRODUCT", 153, 155], ["lung", "ORGAN", 161, 165], ["neutrophils", "CELL", 180, 191], ["lung", "ORGAN", 203, 207], ["macrophages", "CELL", 243, 254], ["HO-1", "GENE_OR_GENE_PRODUCT", 272, 276], ["Hemin", "SIMPLE_CHEMICAL", 305, 310], ["renal", "ORGAN", 339, 344], ["HO-1", "GENE_OR_GENE_PRODUCT", 381, 385], ["myeloid cells", "CELL", 393, 406], ["CD11", "GENE_OR_GENE_PRODUCT", 414, 418], ["HO", "PROTEIN", 47, 49], ["IRI", "PROTEIN", 60, 63], ["cytokine", "PROTEIN", 72, 80], ["IL-6", "PROTEIN", 144, 148], ["KC", "PROTEIN", 153, 155], ["neutrophils", "CELL_TYPE", 180, 191], ["macrophages", "CELL_TYPE", 243, 254], ["HO", "PROTEIN", 272, 274], ["HO", "PROTEIN", 381, 383], ["myeloid cells", "CELL_TYPE", 393, 406], ["macrophages", "CELL_TYPE", 431, 442], ["IRI", "PROBLEM", 60, 63], ["cytokine storm", "PROBLEM", 72, 86], ["subsequent lung injury", "PROBLEM", 91, 113], ["IL", "TEST", 144, 146], ["KC", "TEST", 153, 155], ["lung inflammation", "PROBLEM", 161, 178], ["neutrophils influx", "TEST", 180, 198], ["lung KC", "TEST", 203, 210], ["1 anti-inflammatory properties", "TREATMENT", 275, 305], ["Hemin-mediated protection", "TREATMENT", 305, 330], ["renal IRI", "PROBLEM", 339, 348], ["HO", "TEST", 381, 383], ["myeloid cells", "TEST", 393, 406], ["CD11", "TEST", 414, 418], ["cytokine storm", "OBSERVATION", 72, 86], ["lung", "ANATOMY", 102, 106], ["injury", "OBSERVATION", 107, 113], ["lung", "ANATOMY", 161, 165], ["inflammation", "OBSERVATION", 166, 178], ["lung", "ANATOMY", 203, 207], ["renal", "ANATOMY", 339, 344], ["IRI", "OBSERVATION", 345, 348], ["myeloid cells", "OBSERVATION", 393, 406]]], ["Interestingly, this myeloid cell subpopulation was observed in the kidney and spleen, suggesting that protective effects might be provided by both tissue-resident and infiltrating/circulating HO-1 + myeloid cells (20) .", [["myeloid cell", "ANATOMY", 20, 32], ["kidney", "ANATOMY", 67, 73], ["spleen", "ANATOMY", 78, 84], ["tissue", "ANATOMY", 147, 153], ["HO-1 + myeloid cells", "ANATOMY", 192, 212], ["myeloid cell", "CELL", 20, 32], ["kidney", "ORGAN", 67, 73], ["spleen", "ORGAN", 78, 84], ["tissue", "TISSUE", 147, 153], ["HO-1", "GENE_OR_GENE_PRODUCT", 192, 196], ["myeloid cells", "CELL", 199, 212], ["myeloid cell subpopulation", "CELL_TYPE", 20, 46], ["HO-1 + myeloid cells", "CELL_LINE", 192, 212], ["this myeloid cell subpopulation", "PROBLEM", 15, 46], ["infiltrating/circulating HO", "TEST", 167, 194], ["myeloid cells", "TEST", 199, 212], ["myeloid cell subpopulation", "OBSERVATION", 20, 46], ["kidney", "ANATOMY", 67, 73], ["spleen", "ANATOMY", 78, 84], ["myeloid cells", "OBSERVATION", 199, 212]]], ["In term of lung injury, resident alveolar macrophages (AMs) prevent lung inflammation and repair tissue damage through several anti-inflammatory mechanisms including HO-1 (23) .", [["lung", "ANATOMY", 11, 15], ["alveolar macrophages", "ANATOMY", 33, 53], ["AMs", "ANATOMY", 55, 58], ["lung", "ANATOMY", 68, 72], ["tissue", "ANATOMY", 97, 103], ["lung injury", "DISEASE", 11, 22], ["inflammation", "DISEASE", 73, 85], ["lung", "ORGAN", 11, 15], ["alveolar macrophages", "CELL", 33, 53], ["AMs", "CELL", 55, 58], ["lung", "ORGAN", 68, 72], ["tissue", "TISSUE", 97, 103], ["HO-1", "GENE_OR_GENE_PRODUCT", 166, 170], ["resident alveolar macrophages", "CELL_TYPE", 24, 53], ["AMs", "CELL_TYPE", 55, 58], ["HO", "PROTEIN", 166, 168], ["lung injury", "PROBLEM", 11, 22], ["alveolar macrophages", "PROBLEM", 33, 53], ["lung inflammation", "PROBLEM", 68, 85], ["repair tissue damage", "PROBLEM", 90, 110], ["lung", "ANATOMY", 11, 15], ["injury", "OBSERVATION", 16, 22], ["alveolar macrophages", "OBSERVATION", 33, 53], ["lung", "ANATOMY", 68, 72], ["inflammation", "OBSERVATION", 73, 85], ["repair tissue damage", "OBSERVATION", 90, 110], ["several", "OBSERVATION_MODIFIER", 119, 126], ["anti-inflammatory", "OBSERVATION_MODIFIER", 127, 144]]], ["Then, in vitro hemin significantly induced HO-1 expression in primary rat AMs (23).", [["AMs", "ANATOMY", 74, 77], ["hemin", "CHEMICAL", 15, 20], ["hemin", "CHEMICAL", 15, 20], ["hemin", "SIMPLE_CHEMICAL", 15, 20], ["HO-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["rat", "ORGANISM", 70, 73], ["AMs", "CELL", 74, 77], ["HO", "PROTEIN", 43, 45], ["primary rat AMs", "CELL_TYPE", 62, 77], ["rat", "SPECIES", 70, 73]]], ["Moreover, it was shown that M2 macrophages promote recovery in sepsis-induced lung injury through overexpression of anti-inflammatory cytokines (24) .", [["M2 macrophages", "ANATOMY", 28, 42], ["lung", "ANATOMY", 78, 82], ["sepsis", "DISEASE", 63, 69], ["lung injury", "DISEASE", 78, 89], ["M2 macrophages", "CELL", 28, 42], ["lung", "ORGAN", 78, 82], ["M2 macrophages", "CELL_TYPE", 28, 42], ["anti-inflammatory cytokines", "PROTEIN", 116, 143], ["M2 macrophages", "PROBLEM", 28, 42], ["sepsis", "PROBLEM", 63, 69], ["lung injury", "PROBLEM", 78, 89], ["anti-inflammatory cytokines", "TREATMENT", 116, 143], ["sepsis", "OBSERVATION", 63, 69], ["lung", "ANATOMY", 78, 82], ["injury", "OBSERVATION", 83, 89], ["anti-inflammatory cytokines", "OBSERVATION", 116, 143]]], ["By inference, tissue-resident AMs expressing HO-1 might explain the mitigation of renal IRI/sepsis-induced lung injury observed with hemin.", [["tissue", "ANATOMY", 14, 20], ["AMs", "ANATOMY", 30, 33], ["renal", "ANATOMY", 82, 87], ["lung", "ANATOMY", 107, 111], ["renal IRI", "DISEASE", 82, 91], ["sepsis", "DISEASE", 92, 98], ["lung injury", "DISEASE", 107, 118], ["hemin", "CHEMICAL", 133, 138], ["hemin", "CHEMICAL", 133, 138], ["tissue", "TISSUE", 14, 20], ["AMs", "CELL", 30, 33], ["HO-1", "GENE_OR_GENE_PRODUCT", 45, 49], ["renal", "ORGAN", 82, 87], ["lung", "ORGAN", 107, 111], ["hemin", "SIMPLE_CHEMICAL", 133, 138], ["AMs", "CELL_TYPE", 30, 33], ["HO", "PROTEIN", 45, 47], ["hemin", "PROTEIN", 133, 138], ["renal IRI", "PROBLEM", 82, 91], ["sepsis", "PROBLEM", 92, 98], ["lung injury", "PROBLEM", 107, 118], ["renal", "ANATOMY", 82, 87], ["IRI", "OBSERVATION", 88, 91], ["sepsis", "OBSERVATION", 92, 98], ["lung", "ANATOMY", 107, 111], ["injury", "OBSERVATION", 112, 118]]], ["Altogether, these data show the importance of lung-resident macrophages, which might be targeted by hemin to mitigate local inflammation and subsequent ARDS following cytokine storm.Resident-and circulating-macrophages are critical for HO-1 anti-inflammatory propertiesOtherwise, splenectomy was associated with an exacerbated pro-inflammatory response and lung injury after renal IRI due to decreased splenic IL-10 production, suggesting that circulating macrophages are also involved in the control of lung injury (25) .", [["lung-resident macrophages", "ANATOMY", 46, 71], ["macrophages", "ANATOMY", 207, 218], ["lung", "ANATOMY", 357, 361], ["renal", "ANATOMY", 375, 380], ["splenic", "ANATOMY", 402, 409], ["macrophages", "ANATOMY", 456, 467], ["lung", "ANATOMY", 504, 508], ["hemin", "CHEMICAL", 100, 105], ["inflammation", "DISEASE", 124, 136], ["ARDS", "DISEASE", 152, 156], ["lung injury", "DISEASE", 357, 368], ["lung injury", "DISEASE", 504, 515], ["hemin", "CHEMICAL", 100, 105], ["lung-resident macrophages", "CELL", 46, 71], ["hemin", "SIMPLE_CHEMICAL", 100, 105], ["macrophages", "CELL", 207, 218], ["HO-1", "GENE_OR_GENE_PRODUCT", 236, 240], ["lung", "ORGAN", 357, 361], ["renal", "ORGAN", 375, 380], ["IL-10", "GENE_OR_GENE_PRODUCT", 410, 415], ["macrophages", "CELL", 456, 467], ["lung", "ORGAN", 504, 508], ["lung-resident macrophages", "CELL_TYPE", 46, 71], ["cytokine", "PROTEIN", 167, 175], ["macrophages", "CELL_TYPE", 207, 218], ["HO", "PROTEIN", 236, 238], ["circulating macrophages", "CELL_TYPE", 444, 467], ["local inflammation", "PROBLEM", 118, 136], ["subsequent ARDS", "PROBLEM", 141, 156], ["cytokine storm", "TREATMENT", 167, 181], ["HO-1 anti-inflammatory properties", "TREATMENT", 236, 269], ["splenectomy", "TREATMENT", 280, 291], ["an exacerbated pro-inflammatory response", "PROBLEM", 312, 352], ["lung injury", "PROBLEM", 357, 368], ["renal IRI", "PROBLEM", 375, 384], ["decreased splenic IL", "PROBLEM", 392, 412], ["circulating macrophages", "PROBLEM", 444, 467], ["lung injury", "PROBLEM", 504, 515], ["lung", "ANATOMY", 46, 50], ["macrophages", "OBSERVATION", 60, 71], ["inflammation", "OBSERVATION", 124, 136], ["ARDS", "OBSERVATION", 152, 156], ["cytokine storm", "OBSERVATION", 167, 181], ["macrophages", "ANATOMY", 207, 218], ["splenectomy", "OBSERVATION", 280, 291], ["exacerbated", "OBSERVATION_MODIFIER", 315, 326], ["pro-inflammatory response", "OBSERVATION", 327, 352], ["lung", "ANATOMY", 357, 361], ["injury", "OBSERVATION", 362, 368], ["renal", "ANATOMY", 375, 380], ["IRI", "OBSERVATION", 381, 384], ["decreased", "OBSERVATION_MODIFIER", 392, 401], ["splenic", "ANATOMY", 402, 409], ["IL", "OBSERVATION", 410, 412], ["circulating macrophages", "OBSERVATION", 444, 467], ["lung", "ANATOMY", 504, 508], ["injury", "OBSERVATION", 509, 515]]], ["HO-1 + spleen myeloid cells might therefore reduce cytokine storm and constitute a reservoir that might be recruited to remote injured lung and dampen subsequent ARDS.", [["HO-1 + spleen myeloid cells", "ANATOMY", 0, 27], ["lung", "ANATOMY", 135, 139], ["ARDS", "DISEASE", 162, 166], ["HO-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["spleen myeloid cells", "CELL", 7, 27], ["lung", "ORGAN", 135, 139], ["HO", "PROTEIN", 0, 2], ["spleen myeloid cells", "CELL_TYPE", 7, 27], ["cytokine", "PROTEIN", 51, 59], ["HO", "TEST", 0, 2], ["spleen myeloid cells", "PROBLEM", 7, 27], ["cytokine storm", "PROBLEM", 51, 65], ["a reservoir", "TREATMENT", 81, 92], ["subsequent ARDS", "PROBLEM", 151, 166], ["spleen", "ANATOMY", 7, 13], ["myeloid cells", "OBSERVATION", 14, 27], ["lung", "ANATOMY", 135, 139], ["ARDS", "OBSERVATION", 162, 166]]], ["Accordingly, these observations suggest that hemin-mediated improvement of lung injury following systemic inflammatory response might also be provided by both tissue-resident and infiltrating/circulating HO-1 + M2 macrophages.Antiviral effect of HO-1A recent study has highlighted the antiviral effect of HO-1 against influenza viruses.", [["lung", "ANATOMY", 75, 79], ["tissue", "ANATOMY", 159, 165], ["HO-1 + M2 macrophages", "ANATOMY", 204, 225], ["hemin", "CHEMICAL", 45, 50], ["lung injury", "DISEASE", 75, 86], ["influenza viruses", "DISEASE", 318, 335], ["hemin", "CHEMICAL", 45, 50], ["hemin", "SIMPLE_CHEMICAL", 45, 50], ["lung", "ORGAN", 75, 79], ["tissue", "TISSUE", 159, 165], ["HO-1", "GENE_OR_GENE_PRODUCT", 204, 208], ["HO-1A", "GENE_OR_GENE_PRODUCT", 246, 251], ["HO-1", "GENE_OR_GENE_PRODUCT", 305, 309], ["influenza viruses", "ORGANISM", 318, 335], ["hemin", "PROTEIN", 45, 50], ["HO-1 + M2 macrophages", "CELL_LINE", 204, 225], ["HO", "PROTEIN", 246, 248], ["HO", "PROTEIN", 305, 307], ["these observations", "TEST", 13, 31], ["lung injury", "PROBLEM", 75, 86], ["systemic inflammatory response", "PROBLEM", 97, 127], ["infiltrating/circulating HO", "TEST", 179, 206], ["1A recent study", "TEST", 249, 264], ["influenza viruses", "PROBLEM", 318, 335], ["lung", "ANATOMY", 75, 79], ["injury", "OBSERVATION", 80, 86], ["systemic", "OBSERVATION_MODIFIER", 97, 105], ["inflammatory", "OBSERVATION", 106, 118]]], ["Indeed, authors showed that cobalt protoporphyrin (CoPP), a potent HO-1 inducer similar to hemin, inhibits influenza A virus replication through HO-1 interaction with IRF3 and subsequent expression of IFN\uf061/\uf062 (26) .", [["cobalt protoporphyrin", "CHEMICAL", 28, 49], ["CoPP", "CHEMICAL", 51, 55], ["hemin", "CHEMICAL", 91, 96], ["cobalt protoporphyrin", "CHEMICAL", 28, 49], ["CoPP", "CHEMICAL", 51, 55], ["hemin", "CHEMICAL", 91, 96], ["cobalt protoporphyrin", "SIMPLE_CHEMICAL", 28, 49], ["CoPP", "SIMPLE_CHEMICAL", 51, 55], ["HO-1", "GENE_OR_GENE_PRODUCT", 67, 71], ["hemin", "SIMPLE_CHEMICAL", 91, 96], ["influenza A virus", "ORGANISM", 107, 124], ["HO-1", "GENE_OR_GENE_PRODUCT", 145, 149], ["IRF3", "GENE_OR_GENE_PRODUCT", 167, 171], ["IFN\uf061", "GENE_OR_GENE_PRODUCT", 201, 205], ["\uf062 (26)", "GENE_OR_GENE_PRODUCT", 206, 212], ["HO", "PROTEIN", 67, 69], ["HO", "PROTEIN", 145, 147], ["IRF3", "PROTEIN", 167, 171], ["IFN\uf061", "PROTEIN", 201, 205], ["\uf062 (26)", "PROTEIN", 206, 212], ["influenza A virus", "SPECIES", 107, 124], ["influenza A virus", "SPECIES", 107, 124], ["cobalt protoporphyrin (CoPP)", "PROBLEM", 28, 56], ["a potent HO", "PROBLEM", 58, 69], ["influenza A virus replication", "TREATMENT", 107, 136], ["IRF3", "TREATMENT", 167, 171]]], ["A same mechanism was found in human respiratory syncytial virus infection with attenuation of viral replication and lung inflammation upon HO-1 induction and expression of IFN\uf061/\uf062 in the infected lung (27) .", [["lung", "ANATOMY", 116, 120], ["lung", "ANATOMY", 195, 199], ["respiratory syncytial virus infection", "DISEASE", 36, 73], ["inflammation", "DISEASE", 121, 133], ["human", "ORGANISM", 30, 35], ["respiratory syncytial virus", "ORGANISM", 36, 63], ["lung", "ORGAN", 116, 120], ["HO-1", "GENE_OR_GENE_PRODUCT", 139, 143], ["IFN\uf061", "GENE_OR_GENE_PRODUCT", 172, 176], ["\uf062", "GENE_OR_GENE_PRODUCT", 177, 178], ["lung", "ORGAN", 195, 199], ["HO", "PROTEIN", 139, 141], ["IFN\uf061", "PROTEIN", 172, 176], ["\uf062", "PROTEIN", 177, 178], ["human", "SPECIES", 30, 35], ["respiratory syncytial virus", "SPECIES", 36, 63], ["human respiratory syncytial virus", "SPECIES", 30, 63], ["human respiratory syncytial virus infection", "PROBLEM", 30, 73], ["viral replication", "PROBLEM", 94, 111], ["lung inflammation", "PROBLEM", 116, 133], ["IFN\uf061/\uf062 in the infected lung", "PROBLEM", 172, 199], ["respiratory syncytial virus", "OBSERVATION", 36, 63], ["attenuation", "OBSERVATION_MODIFIER", 79, 90], ["viral replication", "OBSERVATION", 94, 111], ["lung", "ANATOMY", 116, 120], ["inflammation", "OBSERVATION", 121, 133], ["infected", "OBSERVATION", 186, 194], ["lung", "ANATOMY", 195, 199]]], ["Of note, HO-1-mediated type I IFN response may control numerous of other viral infections, such as hepatitis B/C virus, Ebola virus, and human immunodeficiency virus by inhibiting virus replication (26) .", [["viral infections", "DISEASE", 73, 89], ["hepatitis B", "DISEASE", 99, 110], ["Ebola virus", "DISEASE", 120, 131], ["human immunodeficiency virus", "DISEASE", 137, 165], ["HO-1", "GENE_OR_GENE_PRODUCT", 9, 13], ["type I IFN", "GENE_OR_GENE_PRODUCT", 23, 33], ["hepatitis B/C virus", "ORGANISM", 99, 118], ["Ebola virus", "ORGANISM", 120, 131], ["human immunodeficiency virus", "ORGANISM", 137, 165], ["HO", "PROTEIN", 9, 11], ["IFN", "PROTEIN", 30, 33], ["hepatitis B/C virus", "SPECIES", 99, 118], ["Ebola virus", "SPECIES", 120, 131], ["human", "SPECIES", 137, 142], ["immunodeficiency virus", "SPECIES", 143, 165], ["hepatitis B/C virus", "SPECIES", 99, 118], ["Ebola virus", "SPECIES", 120, 131], ["human immunodeficiency virus", "SPECIES", 137, 165], ["HO", "TEST", 9, 11], ["type I IFN response", "PROBLEM", 23, 42], ["other viral infections", "PROBLEM", 67, 89], ["hepatitis B/C virus", "PROBLEM", 99, 118], ["Ebola virus", "PROBLEM", 120, 131], ["human immunodeficiency virus", "PROBLEM", 137, 165], ["viral infections", "OBSERVATION", 73, 89]]], ["By inference, these data suggest that hemin-induced HO-1may be also used to overcome the outbreak of COVID-19 by inhibiting SARS-CoV-2 replication.Hemin use in humansHemin was shown to increase efficiently HO-1 protein expression and activity in humans (17) .Hemin use in humansCurrently, hemin is only approved for the treatment of acute intermittent porphyria by the US Food and Drug Administration (18) .", [["COVID-19", "CHEMICAL", 101, 109], ["Hemin", "CHEMICAL", 147, 152], ["Hemin", "CHEMICAL", 166, 171], ["Hemin", "CHEMICAL", 259, 264], ["hemin", "CHEMICAL", 289, 294], ["porphyria", "DISEASE", 352, 361], ["COVID-19", "CHEMICAL", 101, 109], ["Hemin", "CHEMICAL", 147, 152], ["Hemin", "CHEMICAL", 166, 171], ["Hemin", "CHEMICAL", 259, 264], ["hemin", "CHEMICAL", 289, 294], ["HO-1may", "GENE_OR_GENE_PRODUCT", 52, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 124, 134], ["Hemin", "SIMPLE_CHEMICAL", 147, 152], ["humans", "ORGANISM", 160, 166], ["Hemin", "SIMPLE_CHEMICAL", 166, 171], ["HO-1", "GENE_OR_GENE_PRODUCT", 206, 210], ["humans", "ORGANISM", 246, 252], ["Hemin", "SIMPLE_CHEMICAL", 259, 264], ["hemin", "SIMPLE_CHEMICAL", 289, 294], ["HO", "PROTEIN", 52, 54], ["HO", "PROTEIN", 206, 208], ["humans", "SPECIES", 160, 166], ["humans", "SPECIES", 246, 252], ["humans", "SPECIES", 160, 166], ["humans", "SPECIES", 246, 252], ["COVID", "TEST", 101, 106], ["Hemin", "TEST", 166, 171], ["acute intermittent porphyria", "PROBLEM", 333, 361], ["acute", "OBSERVATION_MODIFIER", 333, 338], ["intermittent", "OBSERVATION_MODIFIER", 339, 351], ["porphyria", "OBSERVATION", 352, 361]]], ["Interestingly, hemin is a well-tolerated molecule with low rate of adverse effects, such as headache, fever, and phlebitis at the site of infusion (17, 18) .Hemin use in humansRecently, hemin safely induced HO-1 in renal transplant recipients and further studies are expected to determine the impact of HO-1 expression on clinical outcomes (28) .Dual effect of heminThe timing of hemin administration is a critical point to consider in this hypothesis.", [["renal transplant", "ANATOMY", 215, 231], ["hemin", "CHEMICAL", 15, 20], ["headache", "DISEASE", 92, 100], ["fever", "DISEASE", 102, 107], ["phlebitis", "DISEASE", 113, 122], ["Hemin", "CHEMICAL", 157, 162], ["hemin", "CHEMICAL", 186, 191], ["hemin", "CHEMICAL", 361, 366], ["hemin", "CHEMICAL", 380, 385], ["hemin", "CHEMICAL", 15, 20], ["Hemin", "CHEMICAL", 157, 162], ["hemin", "CHEMICAL", 186, 191], ["hemin", "CHEMICAL", 361, 366], ["hemin", "CHEMICAL", 380, 385], ["hemin", "SIMPLE_CHEMICAL", 15, 20], ["Hemin", "SIMPLE_CHEMICAL", 157, 162], ["hemin", "SIMPLE_CHEMICAL", 186, 191], ["HO-1", "GENE_OR_GENE_PRODUCT", 207, 211], ["renal", "ORGAN", 215, 220], ["HO-1", "GENE_OR_GENE_PRODUCT", 303, 307], ["hemin", "SIMPLE_CHEMICAL", 361, 366], ["hemin", "SIMPLE_CHEMICAL", 380, 385], ["HO", "PROTEIN", 207, 209], ["HO", "PROTEIN", 303, 305], ["hemin", "PROTEIN", 361, 366], ["adverse effects", "PROBLEM", 67, 82], ["headache", "PROBLEM", 92, 100], ["fever", "PROBLEM", 102, 107], ["phlebitis", "PROBLEM", 113, 122], ["infusion", "TREATMENT", 138, 146], ["renal transplant recipients", "TREATMENT", 215, 242], ["further studies", "TEST", 247, 262], ["hemin administration", "TREATMENT", 380, 400], ["fever", "OBSERVATION", 102, 107], ["phlebitis", "OBSERVATION", 113, 122], ["renal", "ANATOMY", 215, 220], ["transplant", "OBSERVATION", 221, 231], ["hemin", "OBSERVATION", 361, 366]]], ["Indeed, hemin-induced HO-1 protects against renal IRI when hemin is given preemptively to renal insult (i.e. hemin preconditioning) (20, 21) .", [["renal", "ANATOMY", 44, 49], ["renal", "ANATOMY", 90, 95], ["hemin", "CHEMICAL", 59, 64], ["renal insult", "DISEASE", 90, 102], ["hemin", "CHEMICAL", 109, 114], ["hemin", "CHEMICAL", 59, 64], ["hemin", "CHEMICAL", 109, 114], ["HO-1", "GENE_OR_GENE_PRODUCT", 22, 26], ["renal", "ORGAN", 44, 49], ["hemin", "SIMPLE_CHEMICAL", 59, 64], ["renal", "ORGAN", 90, 95], ["hemin", "SIMPLE_CHEMICAL", 109, 114], ["hemin-induced HO-1", "PROTEIN", 8, 26], ["renal IRI", "TREATMENT", 44, 53], ["renal insult", "PROBLEM", 90, 102], ["hemin preconditioning", "TREATMENT", 109, 130], ["renal", "ANATOMY", 44, 49], ["IRI", "OBSERVATION", 50, 53], ["renal", "ANATOMY", 90, 95], ["insult", "OBSERVATION", 96, 102]]], ["However, hemin does not protect kidney and even worsened renal insult when acute kidney injury is already established (29) .", [["kidney", "ANATOMY", 32, 38], ["renal", "ANATOMY", 57, 62], ["kidney", "ANATOMY", 81, 87], ["hemin", "CHEMICAL", 9, 14], ["renal insult", "DISEASE", 57, 69], ["acute kidney injury", "DISEASE", 75, 94], ["hemin", "CHEMICAL", 9, 14], ["hemin", "SIMPLE_CHEMICAL", 9, 14], ["kidney", "ORGAN", 32, 38], ["renal", "ORGAN", 57, 62], ["kidney", "ORGAN", 81, 87], ["worsened renal insult", "PROBLEM", 48, 69], ["acute kidney injury", "PROBLEM", 75, 94], ["kidney", "ANATOMY", 32, 38], ["worsened", "OBSERVATION_MODIFIER", 48, 56], ["renal", "ANATOMY", 57, 62], ["insult", "OBSERVATION", 63, 69], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["kidney", "ANATOMY", 81, 87], ["injury", "OBSERVATION", 88, 94]]], ["Hemin may therefore have a dual effect, protective or deleterious, depending on the timing of its administration.Hemin-induced HO-1 therapy: a polymorphism dependencyThe polymorphism of human Hmox1 gene should be carefully considered.", [["Hemin", "CHEMICAL", 0, 5], ["Hemin", "CHEMICAL", 113, 118], ["Hemin", "CHEMICAL", 113, 118], ["Hemin", "SIMPLE_CHEMICAL", 0, 5], ["Hemin", "SIMPLE_CHEMICAL", 113, 118], ["HO-1", "GENE_OR_GENE_PRODUCT", 127, 131], ["human", "ORGANISM", 186, 191], ["Hmox1", "GENE_OR_GENE_PRODUCT", 192, 197], ["HO", "PROTEIN", 127, 129], ["human Hmox1 gene", "DNA", 186, 202], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["Hemin", "TREATMENT", 0, 5], ["deleterious", "PROBLEM", 54, 65], ["its administration", "TREATMENT", 94, 112], ["Hemin", "TEST", 113, 118], ["a polymorphism dependency", "PROBLEM", 141, 166], ["The polymorphism of human Hmox1 gene", "TREATMENT", 166, 202], ["dual effect", "OBSERVATION_MODIFIER", 27, 38], ["deleterious", "OBSERVATION", 54, 65]]], ["Indeed, polymorphisms of guanosine thymidine dinucleotide (GT)n repeats in the promoter of Hmox1 are inversely correlated with HO-1 mRNA level and enzyme activity (11) .", [["guanosine", "CHEMICAL", 25, 34], ["thymidine", "CHEMICAL", 35, 44], ["guanosine thymidine dinucleotide", "CHEMICAL", 25, 57], ["guanosine thymidine dinucleotide (GT)n", "GENE_OR_GENE_PRODUCT", 25, 63], ["Hmox1", "GENE_OR_GENE_PRODUCT", 91, 96], ["HO-1", "GENE_OR_GENE_PRODUCT", 127, 131], ["guanosine thymidine dinucleotide (GT)n repeats", "DNA", 25, 71], ["promoter", "DNA", 79, 87], ["Hmox1", "DNA", 91, 96], ["HO", "PROTEIN", 127, 129], ["guanosine thymidine dinucleotide (GT)n repeats in the promoter of Hmox1", "TREATMENT", 25, 96], ["HO", "TEST", 127, 129], ["mRNA level", "TEST", 132, 142], ["enzyme activity", "TEST", 147, 162]]], ["Individuals carrying the long (L) allele [(GT)n \uf0b3 30] display impaired transcriptional regulation and decreased expression of HO-1 (11) .", [["long (L)", "GENE_OR_GENE_PRODUCT", 25, 33], ["HO-1", "GENE_OR_GENE_PRODUCT", 126, 130], ["long (L) allele", "DNA", 25, 40], ["HO", "PROTEIN", 126, 128], ["allele [(GT)n \uf0b3", "TEST", 34, 49], ["impaired transcriptional regulation", "PROBLEM", 62, 97]]], ["This genetic variation influences the ability to induce HO-1 and, thereby, hemin treatment efficiency.", [["hemin", "CHEMICAL", 75, 80], ["hemin", "CHEMICAL", 75, 80], ["HO-1", "GENE_OR_GENE_PRODUCT", 56, 60], ["hemin", "SIMPLE_CHEMICAL", 75, 80], ["HO", "PROTEIN", 56, 58], ["hemin treatment efficiency", "TREATMENT", 75, 101]]], ["Of note, HO-1 was found to be elevated in the lungs of patients with ARDS and Hmox1 promoter polymorphisms also influence the occurrence of ARDS (30, 31) .", [["lungs", "ANATOMY", 46, 51], ["ARDS", "DISEASE", 69, 73], ["ARDS", "DISEASE", 140, 144], ["HO-1", "GENE_OR_GENE_PRODUCT", 9, 13], ["lungs", "ORGAN", 46, 51], ["patients", "ORGANISM", 55, 63], ["Hmox1", "GENE_OR_GENE_PRODUCT", 78, 83], ["HO", "PROTEIN", 9, 11], ["Hmox1 promoter polymorphisms", "DNA", 78, 106], ["patients", "SPECIES", 55, 63], ["ARDS", "PROBLEM", 69, 73], ["Hmox1 promoter polymorphisms", "PROBLEM", 78, 106], ["ARDS", "PROBLEM", 140, 144], ["elevated", "OBSERVATION", 30, 38], ["lungs", "ANATOMY", 46, 51], ["ARDS", "OBSERVATION", 69, 73], ["ARDS", "OBSERVATION", 140, 144]]], ["Polymorphisms in HO-1 might be therefore involved in the heterogeneity reported in critically ill COVID-19 patients, and it even more influences susceptibility to various human diseases (e.g., cardiovascular disease, necrotizing acute pancreatitis, chronic obstructive pulmonary disease) (11) .", [["cardiovascular", "ANATOMY", 193, 207], ["pulmonary", "ANATOMY", 269, 278], ["critically ill", "DISEASE", 83, 97], ["human diseases", "DISEASE", 171, 185], ["cardiovascular disease", "DISEASE", 193, 215], ["necrotizing acute pancreatitis", "DISEASE", 217, 247], ["chronic obstructive pulmonary disease", "DISEASE", 249, 286], ["HO-1", "GENE_OR_GENE_PRODUCT", 17, 21], ["patients", "ORGANISM", 107, 115], ["human", "ORGANISM", 171, 176], ["pulmonary", "ORGAN", 269, 278], ["HO", "PROTEIN", 17, 19], ["patients", "SPECIES", 107, 115], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["Polymorphisms in HO", "PROBLEM", 0, 19], ["various human diseases", "PROBLEM", 163, 185], ["cardiovascular disease", "PROBLEM", 193, 215], ["necrotizing acute pancreatitis", "PROBLEM", 217, 247], ["chronic obstructive pulmonary disease)", "PROBLEM", 249, 287], ["cardiovascular", "ANATOMY", 193, 207], ["necrotizing", "OBSERVATION_MODIFIER", 217, 228], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["pancreatitis", "OBSERVATION", 235, 247], ["chronic", "OBSERVATION_MODIFIER", 249, 256], ["obstructive", "OBSERVATION_MODIFIER", 257, 268], ["pulmonary", "ANATOMY", 269, 278], ["disease", "OBSERVATION", 279, 286]]], ["Accordingly, these data provide critical information about eventual pharmacologic targeting of HO-1 in COVID-19 + patients.Hypothesis testingWe would perform a clinical study with hospitalized severe COVID-19 + patients, which would be randomized into hemin and placebo groups.", [["hemin", "CHEMICAL", 252, 257], ["hemin", "CHEMICAL", 252, 257], ["HO-1", "GENE_OR_GENE_PRODUCT", 95, 99], ["COVID-19", "CELL", 103, 111], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 211, 219], ["hemin", "SIMPLE_CHEMICAL", 252, 257], ["HO", "PROTEIN", 95, 97], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 211, 219], ["HO", "TEST", 95, 97], ["Hypothesis testing", "TEST", 123, 141], ["a clinical study", "TEST", 158, 174], ["hemin and placebo groups", "TREATMENT", 252, 276]]], ["Patients would be monitored clinically and by usual laboratory tests and plasma cytokines/chemokines/HO-1 measurement.", [["plasma", "ANATOMY", 73, 79], ["Patients", "ORGANISM", 0, 8], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["HO-1", "GENE_OR_GENE_PRODUCT", 101, 105], ["plasma cytokines", "PROTEIN", 73, 89], ["chemokines", "PROTEIN", 90, 100], ["HO", "PROTEIN", 101, 103], ["Patients", "SPECIES", 0, 8], ["usual laboratory tests", "TEST", 46, 68], ["plasma cytokines", "TEST", 73, 89], ["chemokines", "TEST", 90, 100], ["HO", "TEST", 101, 103]]], ["Although it would be practically difficult, we think that polymorphisms in HO-1 should be considered to assess rigorously hemin treatment efficiency.", [["hemin", "CHEMICAL", 122, 127], ["hemin", "CHEMICAL", 122, 127], ["HO-1", "GENE_OR_GENE_PRODUCT", 75, 79], ["hemin", "SIMPLE_CHEMICAL", 122, 127], ["HO", "PROTEIN", 75, 77], ["polymorphisms in HO", "PROBLEM", 58, 77], ["rigorously hemin treatment efficiency", "TREATMENT", 111, 148]]], ["DNA fragments would be extracted from peripheral blood stem cells, and the Hmox1 locus containing the GT repeat would be amplified by using polymerase chain reaction (PCR).Hypothesis testingBased on current knowledge about hemin pharmacology in humans, we propose intravenous dose of 3-4 mg/kg/day (maximum dose of 6 mg/kg/day) similar to that recommended for treating acute intermittent porphyria (17, 18) .", [["fragments", "ANATOMY", 4, 13], ["peripheral blood stem cells", "ANATOMY", 38, 65], ["intravenous", "ANATOMY", 264, 275], ["hemin", "CHEMICAL", 223, 228], ["acute intermittent porphyria", "DISEASE", 369, 397], ["hemin", "CHEMICAL", 223, 228], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["peripheral blood stem cells", "CELL", 38, 65], ["Hmox1", "GENE_OR_GENE_PRODUCT", 75, 80], ["GT", "GENE_OR_GENE_PRODUCT", 102, 104], ["hemin", "SIMPLE_CHEMICAL", 223, 228], ["humans", "ORGANISM", 245, 251], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 264, 275], ["DNA fragments", "DNA", 0, 13], ["peripheral blood stem cells", "CELL_TYPE", 38, 65], ["Hmox1 locus", "DNA", 75, 86], ["GT repeat", "DNA", 102, 111], ["humans", "SPECIES", 245, 251], ["humans", "SPECIES", 245, 251], ["DNA fragments", "PROBLEM", 0, 13], ["peripheral blood stem cells", "PROBLEM", 38, 65], ["the Hmox1 locus", "TREATMENT", 71, 86], ["the GT repeat", "TEST", 98, 111], ["polymerase chain reaction", "PROBLEM", 140, 165], ["PCR", "TEST", 167, 170], ["Hypothesis testing", "TEST", 172, 190], ["acute intermittent porphyria", "PROBLEM", 369, 397], ["fragments", "OBSERVATION", 4, 13], ["peripheral", "ANATOMY_MODIFIER", 38, 48], ["blood", "ANATOMY", 49, 54], ["stem cells", "OBSERVATION", 55, 65], ["acute", "OBSERVATION_MODIFIER", 369, 374], ["intermittent", "OBSERVATION_MODIFIER", 375, 387], ["porphyria", "OBSERVATION", 388, 397]]], ["The duration of the treatment should be considered according to clinical response (e.g. 3-14 days for the treatment of acute intermittent porphyria) (17, 18) .", [["porphyria", "DISEASE", 138, 147], ["the treatment", "TREATMENT", 16, 29], ["acute intermittent porphyria", "PROBLEM", 119, 147], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["intermittent", "OBSERVATION_MODIFIER", 125, 137], ["porphyria", "OBSERVATION", 138, 147]]], ["Due to its dual effect, hemin should be administrated on the onset of respiratory symptoms to prevent ARDS and subsequent overloaded ICU.", [["respiratory", "ANATOMY", 70, 81], ["hemin", "CHEMICAL", 24, 29], ["respiratory symptoms", "DISEASE", 70, 90], ["ARDS", "DISEASE", 102, 106], ["hemin", "CHEMICAL", 24, 29], ["hemin", "SIMPLE_CHEMICAL", 24, 29], ["hemin", "TREATMENT", 24, 29], ["respiratory symptoms", "PROBLEM", 70, 90], ["ARDS", "PROBLEM", 102, 106], ["subsequent overloaded ICU", "PROBLEM", 111, 136], ["ARDS", "OBSERVATION", 102, 106], ["overloaded", "OBSERVATION_MODIFIER", 122, 132], ["ICU", "OBSERVATION", 133, 136]]], ["Hence, we do not recommend hemin use in case of established ARDS because it might worsen the disease based on experimental data (29) .ConclusionWith respect to current literature, there is a series of compelling evidence indicating a potential role for hemin-induced HO-1 as a treatment strategy against COVID-19-induced cytokine storm syndrome.", [["hemin", "CHEMICAL", 27, 32], ["ARDS", "DISEASE", 60, 64], ["hemin", "CHEMICAL", 253, 258], ["COVID-19", "CHEMICAL", 304, 312], ["hemin", "CHEMICAL", 27, 32], ["hemin", "CHEMICAL", 253, 258], ["COVID-19", "CHEMICAL", 304, 312], ["hemin", "SIMPLE_CHEMICAL", 27, 32], ["hemin", "SIMPLE_CHEMICAL", 253, 258], ["HO-1", "GENE_OR_GENE_PRODUCT", 267, 271], ["COVID-19", "SIMPLE_CHEMICAL", 304, 312], ["HO", "PROTEIN", 267, 269], ["cytokine", "PROTEIN", 321, 329], ["ARDS", "PROBLEM", 60, 64], ["the disease", "PROBLEM", 89, 100], ["experimental data", "TEST", 110, 127], ["a treatment strategy", "TREATMENT", 275, 295], ["COVID", "TEST", 304, 309], ["cytokine storm syndrome", "PROBLEM", 321, 344], ["ARDS", "OBSERVATION", 60, 64], ["cytokine storm syndrome", "OBSERVATION", 321, 344]]], ["Conversely to tocilizumab and glucocorticoids, hemin-induced HO-1 is able to mitigate cytokine storm and subsequent ARDS with a deciphered mechanism, by targeting wide range of proinflammatory mediators in animal models of sepsis and IRI.", [["tocilizumab", "CHEMICAL", 14, 25], ["ARDS", "DISEASE", 116, 120], ["sepsis", "DISEASE", 223, 229], ["IRI", "DISEASE", 234, 237], ["tocilizumab", "SIMPLE_CHEMICAL", 14, 25], ["glucocorticoids", "SIMPLE_CHEMICAL", 30, 45], ["HO-1", "GENE_OR_GENE_PRODUCT", 61, 65], ["HO", "PROTEIN", 61, 63], ["cytokine", "PROTEIN", 86, 94], ["proinflammatory mediators", "PROTEIN", 177, 202], ["tocilizumab and glucocorticoids", "TREATMENT", 14, 45], ["cytokine storm", "PROBLEM", 86, 100], ["subsequent ARDS", "PROBLEM", 105, 120], ["proinflammatory mediators", "PROBLEM", 177, 202], ["sepsis", "PROBLEM", 223, 229], ["IRI", "PROBLEM", 234, 237], ["ARDS", "OBSERVATION", 116, 120], ["sepsis", "OBSERVATION", 223, 229]]], ["Moreover, due to its antiviral properties, hemin-induced HO-1 might be an interesting target to control the outbreak of COVID-19 by inhibiting SARS-CoV-2 replication.ConclusionObviously, the relevance and translation of animal/in vitro findings to humans require further investigations.", [["COVID-19", "CHEMICAL", 120, 128], ["COVID-19", "CHEMICAL", 120, 128], ["HO-1", "GENE_OR_GENE_PRODUCT", 57, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 143, 153], ["humans", "ORGANISM", 248, 254], ["HO", "PROTEIN", 57, 59], ["humans", "SPECIES", 248, 254], ["SARS-CoV", "SPECIES", 143, 151], ["humans", "SPECIES", 248, 254], ["COVID", "TEST", 120, 125], ["further investigations", "TEST", 263, 285]]], ["However, hemin efficiently induces HO-1 in humans and is used safely for decades in the treatment of acute intermittent porphyria and recently in renal transplant (17, 18, 28) .", [["renal", "ANATOMY", 146, 151], ["hemin", "CHEMICAL", 9, 14], ["acute intermittent porphyria", "DISEASE", 101, 129], ["hemin", "CHEMICAL", 9, 14], ["hemin", "SIMPLE_CHEMICAL", 9, 14], ["HO-1", "GENE_OR_GENE_PRODUCT", 35, 39], ["humans", "ORGANISM", 43, 49], ["renal", "ORGAN", 146, 151], ["HO", "PROTEIN", 35, 37], ["humans", "SPECIES", 43, 49], ["humans", "SPECIES", 43, 49], ["acute intermittent porphyria", "PROBLEM", 101, 129], ["renal transplant", "TREATMENT", 146, 162], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["intermittent", "OBSERVATION_MODIFIER", 107, 119], ["porphyria", "OBSERVATION", 120, 129], ["renal", "ANATOMY", 146, 151], ["transplant", "OBSERVATION", 152, 162]]], ["Due to the low rate of adverse events, hemin appears to be a safer treatment than glucocorticoids.", [["hemin", "CHEMICAL", 39, 44], ["hemin", "CHEMICAL", 39, 44], ["hemin", "SIMPLE_CHEMICAL", 39, 44], ["glucocorticoids", "SIMPLE_CHEMICAL", 82, 97], ["the low rate of adverse events", "PROBLEM", 7, 37], ["a safer treatment than glucocorticoids", "TREATMENT", 59, 97]]], ["Furthermore, glucocorticoids might exacerbate COVID-19-associated lung injury (5, 9) .", [["lung", "ANATOMY", 66, 70], ["glucocorticoids", "CHEMICAL", 13, 28], ["COVID-19", "CHEMICAL", 46, 54], ["lung injury", "DISEASE", 66, 77], ["COVID-19", "CHEMICAL", 46, 54], ["glucocorticoids", "SIMPLE_CHEMICAL", 13, 28], ["COVID-19", "GENE_OR_GENE_PRODUCT", 46, 54], ["lung", "ORGAN", 66, 70], ["glucocorticoids", "TREATMENT", 13, 28], ["COVID", "TEST", 46, 51], ["lung injury", "PROBLEM", 66, 77], ["lung", "ANATOMY", 66, 70], ["injury", "OBSERVATION", 71, 77]]], ["Hence, hemin-induced HO-1 might be a harmless, novel, and promising approach for controlling SARS-CoV-2 infection and limiting cytokine storm syndrome with subsequent ARDS following COVID-19.ContributionMR did the literature search and drafted the paper.", [["hemin-", "CHEMICAL", 7, 13], ["infection", "DISEASE", 104, 113], ["ARDS", "DISEASE", 167, 171], ["hemin-", "SIMPLE_CHEMICAL", 7, 13], ["HO-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV-2", "ORGANISM", 93, 103], ["HO", "PROTEIN", 21, 23], ["cytokine", "PROTEIN", 127, 135], ["MR", "PROTEIN", 203, 205], ["SARS-CoV-2", "SPECIES", 93, 103], ["controlling SARS", "PROBLEM", 81, 97], ["CoV-2 infection", "PROBLEM", 98, 113], ["limiting cytokine storm syndrome", "PROBLEM", 118, 150], ["subsequent ARDS", "PROBLEM", 156, 171], ["COVID", "TEST", 182, 187], ["infection", "OBSERVATION", 104, 113], ["ARDS", "OBSERVATION", 167, 171]]], ["MR, MP, AVM, and KZB put forward the hypothesis.", [["MP", "DISEASE", 4, 6], ["AVM", "DISEASE", 8, 11], ["MR", "PROTEIN", 0, 2], ["KZB", "PROTEIN", 17, 20], ["MR", "TEST", 0, 2], ["MP", "TEST", 4, 6], ["AVM", "PROBLEM", 8, 11], ["KZB", "TEST", 17, 20], ["the hypothesis", "PROBLEM", 33, 47], ["AVM", "OBSERVATION", 8, 11]]], ["MP, AVM, and KZB revised the manuscript.Financial supportNo financial support was used for the writing of this manuscript.Declaration of interestsThe authors of this manuscript have no conflict of interest to disclose.", [["MP", "DISEASE", 0, 2], ["AVM", "DISEASE", 4, 7], ["MP", "GENE_OR_GENE_PRODUCT", 0, 2], ["AVM", "PROBLEM", 4, 7], ["Financial supportNo financial support", "TREATMENT", 40, 77], ["AVM", "OBSERVATION", 4, 7]]]], "31ad889cf72119d41aea910b88e0b57d2aa45132": [["The basic reproduction number R 0 corresponds to the expected number of new cases generated by a single infectious case in a fully susceptible population [3] .", [["new", "OBSERVATION_MODIFIER", 72, 75]]], ["Several studies, mostly based on Chinese data, aimed at estimating the R 0 associated with the COVID-19 epidemic, leading to values from 1.4 to 6.49, with an average of 3.28 [4] .", [["Several studies", "TEST", 0, 15], ["Chinese data", "TEST", 33, 45], ["the COVID", "TEST", 91, 100], ["epidemic", "PROBLEM", 104, 112]]], ["As the value of R 0 can be interpreted as the product of the contact rate and of the duration of the infectious period, and since the objective of the lockdown and associated restriction strategies are precisely to decrease the contact rate, an important effect on the number R e of secondary cases generated by an infectious individual is to be expected.", [["R 0", "GENE_OR_GENE_PRODUCT", 16, 19], ["associated restriction strategies", "TREATMENT", 164, 197], ["infectious", "OBSERVATION", 101, 111], ["infectious", "OBSERVATION", 315, 325]]], ["If R e > 1, the number of infectious cases in the population follows an increasing trend, and the larger R e , the faster this trend.", [["infectious", "OBSERVATION", 26, 36], ["increasing", "OBSERVATION_MODIFIER", 72, 82], ["trend", "OBSERVATION_MODIFIER", 83, 88], ["larger", "OBSERVATION_MODIFIER", 98, 104]]], ["The study [6] showed that containment policies in Hubei province indeed led to a subexponential growth in the number of cases, consistent with a decrease in the effective reproduction number R e .", [["The study", "TEST", 0, 9], ["a subexponential growth", "PROBLEM", 79, 102], ["a decrease", "PROBLEM", 143, 153], ["growth", "OBSERVATION_MODIFIER", 96, 102], ["consistent with", "UNCERTAINTY", 127, 142], ["decrease", "OBSERVATION_MODIFIER", 145, 153], ["effective", "OBSERVATION_MODIFIER", 161, 170]]]], "7afeb12a48bbbe2aa4c94f3d27e35042c60607c1": [["Accepted ArticleThree leading factors are reported to strongly influence the risk of dying from COVID-19: male sex, advanced age (i.e., >60 years), and the presence of comorbidities such as diabetes, hypertension, chronic respiratory diseases, cancer and cardiovascular disorders.", [["respiratory", "ANATOMY", 222, 233], ["cancer", "ANATOMY", 244, 250], ["cardiovascular", "ANATOMY", 255, 269], ["diabetes", "DISEASE", 190, 198], ["hypertension", "DISEASE", 200, 212], ["chronic respiratory diseases", "DISEASE", 214, 242], ["cancer", "DISEASE", 244, 250], ["cardiovascular disorders", "DISEASE", 255, 279], ["cancer", "CANCER", 244, 250], ["cardiovascular", "ANATOMICAL_SYSTEM", 255, 269], ["ArticleThree leading factors", "PROTEIN", 9, 37], ["comorbidities", "PROBLEM", 168, 181], ["diabetes", "PROBLEM", 190, 198], ["hypertension", "PROBLEM", 200, 212], ["chronic respiratory diseases", "PROBLEM", 214, 242], ["cancer", "PROBLEM", 244, 250], ["cardiovascular disorders", "PROBLEM", 255, 279], ["diabetes", "OBSERVATION", 190, 198], ["hypertension", "OBSERVATION", 200, 212], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["respiratory diseases", "OBSERVATION", 222, 242], ["cancer", "OBSERVATION", 244, 250], ["cardiovascular", "ANATOMY", 255, 269]]], ["5 Since the frequency of these factors may vary across different populations, we compared and summarized the impact of these variables on COVID-19 mortality rates between Italy and China.", [["COVID", "TEST", 138, 143]]], ["11 Overall, COVID-19 mortality risk increases with age, especially in men older than 60 and with chronic conditions such as diabetes, cancer and cardiovascular disease.", [["cancer", "ANATOMY", 134, 140], ["cardiovascular", "ANATOMY", 145, 159], ["diabetes", "DISEASE", 124, 132], ["cancer", "DISEASE", 134, 140], ["cardiovascular disease", "DISEASE", 145, 167], ["men", "ORGANISM", 70, 73], ["cancer", "CANCER", 134, 140], ["cardiovascular", "ANATOMICAL_SYSTEM", 145, 159], ["men", "SPECIES", 70, 73], ["COVID", "TEST", 12, 17], ["chronic conditions", "PROBLEM", 97, 115], ["diabetes", "PROBLEM", 124, 132], ["cancer", "PROBLEM", 134, 140], ["cardiovascular disease", "PROBLEM", 145, 167], ["diabetes", "OBSERVATION", 124, 132], ["cancer", "OBSERVATION", 134, 140], ["cardiovascular disease", "OBSERVATION", 145, 167]]]], "PMC7166722": [["Samples and RNA Purification ::: Materials and MethodsSamples were obtained from 4 kittens with suspected FIP.", [["FIP", "DISEASE", 106, 109], ["kittens", "ORGANISM", 83, 90], ["MethodsSamples", "TEST", 47, 61], ["FIP", "OBSERVATION", 106, 109]]], ["Postmortem examination was performed immediately after euthanasia of 3 kittens with FIP (named Z/FIP, F/FIP, and J/FIP; euthanized January 19, January 29, and February 4, 2011, respectively), at which time tissue samples were collected and stored in 10% neutral buffered formalin for routine histopathology, and RNA later1 (according to manufacturer's instructions) for RNA purification.", [["tissue samples", "ANATOMY", 206, 220], ["formalin", "CHEMICAL", 271, 279], ["tissue samples", "CANCER", 206, 220], ["formalin", "SIMPLE_CHEMICAL", 271, 279], ["Postmortem examination", "TEST", 0, 22], ["euthanasia", "TEST", 55, 65], ["FIP", "TEST", 84, 87], ["J/FIP", "TREATMENT", 113, 118], ["tissue samples", "TEST", 206, 220], ["routine histopathology", "TEST", 284, 306], ["RNA later1", "TEST", 312, 322], ["RNA purification", "TREATMENT", 370, 386]]], ["Ascitic fluid collected as part of a diagnostic investigation was available for another kitten with suspected FIP (U/FIP; euthanized January 30, 2011).", [["Ascitic fluid", "ANATOMY", 0, 13], ["FIP", "DISEASE", 110, 113], ["Ascitic fluid", "PROBLEM", 0, 13], ["a diagnostic investigation", "TEST", 35, 61], ["fluid", "OBSERVATION", 8, 13], ["FIP", "OBSERVATION", 110, 113]]], ["In January 2011, fecal samples were collected from 16 clinically healthy kittens and cats (identified by number) at the same rescue and rehoming center and stored immediately at \u221280\u00b0C. Total RNA was purified from 20 mg of tissue (omentum from kitten J/FIP; colonic lymph node from kitten Z/FIP; mesentery from kitten F/FIP), 100 \u03bcL of ascitic fluid (from kitten U/FIP) and from 0.5 g feces (clinically asymptomatic kittens) using a commercially available kit (NucleoSpin RNA II2) as described previously.12 Formalin fixed tissue from the 3 kittens with FIP for which samples were available (Z/FIP, F/FIP and J/FIP) were subjected to immunohistologic examination for the presence of FCoV antigen.13 All kittens had been resident at a single site cat rescue and rehoming center in the UK.", [["fecal samples", "ANATOMY", 17, 30], ["tissue", "ANATOMY", 222, 228], ["omentum", "ANATOMY", 230, 237], ["colonic lymph node", "ANATOMY", 257, 275], ["mesentery", "ANATOMY", 295, 304], ["ascitic fluid", "ANATOMY", 335, 348], ["tissue", "ANATOMY", 522, 528], ["samples", "ANATOMY", 567, 574], ["fecal samples", "ORGANISM_SUBSTANCE", 17, 30], ["kittens", "ORGANISM", 73, 80], ["cats", "ORGANISM", 85, 89], ["tissue", "TISSUE", 222, 228], ["omentum", "TISSUE", 230, 237], ["colonic lymph node", "MULTI-TISSUE_STRUCTURE", 257, 275], ["mesentery", "ORGAN", 295, 304], ["ascitic fluid", "ORGANISM_SUBSTANCE", 335, 348], ["feces", "ORGANISM_SUBDIVISION", 384, 389], ["tissue", "TISSUE", 522, 528], ["kittens", "ORGANISM", 540, 547], ["samples", "CANCER", 567, 574], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 682, 694], ["kittens", "ORGANISM", 702, 709], ["cat", "ORGANISM", 745, 748], ["FCoV antigen", "PROTEIN", 682, 694], ["kittens", "SPECIES", 73, 80], ["cats", "SPECIES", 85, 89], ["fecal samples", "TEST", 17, 30], ["Total RNA", "TREATMENT", 185, 194], ["tissue (omentum", "TREATMENT", 222, 237], ["kitten J/FIP", "TREATMENT", 243, 255], ["colonic lymph node", "PROBLEM", 257, 275], ["kitten Z/FIP", "TEST", 281, 293], ["ascitic fluid", "PROBLEM", 335, 348], ["kitten U/FIP", "TEST", 355, 367], ["a commercially available kit (NucleoSpin RNA II2", "TREATMENT", 430, 478], ["12 Formalin fixed tissue", "PROBLEM", 504, 528], ["FIP", "PROBLEM", 553, 556], ["samples", "TEST", 567, 574], ["Z/FIP", "TEST", 591, 596], ["J/FIP", "TREATMENT", 608, 613], ["immunohistologic examination", "TEST", 633, 661], ["FCoV antigen", "PROBLEM", 682, 694], ["fecal", "ANATOMY", 17, 22], ["omentum", "ANATOMY", 230, 237], ["colonic", "ANATOMY", 257, 264], ["lymph node", "OBSERVATION", 265, 275], ["mesentery", "ANATOMY", 295, 304], ["ascitic", "ANATOMY", 335, 342], ["fluid", "OBSERVATION", 343, 348], ["fixed tissue", "OBSERVATION_MODIFIER", 516, 528], ["FCoV", "OBSERVATION", 682, 686]]], ["The following pairs of kittens were litter mates and resident within the same pen: kittens Z\u2010FIP and #80; #65 and #73; #66 and #75.", [["kittens", "ORGANISM", 23, 30]]], ["Otherwise the kittens were housed in separate pens within the same complex.", [["kittens", "ORGANISM", 14, 21]]], ["Each litter of kittens had been relinquished to the center from different private households and kittens that subsequently went on to develop FIP had been rehomed separately to private households before the onset of clinical signs.Reverse Transcription PCR and Sequencing ::: Materials and MethodsFCoV RNA was amplified by real\u2010time, reverse transcriptase polymerase chain reaction (RT\u2010qPCR) as described previously.12", [["FIP", "DISEASE", 142, 145], ["kittens", "ORGANISM", 15, 22], ["kittens", "ORGANISM", 97, 104], ["MethodsFCoV RNA", "RNA", 290, 305], ["reverse transcriptase", "PROTEIN", 334, 355], ["FIP", "PROBLEM", 142, 145], ["clinical signs", "PROBLEM", 216, 230], ["MethodsFCoV RNA", "TREATMENT", 290, 305], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 334, 381]]]], "556d59d3314525cd6f6be34798cafa539e9a1a66": [["IntroductionThe coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread throughout the world.", [["coronavirus disease", "DISEASE", 16, 35], ["acute respiratory syndrome coronavirus", "DISEASE", 64, 102], ["coronavirus", "ORGANISM", 16, 27], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 57, 104], ["SARS-CoV-2", "ORGANISM", 106, 116], ["coronavirus disease 2019", "SPECIES", 16, 40], ["severe acute respiratory syndrome coronavirus", "SPECIES", 57, 102], ["SARS-CoV-2", "SPECIES", 106, 116], ["The coronavirus disease", "PROBLEM", 12, 35], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 53, 102], ["coronavirus disease", "OBSERVATION", 16, 35], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory syndrome coronavirus", "OBSERVATION", 70, 102]]], ["1 Despite exponential growth in Covid-19 related research, better understanding of this highly contagious and lethal virus is needed.", [["exponential growth", "PROBLEM", 10, 28], ["Covid", "TEST", 32, 37], ["lethal virus", "PROBLEM", 110, 122], ["exponential", "OBSERVATION_MODIFIER", 10, 21], ["growth", "OBSERVATION_MODIFIER", 22, 28]]], ["An overall mortality rate over 5% for all patients hospitalized with Covid-19 highlights the urgent need for treatments while vaccines are developed.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Covid", "TEST", 69, 74], ["treatments", "TREATMENT", 109, 119], ["vaccines", "TREATMENT", 126, 134], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["mortality", "OBSERVATION_MODIFIER", 11, 20]]], ["2 Observational data early in the outbreak identified male sex and increased age as leading risk factors in Covid-19.", [["Observational data", "TEST", 2, 20], ["Covid", "TEST", 108, 113]]], ["3 Subsequent studies have identified hypertension, diabetes, coronary artery disease, tobacco use, and obesity as important risk factors for Covid-19 outcomes.", [["coronary artery", "ANATOMY", 61, 76], ["hypertension", "DISEASE", 37, 49], ["diabetes", "DISEASE", 51, 59], ["coronary artery disease", "DISEASE", 61, 84], ["obesity", "DISEASE", 103, 110], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 61, 76], ["tobacco", "ORGANISM", 86, 93], ["tobacco", "SPECIES", 86, 93], ["Subsequent studies", "TEST", 2, 20], ["hypertension", "PROBLEM", 37, 49], ["diabetes", "PROBLEM", 51, 59], ["coronary artery disease", "PROBLEM", 61, 84], ["obesity", "PROBLEM", 103, 110], ["Covid", "TEST", 141, 146], ["hypertension", "OBSERVATION", 37, 49], ["diabetes", "OBSERVATION", 51, 59], ["coronary artery", "ANATOMY", 61, 76], ["disease", "OBSERVATION", 77, 84], ["obesity", "OBSERVATION", 103, 110]]], ["2, [4] [5] [6] Persons hospitalized with Covid-19 with overweight or obesity (body mass index, BMI\u226525kg/m 2 ) had a higher risk of needing mechanical ventilation, after controlling for diabetes, hypertension, and cardiovascular disease.", [["body", "ANATOMY", 78, 82], ["cardiovascular", "ANATOMY", 213, 227], ["overweight", "DISEASE", 55, 65], ["obesity", "DISEASE", 69, 76], ["diabetes", "DISEASE", 185, 193], ["hypertension", "DISEASE", 195, 207], ["cardiovascular disease", "DISEASE", 213, 235], ["[4] [5] [6", "SIMPLE_CHEMICAL", 3, 13], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["Covid", "TEST", 41, 46], ["obesity (body mass index", "PROBLEM", 69, 93], ["mechanical ventilation", "TREATMENT", 139, 161], ["diabetes", "PROBLEM", 185, 193], ["hypertension", "PROBLEM", 195, 207], ["cardiovascular disease", "PROBLEM", 213, 235], ["mechanical ventilation", "OBSERVATION", 139, 161], ["hypertension", "OBSERVATION", 195, 207], ["cardiovascular", "ANATOMY", 213, 227], ["disease", "OBSERVATION", 228, 235]]], ["6 Additionally, among individuals with Covid-19 and a BMI \u226528kg/m, 2 men have a higher risk of developing severe Covid-19 than women.", [["men", "ORGANISM", 69, 72], ["women", "ORGANISM", 127, 132], ["men", "SPECIES", 69, 72], ["women", "SPECIES", 127, 132], ["Covid", "TEST", 39, 44], ["a BMI", "TEST", 52, 57], ["developing severe Covid", "PROBLEM", 95, 118], ["severe", "OBSERVATION_MODIFIER", 106, 112]]], ["7 This sex difference may be explained by the accumulation of visceral adiposity at lower BMI levels in men.", [["visceral", "ANATOMY", 62, 70], ["visceral adiposity", "DISEASE", 62, 80], ["visceral", "TISSUE", 62, 70], ["men", "ORGANISM", 104, 107], ["men", "SPECIES", 104, 107], ["visceral adiposity at lower BMI levels", "PROBLEM", 62, 100], ["may be explained", "UNCERTAINTY", 22, 38], ["accumulation", "OBSERVATION_MODIFIER", 46, 58], ["visceral", "ANATOMY", 62, 70], ["adiposity", "OBSERVATION", 71, 80]]], ["8 Adipocytes, specifically visceral adipocytes, secrete many of the inflammatory and coagulopathic molecules that are implicated in Covid-19 morbidity, including interleukin-6 (IL-6), tumor-necrosis-factor\u03b1 (TNF\u03b1), d-dimer, and others.", [["Adipocytes", "ANATOMY", 2, 12], ["visceral adipocytes", "ANATOMY", 27, 46], ["necrosis", "DISEASE", 190, 198], ["d-", "CHEMICAL", 215, 217], ["Adipocytes", "CELL", 2, 12], ["visceral adipocytes", "CELL", 27, 46], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 162, 175], ["IL-6", "GENE_OR_GENE_PRODUCT", 177, 181], ["tumor-necrosis-factor\u03b1", "GENE_OR_GENE_PRODUCT", 184, 206], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 208, 212], ["d-dimer", "SIMPLE_CHEMICAL", 215, 222], ["Adipocytes", "CELL_TYPE", 2, 12], ["visceral adipocytes", "CELL_TYPE", 27, 46], ["inflammatory and coagulopathic molecules", "PROTEIN", 68, 108], ["interleukin-6 (IL-6", "PROTEIN", 162, 181], ["tumor-necrosis-factor\u03b1", "PROTEIN", 184, 206], ["TNF\u03b1", "PROTEIN", 208, 212], ["d-dimer", "PROTEIN", 215, 222], ["visceral adipocytes", "PROBLEM", 27, 46], ["the inflammatory and coagulopathic molecules", "PROBLEM", 64, 108], ["Covid", "TEST", 132, 137], ["interleukin", "TEST", 162, 173], ["IL", "TEST", 177, 179], ["tumor-necrosis", "PROBLEM", 184, 198], ["factor\u03b1", "PROBLEM", 199, 206], ["visceral", "ANATOMY_MODIFIER", 27, 35], ["adipocytes", "ANATOMY", 36, 46], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80], ["coagulopathic molecules", "OBSERVATION", 85, 108], ["tumor", "OBSERVATION", 184, 189], ["necrosis", "OBSERVATION", 190, 198]]], ["[9] [10] [11] [12] TNF\u03b1 has been particularly important, with high levels of TNF\u03b1 found in lung tissue of persons with Covid-19.", [["lung tissue", "ANATOMY", 91, 102], ["[9] [10] [11", "CHEMICAL", 0, 12], ["[9] [10] [11] [12] TNF\u03b1", "SIMPLE_CHEMICAL", 0, 23], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 77, 81], ["lung tissue", "TISSUE", 91, 102], ["persons", "ORGANISM", 106, 113], ["TNF\u03b1", "PROTEIN", 19, 23], ["TNF\u03b1", "PROTEIN", 77, 81], ["persons", "SPECIES", 106, 113], ["high levels of TNF", "PROBLEM", 62, 80], ["Covid", "TEST", 119, 124], ["lung", "ANATOMY", 91, 95]]], ["13 TNF\u03b1 contributes to insulin resistance, and levels of TNF\u03b1 are higher in individuals with type 2 diabetes (T2DM).", [["type 2 diabetes", "DISEASE", 93, 108], ["T2DM", "DISEASE", 110, 114], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 3, 7], ["insulin", "GENE_OR_GENE_PRODUCT", 23, 30], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 57, 61], ["TNF\u03b1", "PROTEIN", 3, 7], ["TNF\u03b1", "PROTEIN", 57, 61], ["insulin resistance", "TEST", 23, 41], ["levels of TNF", "TEST", 47, 60], ["type 2 diabetes (T2DM)", "PROBLEM", 93, 115], ["insulin resistance", "OBSERVATION", 23, 41], ["diabetes", "OBSERVATION", 100, 108]]], ["14 Both T2DM and obesity are associated with lower levels of the anti-inflammatory cytokine, IL-10.", [["T2DM", "DISEASE", 8, 12], ["obesity", "DISEASE", 17, 24], ["IL-10", "GENE_OR_GENE_PRODUCT", 93, 98], ["anti-inflammatory cytokine", "PROTEIN", 65, 91], ["IL-10", "PROTEIN", 93, 98], ["Both T2DM", "PROBLEM", 3, 12], ["obesity", "PROBLEM", 17, 24], ["the anti-inflammatory cytokine", "TREATMENT", 61, 91], ["T2DM", "OBSERVATION", 8, 12], ["obesity", "OBSERVATION", 17, 24], ["lower levels", "OBSERVATION_MODIFIER", 45, 57], ["anti-inflammatory cytokine", "OBSERVATION", 65, 91]]], ["15 Metformin, the first-line medication for type 2 diabetes (T2DM) decreases TNF\u03b1 and IL-6, boost levels of IL-10, and has been found to cause these beneficial effects significantly more in females more than males.", [["Metformin", "CHEMICAL", 3, 12], ["type 2 diabetes", "DISEASE", 44, 59], ["T2DM", "DISEASE", 61, 65], ["Metformin", "CHEMICAL", 3, 12], ["Metformin", "SIMPLE_CHEMICAL", 3, 12], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 77, 81], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["IL-10", "GENE_OR_GENE_PRODUCT", 108, 113], ["TNF\u03b1", "PROTEIN", 77, 81], ["IL-6", "PROTEIN", 86, 90], ["IL", "PROTEIN", 108, 110], ["Metformin", "TREATMENT", 3, 12], ["the first-line medication", "TREATMENT", 14, 39], ["type 2 diabetes (T2DM", "PROBLEM", 44, 65], ["TNF", "TEST", 77, 80], ["IL", "TEST", 86, 88], ["boost levels of IL", "TREATMENT", 92, 110], ["diabetes", "OBSERVATION", 51, 59]]], ["[16] [17] [18] [19] [20] Metformin also increases activation of AMP-activated protein kinase (AMPK), which has important downstream effects in Covid-19.", [["[16] [17] [18] [19] [20]", "CHEMICAL", 0, 24], ["Metformin", "CHEMICAL", 25, 34], ["AMP", "CHEMICAL", 64, 67], ["[16] [17] [18] [19] [20] Metformin", "CHEMICAL", 0, 34], ["AMP", "CHEMICAL", 64, 67], ["[16] [17] [18] [19] [20] Metformin", "SIMPLE_CHEMICAL", 0, 34], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 64, 92], ["AMPK", "GENE_OR_GENE_PRODUCT", 94, 98], ["AMP-activated protein kinase", "PROTEIN", 64, 92], ["AMPK", "PROTEIN", 94, 98], ["Metformin", "TREATMENT", 25, 34], ["AMP-activated protein kinase", "TREATMENT", 64, 92], ["Covid", "TEST", 143, 148]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["19.20135095 doi: medRxiv preprint Given these favorable effects of metformin on TNF\u03b1 and other inflammatory cytokines that contribute to Covid-19, our primary objective was to understand whether home metformin use was associated with decreased mortality in persons hospitalized with Covid-19.", [["metformin", "CHEMICAL", 67, 76], ["metformin", "CHEMICAL", 200, 209], ["metformin", "CHEMICAL", 67, 76], ["metformin", "CHEMICAL", 200, 209], ["metformin", "SIMPLE_CHEMICAL", 67, 76], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 80, 84], ["metformin", "SIMPLE_CHEMICAL", 200, 209], ["persons", "ORGANISM", 257, 264], ["TNF\u03b1", "PROTEIN", 80, 84], ["inflammatory cytokines", "PROTEIN", 95, 117], ["persons", "SPECIES", 257, 264], ["medRxiv", "TREATMENT", 17, 24], ["metformin", "TREATMENT", 67, 76], ["TNF", "TREATMENT", 80, 83], ["other inflammatory cytokines", "PROBLEM", 89, 117], ["Covid", "TEST", 137, 142], ["home metformin", "TREATMENT", 195, 209], ["Covid", "TEST", 283, 288]]], ["We hypothesized that metformin would be associated with decreased mortality from Covid-19 in persons with T2DM or obesity, and that this benefit would be higher in women compared to men given metformin's sex-specific anti-inflammatory effects.", [["metformin", "CHEMICAL", 21, 30], ["T2DM", "DISEASE", 106, 110], ["obesity", "DISEASE", 114, 121], ["metformin", "CHEMICAL", 192, 201], ["metformin", "CHEMICAL", 21, 30], ["metformin", "CHEMICAL", 192, 201], ["metformin", "SIMPLE_CHEMICAL", 21, 30], ["persons", "ORGANISM", 93, 100], ["women", "ORGANISM", 164, 169], ["men", "ORGANISM", 182, 185], ["metformin", "SIMPLE_CHEMICAL", 192, 201], ["persons", "SPECIES", 93, 100], ["women", "SPECIES", 164, 169], ["men", "SPECIES", 182, 185], ["metformin", "TREATMENT", 21, 30], ["decreased mortality", "PROBLEM", 56, 75], ["T2DM", "PROBLEM", 106, 110], ["obesity", "PROBLEM", 114, 121], ["metformin", "TREATMENT", 192, 201], ["obesity", "OBSERVATION", 114, 121]]], ["We also hypothesized that TNF\u03b1 inhibitors would be associated with decreased mortality from Covid-19.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 26, 30], ["TNF\u03b1", "PROTEIN", 26, 30], ["TNF\u03b1 inhibitors", "TREATMENT", 26, 41], ["decreased mortality", "PROBLEM", 67, 86], ["Covid", "TEST", 92, 97]]], ["We conducted a retrospective cohort analysis of de-identified claims data from UnitedHealth Group's Clinical Discovery Database of 6,256 persons hospitalized in the US with Covid-19 in 2020.Design and DataRetrospective analysis of claims from UnitedHealth Group (UHG)'s Clinical Discovery Database between January 1, 2020 -June 7, 2020.", [["persons", "ORGANISM", 137, 144], ["persons", "SPECIES", 137, 144], ["Covid", "TEST", 173, 178]]], ["This database includes de-identified individual-level and statelevel data for individuals with Covid-19 admissions in all 50 U.S. states, covering a diverse range of ages, ethnicities, and geographical regions.", [["This database", "TEST", 0, 13], ["Covid", "TEST", 95, 100], ["geographical", "ANATOMY_MODIFIER", 189, 201], ["regions", "ANATOMY_MODIFIER", 202, 209]]], ["This study was approved by the University of Minnesota institutional review board (STUDY00001489) which provided a waiver of consent for this study.PopulationIndividuals 18 years or older with T2DM or obesity, at least 6 months of continuous enrollment in 2019, and a hospitalization for Covid-19 confirmed by polymerase change reaction (PCR), manual chart review by UHG, or reported from the hospital to UHG.", [["T2DM", "DISEASE", 193, 197], ["obesity", "DISEASE", 201, 208], ["This study", "TEST", 0, 10], ["this study", "TEST", 137, 147], ["T2DM", "PROBLEM", 193, 197], ["obesity", "PROBLEM", 201, 208], ["Covid", "TEST", 288, 293], ["polymerase change reaction", "PROBLEM", 310, 336], ["PCR", "TEST", 338, 341], ["obesity", "OBSERVATION", 201, 208]]], ["Eighteen persons (0.12%) were missing age and were excluded.", [["persons", "ORGANISM", 9, 16], ["persons", "SPECIES", 9, 16]]], ["An assumption was made that there was no missingness among the other variables.", [["missingness", "PROBLEM", 41, 52]]], ["Individuals with T2DM or obesity were included in the analysis (definition in Supplemental Materials 1).PopulationOutcomes .", [["T2DM", "DISEASE", 17, 21], ["obesity", "DISEASE", 25, 32], ["T2DM", "PROBLEM", 17, 21], ["obesity", "PROBLEM", 25, 32], ["the analysis", "TEST", 50, 62], ["obesity", "OBSERVATION", 25, 32]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)PopulationThe copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["19.20135095 doi: medRxiv preprint Our primary outcome was in-hospital mortality defined using the hospital disposition indicator.PopulationThe individuals who remained hospitalized on June 7, 2020 without a hospital disposition were censored in Cox proportional hazards model analyses and excluded from mixed model and propensity-matched analyses.", [["individuals", "ORGANISM", 143, 154], ["model analyses", "TEST", 270, 284]]], ["The database did not include data related to in-hospital complications, ICU, or ventilator utilization and thus an analysis on these endpoints was not possible.Independent Variable and confounding variablesThe independent variable was a filled pharmacy prescription (visible through prescription claims, matching the generic drug ingredient with the string \"metformin\") indicating use of metformin, and limited to patients with at least 90 days of metformin prescription from 12 months prior to Covid-19 diagnosis.", [["metformin", "CHEMICAL", 358, 367], ["metformin", "CHEMICAL", 388, 397], ["metformin", "CHEMICAL", 448, 457], ["metformin", "CHEMICAL", 358, 367], ["metformin", "CHEMICAL", 388, 397], ["metformin", "CHEMICAL", 448, 457], ["metformin", "SIMPLE_CHEMICAL", 358, 367], ["metformin", "SIMPLE_CHEMICAL", 388, 397], ["patients", "ORGANISM", 414, 422], ["metformin", "SIMPLE_CHEMICAL", 448, 457], ["patients", "SPECIES", 414, 422], ["ventilator utilization", "TREATMENT", 80, 102], ["an analysis", "TEST", 112, 123], ["the string \"metformin", "TREATMENT", 346, 367], ["metformin", "TREATMENT", 388, 397], ["metformin prescription", "TREATMENT", 448, 470], ["Covid", "TEST", 495, 500]]], ["Potential confounding medications hypothesized to be protective or harmful for patients with Covid-19 determined by a large evidence-based consortium were assessed, as were possible confounding co-morbidities (Supplemental Materials 1).", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Potential confounding medications", "TREATMENT", 0, 33], ["Covid", "TEST", 93, 98], ["confounding co-morbidities", "PROBLEM", 182, 208]]], ["Categorical variables were expressed by percentages.", [["Categorical variables", "TEST", 0, 21]]], ["Univariate analysis compared mortality for persons without vs with home metformin use.Statistical analysisTo determine whether metformin use was independently associated with reduced mortality for patients hospitalized for Covid-19, multivariable models for mortality were developed with the use of the Least absolute shrinkage and selection operator (LASSO) method, 24 with the tuning parameter determined by the Akaike information criterion (AIC).", [["metformin", "CHEMICAL", 72, 81], ["metformin", "CHEMICAL", 127, 136], ["metformin", "CHEMICAL", 72, 81], ["metformin", "CHEMICAL", 127, 136], ["persons", "ORGANISM", 43, 50], ["metformin", "SIMPLE_CHEMICAL", 72, 81], ["metformin", "SIMPLE_CHEMICAL", 127, 136], ["patients", "ORGANISM", 197, 205], ["persons", "SPECIES", 43, 50], ["patients", "SPECIES", 197, 205], ["Univariate analysis", "TEST", 0, 19], ["home metformin", "TREATMENT", 67, 81], ["Statistical analysis", "TEST", 86, 106], ["metformin", "TREATMENT", 127, 136], ["Covid", "TEST", 223, 228], ["the Least absolute shrinkage", "TREATMENT", 299, 327]]], ["We also considered clinically relevant pairwise interactions to determine whether their association with mortality differed according to metformin status.", [["metformin", "CHEMICAL", 137, 146], ["metformin", "CHEMICAL", 137, 146], ["metformin", "SIMPLE_CHEMICAL", 137, 146]]], ["The non-linear effect of age was modeled in two manners, using restricted cubic splines or categorized as (0-55, 56-65, 66-75, 76-85, 86+).", [["restricted cubic splines", "TREATMENT", 63, 87], ["non-linear", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21], ["cubic splines", "OBSERVATION", 74, 87]]], ["Given the low mortality for patients 0-55 (5.1%) compared with other age groupings, this group was not further categorized.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["Subgroup analyses of multivariate models were performed by sex.Statistical analysis.", [["multivariate models", "TEST", 21, 40], ["Statistical analysis", "TEST", 63, 83]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Statistical analysisThe copyright holder for this preprint this version posted June 28, 2020.", [["CC", "CHEMICAL", 0, 2], ["Statistical analysis", "TEST", 199, 219], ["med", "ANATOMY", 102, 105]]], ["(1) Logistic regression, controlling for all covariates in our conceptual framework (Table 1) , and for LASSO variables and state, with and without specific disease-medication interaction terms. (eTable 1).Statistical analysis(2) Mixed-effects logistic regression with state-level random effects, controlling for LASSO variables, with and without specific disease-medication interaction terms.", [["Logistic regression", "PROBLEM", 4, 23], ["Statistical analysis", "TEST", 206, 226], ["Mixed-effects logistic regression", "PROBLEM", 230, 263], ["specific disease", "PROBLEM", 347, 363]]], ["Only patients with known hospital disposition were included in this analysis (eTable 2).Statistical analysis(3) Cox proportional-hazards regression by strata-specific and shared-frailty effects, with and without specific disease-medication interaction terms; censoring determined based on claims made after hospitalization up to June 7, 2020.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["this analysis", "TEST", 63, 76], ["Statistical analysis", "TEST", 88, 108], ["hazards regression", "PROBLEM", 129, 147], ["strata", "TEST", 151, 157], ["specific disease", "PROBLEM", 212, 228]]], ["Using a 'best' outcome approach, patients discharged not to hospice were assigned a censoring time equal to the longest observed hospital stay (169 days).", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["a 'best' outcome approach", "TREATMENT", 6, 31]]], ["25, 26 Scaled Schoenfeld residual graphs and log-log plots were analyzed to confirm adequacy of the proportional hazards assumption for home metformin use (eTable 3, eFigure 1).Statistical analysis(4) Propensity matched mixed effects logistic regression was performed, stratified by metformin use.", [["metformin", "CHEMICAL", 141, 150], ["metformin", "CHEMICAL", 283, 292], ["metformin", "CHEMICAL", 141, 150], ["metformin", "CHEMICAL", 283, 292], ["metformin", "SIMPLE_CHEMICAL", 141, 150], ["metformin", "SIMPLE_CHEMICAL", 283, 292], ["home metformin use", "TREATMENT", 136, 154], ["Statistical analysis", "TEST", 177, 197], ["Propensity matched mixed effects logistic regression", "PROBLEM", 201, 253], ["metformin use", "TREATMENT", 283, 296]]], ["Propensity scores were estimated with logistic regression with variables selected by the aforementioned LASSO logistic model and two evenly matched groups were formed with the common caliper set at 0.2 (eFigure 2), and a model with exact matching.", [["Propensity scores", "PROBLEM", 0, 17]]], ["27, 28 Even distribution of propensity scores was confirmed between matched groups, with standardized differences less than 0.1 for all confounding variables (eFigure 3).", [["propensity scores", "PROBLEM", 28, 45]]], ["Univariate logistic regression was then used to compare mortality for persons who were receiving (vs not receiving) home metformin among the matched cohort.", [["metformin", "CHEMICAL", 121, 130], ["metformin", "CHEMICAL", 121, 130], ["persons", "ORGANISM", 70, 77], ["metformin", "SIMPLE_CHEMICAL", 121, 130], ["persons", "SPECIES", 70, 77], ["Univariate logistic regression", "TREATMENT", 0, 30], ["home metformin", "TREATMENT", 116, 130]]], ["Kaplan-Meier survival curves were also estimated and compared using a log-rank test ( Figure 2 ).", [["Meier survival curves", "TEST", 7, 28], ["a log-rank test", "TEST", 68, 83]]], ["Sensitivity analyses were conducted in individuals with Covid-19 confirmed by PCR (n=4,105).Statistical analysisStatistical analyses were performed using Stata MP, version 16 (StataCorp, College Station, TX).", [["Sensitivity analyses", "TEST", 0, 20], ["Covid", "TEST", 56, 61], ["PCR", "TEST", 78, 81], ["Statistical analysisStatistical analyses", "TEST", 92, 132], ["TX", "TREATMENT", 204, 206]]], ["Statistical significance was defined as a two-tailed p-value < 0.05.Statistical analysis.", [["a two-tailed p-value", "TEST", 40, 60], ["Statistical analysis", "TEST", 68, 88]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprintCharacteristics of CohortBetween Jan 1, 2020 -June 7, 2020, 15,380 individuals with pharmacy claims data and at least 6 months of enrollment were diagnosed and hospitalized with Covid-19 in UHG's Clinical Discovery Database ( Figure 1 ).", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["Covid", "TEST", 517, 522], ["med", "ANATOMY", 102, 105]]], ["Overall 52.8% were female, median age 70 years (IQR 58-80).", [["IQR", "TEST", 48, 51]]], ["Of these, 6Multivariate analyses of mortality by metformin use, in men and women with T2DM or obesityResults of multivariate analyses are presented in Table 2 .", [["metformin", "CHEMICAL", 49, 58], ["T2DM", "DISEASE", 86, 90], ["metformin", "CHEMICAL", 49, 58], ["metformin", "SIMPLE_CHEMICAL", 49, 58], ["men", "ORGANISM", 67, 70], ["women", "ORGANISM", 75, 80], ["men", "SPECIES", 67, 70], ["women", "SPECIES", 75, 80], ["metformin use", "TREATMENT", 49, 62], ["T2DM", "PROBLEM", 86, 90], ["multivariate analyses", "TEST", 112, 133]]], ["Mortality associated with all the variables in the multivariate analyses are shown in Tables S1-S3.", [["the multivariate analyses", "TEST", 47, 72], ["S3", "ANATOMY", 96, 98]]], ["The log-log plot assessing the proportionality assumption is presented in Figure S1 ; the distribution of the estimated propensity-score is in Figure S2 ; the standardized difference in propensity-matched covariates is in Figure S3 .", [["distribution", "OBSERVATION_MODIFIER", 90, 102], ["Figure S3", "OBSERVATION", 222, 231]]], ["Metformin use not associated with statistically significantly decreased mortality in the overall sample (Table 2) . .", [["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["Metformin", "TREATMENT", 0, 9], ["statistically significantly decreased mortality", "PROBLEM", 34, 81], ["decreased", "OBSERVATION_MODIFIER", 62, 71], ["mortality", "OBSERVATION", 72, 81]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020.Sensitivity analyses in patients with Covid-19 disease confirmed by polymerase chain reactionIn unadjusted analyses men and women with T2DM or obesity, metformin was not significantly associated with decreased mortality, OR 0.859 (0.737, 1.002), nor by the Cox proportional hazards shared frailty model in women, HR 0.808 (0.651, 1.003).", [["CC", "CHEMICAL", 0, 2], ["Covid-19 disease", "DISEASE", 309, 325], ["T2DM", "DISEASE", 406, 410], ["obesity", "DISEASE", 414, 421], ["metformin", "CHEMICAL", 423, 432], ["metformin", "CHEMICAL", 423, 432], ["patients", "ORGANISM", 295, 303], ["men", "ORGANISM", 387, 390], ["women", "ORGANISM", 395, 400], ["metformin", "SIMPLE_CHEMICAL", 423, 432], ["women", "ORGANISM", 577, 582], ["patients", "SPECIES", 295, 303], ["men", "SPECIES", 387, 390], ["women", "SPECIES", 395, 400], ["women", "SPECIES", 577, 582], ["Sensitivity analyses", "TEST", 271, 291], ["Covid-19 disease", "PROBLEM", 309, 325], ["T2DM", "PROBLEM", 406, 410], ["obesity", "PROBLEM", 414, 421], ["metformin", "TREATMENT", 423, 432], ["decreased mortality", "PROBLEM", 471, 490], ["HR", "TEST", 584, 586], ["med", "ANATOMY", 102, 105], ["obesity", "OBSERVATION", 414, 421]]], ["Metformin was significantly associated with decreased mortality in women with type-2 diabetes or obesity in the minimally adjusted Cox shared frailty model, (Tables S1-S3) .DiscussionThis is the first study to report decreased mortality with outpatient metformin use in women with T2DM or obesity in a large cohort of patients hospitalized in the US for Covid-19, and to describe a sex difference in this response to metformin.", [["Metformin", "CHEMICAL", 0, 9], ["type-2 diabetes", "DISEASE", 78, 93], ["obesity", "DISEASE", 97, 104], ["metformin", "CHEMICAL", 253, 262], ["T2DM", "DISEASE", 281, 285], ["obesity", "DISEASE", 289, 296], ["metformin", "CHEMICAL", 417, 426], ["Metformin", "CHEMICAL", 0, 9], ["metformin", "CHEMICAL", 253, 262], ["metformin", "CHEMICAL", 417, 426], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["women", "ORGANISM", 67, 72], ["metformin", "SIMPLE_CHEMICAL", 253, 262], ["women", "ORGANISM", 270, 275], ["patients", "ORGANISM", 318, 326], ["metformin", "SIMPLE_CHEMICAL", 417, 426], ["women", "SPECIES", 67, 72], ["women", "SPECIES", 270, 275], ["patients", "SPECIES", 318, 326], ["Metformin", "TREATMENT", 0, 9], ["decreased mortality", "PROBLEM", 44, 63], ["type-2 diabetes", "PROBLEM", 78, 93], ["obesity", "PROBLEM", 97, 104], ["decreased mortality", "PROBLEM", 217, 236], ["outpatient metformin use", "TREATMENT", 242, 266], ["T2DM", "PROBLEM", 281, 285], ["obesity", "PROBLEM", 289, 296], ["Covid", "TEST", 354, 359], ["metformin", "TREATMENT", 417, 426], ["decreased", "OBSERVATION_MODIFIER", 44, 53], ["mortality", "OBSERVATION", 54, 63], ["obesity", "OBSERVATION", 97, 104], ["obesity", "OBSERVATION", 289, 296]]], ["These findings could have wide-reaching effects, as over 42% of women in the US have obesity.", [["obesity", "DISEASE", 85, 92], ["women", "ORGANISM", 64, 69], ["women", "SPECIES", 64, 69], ["obesity", "PROBLEM", 85, 92], ["wide", "OBSERVATION_MODIFIER", 26, 30], ["obesity", "OBSERVATION", 85, 92]]], ["29 We found that metformin use was associated with significantly lower mortality among women across all multivariate analyses: logistic regression, mixed-effects analysis, Cox proportional-hazards, and propensity-matched models.", [["metformin", "CHEMICAL", 17, 26], ["metformin", "CHEMICAL", 17, 26], ["metformin", "SIMPLE_CHEMICAL", 17, 26], ["women", "ORGANISM", 87, 92], ["women", "SPECIES", 87, 92], ["metformin", "TREATMENT", 17, 26], ["significantly lower mortality", "PROBLEM", 51, 80], ["logistic regression", "PROBLEM", 127, 146], ["mixed-effects analysis", "PROBLEM", 148, 170]]], ["The significant protective benefit in women .", [["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["protective", "OBSERVATION_MODIFIER", 16, 26], ["benefit", "OBSERVATION", 27, 34]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprint compared to men may shed light on the mechanism by which metformin decreases mortality from Covid-19, as metformin has been shown to reduce TNF\u03b1 in females more than males.", [["CC", "CHEMICAL", 0, 2], ["metformin", "CHEMICAL", 397, 406], ["Covid-19", "CHEMICAL", 432, 440], ["metformin", "CHEMICAL", 445, 454], ["metformin", "CHEMICAL", 397, 406], ["Covid-19", "CHEMICAL", 432, 440], ["metformin", "CHEMICAL", 445, 454], ["men", "ORGANISM", 352, 355], ["metformin", "SIMPLE_CHEMICAL", 397, 406], ["metformin", "SIMPLE_CHEMICAL", 445, 454], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 480, 484], ["TNF\u03b1", "PROTEIN", 480, 484], ["men", "SPECIES", 352, 355], ["medRxiv", "TREATMENT", 323, 330], ["metformin", "TREATMENT", 397, 406], ["Covid", "TEST", 432, 437], ["metformin", "TREATMENT", 445, 454], ["med", "ANATOMY", 102, 105]]], ["[17] [18] [19] [20] We also found reduced mortality in persons with outpatient use of TNF\u03b1 inhibitors who were hospitalized for Covid-19.", [["[17] [18] [19] [20", "SIMPLE_CHEMICAL", 0, 18], ["persons", "ORGANISM", 55, 62], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 86, 90], ["TNF", "PROTEIN", 86, 89], ["persons", "SPECIES", 55, 62], ["TNF\u03b1 inhibitors", "TREATMENT", 86, 101], ["Covid", "TEST", 128, 133], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["mortality", "OBSERVATION", 42, 51]]], ["TNF\u03b1 inhibitor use was associated with large decreases in odds of mortality, but these findings were not statistically significant, likely because of the small sample size of 38.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNF\u03b1", "PROTEIN", 0, 4], ["TNF\u03b1 inhibitor", "TREATMENT", 0, 14], ["large decreases in odds of mortality", "PROBLEM", 39, 75], ["large", "OBSERVATION_MODIFIER", 39, 44], ["decreases", "OBSERVATION_MODIFIER", 45, 54], ["small", "OBSERVATION_MODIFIER", 154, 159], ["sample", "OBSERVATION_MODIFIER", 160, 166], ["size", "OBSERVATION_MODIFIER", 167, 171]]], ["Reduced mortality in persons who use TNF\u03b1 inhibitors would support previous research that TNF\u03b1 plays a large role in the pathology of Covid-19.", [["persons", "ORGANISM", 21, 28], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 37, 41], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 90, 94], ["TNF\u03b1", "PROTEIN", 37, 41], ["TNF\u03b1", "PROTEIN", 90, 94], ["persons", "SPECIES", 21, 28], ["TNF\u03b1 inhibitors", "TREATMENT", 37, 52], ["Covid", "TEST", 134, 139], ["large", "OBSERVATION_MODIFIER", 103, 108]]], ["30 TNF\u03b1 leads to macrophage activation and increased cytokine release, likely contributing to Covid-19 pathology.", [["macrophage", "ANATOMY", 17, 27], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 3, 7], ["macrophage", "CELL", 17, 27], ["TNF\u03b1", "PROTEIN", 3, 7], ["cytokine", "PROTEIN", 53, 61], ["macrophage activation", "PROBLEM", 17, 38], ["increased cytokine release", "PROBLEM", 43, 69], ["Covid", "TEST", 94, 99], ["macrophage activation", "OBSERVATION", 17, 38], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["cytokine release", "OBSERVATION", 53, 69], ["likely contributing", "UNCERTAINTY", 71, 90]]], ["31 We considered other (overlapping) mechanisms by which metformin could reduce the severity of SARS-CoV-2 infection: ACE2 receptor modulation (via AMPK), decreased cytokine release (IL6, TNF\u03b1, increased IL-10), improved neutrophil to lymphocyte ratio, decreased glycemia (via AMPK), mast cell stabilization, decreased thrombosis, and improved endothelial function.", [["neutrophil", "ANATOMY", 221, 231], ["lymphocyte", "ANATOMY", 235, 245], ["mast cell", "ANATOMY", 284, 293], ["endothelial", "ANATOMY", 344, 355], ["metformin", "CHEMICAL", 57, 66], ["SARS", "DISEASE", 96, 100], ["infection", "DISEASE", 107, 116], ["thrombosis", "DISEASE", 319, 329], ["metformin", "CHEMICAL", 57, 66], ["metformin", "SIMPLE_CHEMICAL", 57, 66], ["CoV-2", "GENE_OR_GENE_PRODUCT", 101, 106], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 118, 131], ["AMPK", "GENE_OR_GENE_PRODUCT", 148, 152], ["IL6", "GENE_OR_GENE_PRODUCT", 183, 186], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 188, 192], ["IL-10", "GENE_OR_GENE_PRODUCT", 204, 209], ["neutrophil", "CELL", 221, 231], ["lymphocyte", "CELL", 235, 245], ["AMPK", "GENE_OR_GENE_PRODUCT", 277, 281], ["mast cell", "CELL", 284, 293], ["endothelial", "CELL", 344, 355], ["ACE2", "PROTEIN", 118, 122], ["AMPK", "PROTEIN", 148, 152], ["cytokine", "PROTEIN", 165, 173], ["IL6", "PROTEIN", 183, 186], ["TNF\u03b1", "PROTEIN", 188, 192], ["AMPK", "PROTEIN", 277, 281], ["SARS-CoV", "SPECIES", 96, 104], ["metformin", "TREATMENT", 57, 66], ["SARS", "PROBLEM", 96, 100], ["CoV-2 infection", "PROBLEM", 101, 116], ["ACE2 receptor modulation", "TREATMENT", 118, 142], ["decreased cytokine release", "PROBLEM", 155, 181], ["IL6", "TEST", 183, 186], ["TNF", "TEST", 188, 191], ["increased IL", "TREATMENT", 194, 206], ["lymphocyte ratio", "TEST", 235, 251], ["decreased glycemia", "PROBLEM", 253, 271], ["mast cell stabilization", "TREATMENT", 284, 307], ["decreased thrombosis", "PROBLEM", 309, 329], ["decreased glycemia", "OBSERVATION", 253, 271], ["mast cell stabilization", "OBSERVATION", 284, 307], ["decreased", "OBSERVATION_MODIFIER", 309, 318], ["thrombosis", "OBSERVATION", 319, 329], ["improved", "OBSERVATION_MODIFIER", 335, 343], ["endothelial function", "OBSERVATION", 344, 364]]], ["[16] [17] [18] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] In patients with and without diabetes, metformin has been shown to decrease inflammatory mediators IL-6 and TNF\u03b1.", [["[16] [17] [18] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43", "CHEMICAL", 0, 73], ["diabetes", "DISEASE", 109, 117], ["metformin", "CHEMICAL", 119, 128], ["[16] [17] [18] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42]", "CHEMICAL", 0, 69], ["metformin", "CHEMICAL", 119, 128], ["[16] [17] [18] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 0, 79], ["patients", "ORGANISM", 83, 91], ["metformin", "SIMPLE_CHEMICAL", 119, 128], ["IL-6", "GENE_OR_GENE_PRODUCT", 179, 183], ["TNF", "GENE_OR_GENE_PRODUCT", 188, 191], ["inflammatory mediators", "PROTEIN", 156, 178], ["IL-6", "PROTEIN", 179, 183], ["TNF", "PROTEIN", 188, 191], ["patients", "SPECIES", 83, 91], ["diabetes", "PROBLEM", 109, 117], ["metformin", "TREATMENT", 119, 128], ["inflammatory mediators IL", "TREATMENT", 156, 181]]], ["16, 43, 45 These effects are notable, as IL-6 and TNF\u03b1 are thought to contribute to Covid-19 pathology.", [["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 50, 54], ["IL-6", "PROTEIN", 41, 45], ["TNF\u03b1", "PROTEIN", 50, 54], ["IL", "TEST", 41, 43], ["TNF", "PROBLEM", 50, 53], ["Covid", "TEST", 84, 89], ["thought to contribute", "UNCERTAINTY", 59, 80]]], ["13 Metformin's effects on these cytokines have been shown to differ by sex, with favorable effects in female over male mice, particularly for TNF\u03b1.", [["Metformin", "CHEMICAL", 3, 12], ["Metformin", "CHEMICAL", 3, 12], ["Metformin", "SIMPLE_CHEMICAL", 3, 12], ["mice", "ORGANISM", 119, 123], ["TNF", "GENE_OR_GENE_PRODUCT", 142, 145], ["cytokines", "PROTEIN", 32, 41], ["TNF", "PROTEIN", 142, 145], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 119, 123], ["Metformin", "TREATMENT", 3, 12], ["these cytokines", "TREATMENT", 26, 41]]], ["18 Our findings of a strong sex-specific response to metformin in Covid-19 suggests that TNF\u03b1 reduction may be the primary way by which metformin reduced mortality from Covid-19.(which was not certified by peer review)Our sex-specific findings are consistent with prior literature showing mortality benefit in women but not men from colorectal cancer.", [["colorectal cancer", "ANATOMY", 333, 350], ["metformin", "CHEMICAL", 53, 62], ["metformin", "CHEMICAL", 136, 145], ["colorectal cancer", "DISEASE", 333, 350], ["metformin", "CHEMICAL", 53, 62], ["metformin", "CHEMICAL", 136, 145], ["Covid-19", "CHEMICAL", 169, 177], ["metformin", "SIMPLE_CHEMICAL", 53, 62], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 89, 93], ["metformin", "SIMPLE_CHEMICAL", 136, 145], ["women", "ORGANISM", 310, 315], ["men", "ORGANISM", 324, 327], ["colorectal cancer", "CANCER", 333, 350], ["TNF\u03b1", "PROTEIN", 89, 93], ["women", "SPECIES", 310, 315], ["men", "SPECIES", 324, 327], ["metformin", "TREATMENT", 53, 62], ["Covid", "TEST", 66, 71], ["TNF\u03b1 reduction", "TREATMENT", 89, 103], ["metformin", "TREATMENT", 136, 145], ["Covid", "TEST", 169, 174], ["colorectal cancer", "PROBLEM", 333, 350], ["consistent with", "UNCERTAINTY", 248, 263], ["colorectal", "ANATOMY", 333, 343], ["cancer", "OBSERVATION", 344, 350]]], ["20 Possible reasons for sex-specific effects of metformin include the influence of sex hormones and epigenetic changes on the Y chromosome.", [["Y chromosome", "ANATOMY", 126, 138], ["metformin", "CHEMICAL", 48, 57], ["metformin", "CHEMICAL", 48, 57], ["metformin", "SIMPLE_CHEMICAL", 48, 57], ["Y chromosome", "CELLULAR_COMPONENT", 126, 138], ["Y chromosome", "DNA", 126, 138], ["metformin", "TREATMENT", 48, 57], ["sex hormones", "TREATMENT", 83, 95], ["epigenetic changes", "PROBLEM", 100, 118]]], ["46 There are 2 other potential ways in which metformin might cause sex-specific responses in Covid-19: Metformin inhibits IgE-and aryl hydrocarbon-mediated mast cell activation, 47 and mast cell activation has been implicated as an early indicator of inflammatory response to SARS-CoV2 and possibly cytokine storm.", [["mast cell", "ANATOMY", 156, 165], ["mast cell", "ANATOMY", 185, 194], ["metformin", "CHEMICAL", 45, 54], ["Metformin", "CHEMICAL", 103, 112], ["aryl hydrocarbon", "CHEMICAL", 130, 146], ["SARS", "DISEASE", 276, 280], ["metformin", "CHEMICAL", 45, 54], ["Covid-19", "CHEMICAL", 93, 101], ["Metformin", "CHEMICAL", 103, 112], ["aryl hydrocarbon", "CHEMICAL", 130, 146], ["metformin", "SIMPLE_CHEMICAL", 45, 54], ["Metformin", "SIMPLE_CHEMICAL", 103, 112], ["IgE", "GENE_OR_GENE_PRODUCT", 122, 125], ["aryl hydrocarbon", "SIMPLE_CHEMICAL", 130, 146], ["mast cell", "CELL", 156, 165], ["mast cell", "CELL", 185, 194], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 276, 285], ["IgE", "PROTEIN", 122, 125], ["cytokine", "PROTEIN", 299, 307], ["metformin", "TREATMENT", 45, 54], ["Covid", "TEST", 93, 98], ["Metformin", "TREATMENT", 103, 112], ["IgE", "TEST", 122, 125], ["aryl hydrocarbon-mediated mast cell activation", "TREATMENT", 130, 176], ["mast cell activation", "TREATMENT", 185, 205], ["inflammatory response", "PROBLEM", 251, 272], ["SARS", "PROBLEM", 276, 280], ["cytokine storm", "PROBLEM", 299, 313], ["mast cell", "OBSERVATION", 156, 165], ["mast cell", "OBSERVATION", 185, 194], ["inflammatory", "OBSERVATION", 251, 263], ["possibly", "UNCERTAINTY", 290, 298], ["cytokine storm", "OBSERVATION", 299, 313]]], ["48 Mast cells from female rats cause a greater increase in TNF\u03b1 than mast cells in male rats, which could be one reason for greater .", [["Mast cells", "ANATOMY", 3, 13], ["mast cells", "ANATOMY", 69, 79], ["Mast cells", "CELL", 3, 13], ["rats", "ORGANISM", 26, 30], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 59, 63], ["mast cells", "CELL", 69, 79], ["rats", "ORGANISM", 88, 92], ["Mast cells", "CELL_TYPE", 3, 13], ["TNF\u03b1", "PROTEIN", 59, 63], ["mast cells", "CELL_TYPE", 69, 79], ["rats", "SPECIES", 26, 30], ["rats", "SPECIES", 88, 92], ["Mast cells", "PROBLEM", 3, 13], ["a greater increase in TNF\u03b1 than mast cells", "PROBLEM", 37, 79], ["greater", "OBSERVATION_MODIFIER", 39, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprint benefit from metformin in women than men.", [["CC", "CHEMICAL", 0, 2], ["metformin", "CHEMICAL", 353, 362], ["metformin", "CHEMICAL", 353, 362], ["metformin", "SIMPLE_CHEMICAL", 353, 362], ["women", "ORGANISM", 366, 371], ["men", "ORGANISM", 377, 380], ["women", "SPECIES", 366, 371], ["men", "SPECIES", 377, 380], ["medRxiv", "TREATMENT", 323, 330], ["metformin", "TREATMENT", 353, 362], ["med", "ANATOMY", 102, 105]]], ["49 Lastly, activation of AMPK by metformin can lead to increased expression of ACE2 and conformational changes to ACE2, and possibly decreasing SARS-CoV-2 binding to the ACE2 receptor.", [["metformin", "CHEMICAL", 33, 42], ["metformin", "CHEMICAL", 33, 42], ["AMPK", "GENE_OR_GENE_PRODUCT", 25, 29], ["metformin", "SIMPLE_CHEMICAL", 33, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 114, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 154], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 170, 183], ["AMPK", "PROTEIN", 25, 29], ["ACE2", "PROTEIN", 79, 83], ["ACE2", "PROTEIN", 114, 118], ["ACE2 receptor", "PROTEIN", 170, 183], ["AMPK", "TREATMENT", 25, 29], ["metformin", "TREATMENT", 33, 42], ["increased expression of ACE2", "PROBLEM", 55, 83], ["conformational changes", "PROBLEM", 88, 110], ["ACE2", "TEST", 114, 118], ["decreasing SARS", "PROBLEM", 133, 148], ["the ACE2 receptor", "TREATMENT", 166, 183], ["possibly", "UNCERTAINTY", 124, 132], ["decreasing", "OBSERVATION_MODIFIER", 133, 143], ["SARS", "OBSERVATION", 144, 148]]], ["[35] [36] [37] 50 Recent work by Li et al found that expression of ACE2 receptor was equal in male and female human lungs, but that cytokine responses differed between men and women.", [["lungs", "ANATOMY", 116, 121], ["Li", "CHEMICAL", 33, 35], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 67, 80], ["human", "ORGANISM", 110, 115], ["lungs", "ORGAN", 116, 121], ["men", "ORGANISM", 168, 171], ["women", "ORGANISM", 176, 181], ["ACE2 receptor", "PROTEIN", 67, 80], ["cytokine", "PROTEIN", 132, 140], ["human", "SPECIES", 110, 115], ["men", "SPECIES", 168, 171], ["women", "SPECIES", 176, 181], ["human", "SPECIES", 110, 115], ["ACE2 receptor", "TEST", 67, 80], ["lungs", "ANATOMY", 116, 121]]], ["38 This difference in subsequent inflammatory response and our sex-specific findings may support metformin's anti-inflammatory effects as the primary means of benefit in Covid-19.(which was not certified by peer review)Additionally, in our multivariate analyses, beta2-agonist use was associated with decreased mortality in patients with asthma across all analyses (Tables S1-S3).", [["metformin", "CHEMICAL", 97, 106], ["asthma", "DISEASE", 338, 344], ["metformin", "CHEMICAL", 97, 106], ["metformin", "SIMPLE_CHEMICAL", 97, 106], ["beta2-agonist", "GENE_OR_GENE_PRODUCT", 263, 276], ["patients", "ORGANISM", 324, 332], ["beta2", "PROTEIN", 263, 268], ["patients", "SPECIES", 324, 332], ["subsequent inflammatory response", "PROBLEM", 22, 54], ["metformin's anti-inflammatory effects", "TREATMENT", 97, 134], ["Covid", "TEST", 170, 175], ["beta2-agonist", "TREATMENT", 263, 276], ["decreased mortality", "PROBLEM", 301, 320], ["asthma", "PROBLEM", 338, 344], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["asthma", "OBSERVATION", 338, 344]]], ["This benefit may come from beta2agonists' effect on boosting IL-10, which is a predominantly anti-inflammatory cytokine that can reduce levels of TNF\u03b1.", [["beta2agonists", "SIMPLE_CHEMICAL", 27, 40], ["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["TNF", "GENE_OR_GENE_PRODUCT", 146, 149], ["IL-10", "PROTEIN", 61, 66], ["anti-inflammatory cytokine", "PROTEIN", 93, 119], ["TNF", "PROTEIN", 146, 149], ["boosting IL", "TREATMENT", 52, 63], ["a predominantly anti-inflammatory cytokine", "TREATMENT", 77, 119]]], ["51 Metformin has also been shown to boost levels of IL-10, in females more than males.", [["Metformin", "CHEMICAL", 3, 12], ["Metformin", "CHEMICAL", 3, 12], ["Metformin", "SIMPLE_CHEMICAL", 3, 12], ["IL-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL", "PROTEIN", 52, 54], ["Metformin", "TREATMENT", 3, 12], ["IL", "TEST", 52, 54]]], ["43, 45 The mortality benefit in persons with asthma on beta2-agonists, combined with our finding of mortality benefit from metformin use, suggest that IL-10 may also be important in Covid-19.(which was not certified by peer review)In summary, we found that metformin was associated with a significant decrease in mortality for women with T2DM or obesity who were hospitalized for Covid-19, in an observational analysis of deidentified claims.", [["asthma", "DISEASE", 45, 51], ["metformin", "CHEMICAL", 123, 132], ["metformin", "CHEMICAL", 257, 266], ["T2DM", "DISEASE", 338, 342], ["obesity", "DISEASE", 346, 353], ["metformin", "CHEMICAL", 123, 132], ["metformin", "CHEMICAL", 257, 266], ["persons", "ORGANISM", 32, 39], ["beta2-agonists", "GENE_OR_GENE_PRODUCT", 55, 69], ["metformin", "SIMPLE_CHEMICAL", 123, 132], ["IL-10", "GENE_OR_GENE_PRODUCT", 151, 156], ["metformin", "SIMPLE_CHEMICAL", 257, 266], ["women", "ORGANISM", 327, 332], ["IL", "PROTEIN", 151, 153], ["persons", "SPECIES", 32, 39], ["women", "SPECIES", 327, 332], ["asthma", "PROBLEM", 45, 51], ["beta2-agonists", "TREATMENT", 55, 69], ["metformin", "TREATMENT", 123, 132], ["metformin", "TREATMENT", 257, 266], ["a significant decrease in mortality", "PROBLEM", 287, 322], ["T2DM", "PROBLEM", 338, 342], ["obesity", "PROBLEM", 346, 353], ["Covid", "TEST", 380, 385], ["an observational analysis", "TEST", 393, 418], ["significant", "OBSERVATION_MODIFIER", 289, 300], ["decrease", "OBSERVATION_MODIFIER", 301, 309], ["obesity", "OBSERVATION", 346, 353]]], ["We found no significant mortality benefit in men with T2DM or obesity who were hospitalized with Covid-19.", [["T2DM", "DISEASE", 54, 58], ["obesity", "DISEASE", 62, 69], ["men", "ORGANISM", 45, 48], ["men", "SPECIES", 45, 48], ["T2DM", "PROBLEM", 54, 58], ["obesity", "PROBLEM", 62, 69], ["Covid", "TEST", 97, 102], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["obesity", "OBSERVATION", 62, 69]]], ["The sex-specific effects of metformin on TNF\u03b1, IL-6, and IL-10, and our findings of benefit in women, might indicate that metformin's protective effect in Covid-19 is primarily through effects on TNF\u03b1, IL-6, and IL-10.", [["metformin", "CHEMICAL", 28, 37], ["metformin", "CHEMICAL", 122, 131], ["Covid-19", "CHEMICAL", 155, 163], ["metformin", "CHEMICAL", 28, 37], ["metformin", "CHEMICAL", 122, 131], ["Covid-19", "CHEMICAL", 155, 163], ["metformin", "SIMPLE_CHEMICAL", 28, 37], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-6", "GENE_OR_GENE_PRODUCT", 47, 51], ["IL-10", "GENE_OR_GENE_PRODUCT", 57, 62], ["women", "ORGANISM", 95, 100], ["metformin", "SIMPLE_CHEMICAL", 122, 131], ["Covid-19", "SIMPLE_CHEMICAL", 155, 163], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 196, 200], ["IL-6", "GENE_OR_GENE_PRODUCT", 202, 206], ["IL-10", "GENE_OR_GENE_PRODUCT", 212, 217], ["TNF\u03b1", "PROTEIN", 41, 45], ["IL", "PROTEIN", 57, 59], ["TNF\u03b1", "PROTEIN", 196, 200], ["IL", "PROTEIN", 212, 214], ["women", "SPECIES", 95, 100], ["metformin", "TREATMENT", 28, 37], ["TNF\u03b1", "TEST", 41, 45], ["IL", "TEST", 47, 49], ["metformin", "TREATMENT", 122, 131], ["Covid", "TEST", 155, 160], ["TNF\u03b1", "TEST", 196, 200], ["IL", "TEST", 202, 204]]], ["The importance of TNF\u03b1 in Covid-19 is supported by our finding that TNF\u03b1 inhibitor use was associated with decreased mortality from Covid-19.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 18, 22], ["Covid-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 68, 72], ["TNF\u03b1", "PROTEIN", 18, 22], ["TNF\u03b1", "PROTEIN", 68, 72], ["TNF", "TEST", 18, 21], ["TNF\u03b1 inhibitor", "TREATMENT", 68, 82], ["decreased mortality", "PROBLEM", 107, 126], ["Covid", "TEST", 132, 137]]], ["The fact that these outpatient medications convey benefit in patients hospitalized for Covid-19 is interesting because metformin is universally stopped at hospital admission, suggesting its protective effects begin prior to hospitalization.(which was not certified by peer review)Given metformin's good safety profile and availability, 52 it should be prospectively assessed for protective benefit from Covid-19.", [["metformin", "CHEMICAL", 119, 128], ["metformin", "CHEMICAL", 286, 295], ["Covid-19", "CHEMICAL", 87, 95], ["metformin", "CHEMICAL", 119, 128], ["metformin", "CHEMICAL", 286, 295], ["Covid-19", "CHEMICAL", 403, 411], ["patients", "ORGANISM", 61, 69], ["metformin", "SIMPLE_CHEMICAL", 119, 128], ["metformin", "SIMPLE_CHEMICAL", 286, 295], ["patients", "SPECIES", 61, 69], ["these outpatient medications", "TREATMENT", 14, 42], ["Covid", "TEST", 87, 92], ["metformin", "TREATMENT", 119, 128], ["metformin", "TREATMENT", 286, 295], ["Covid", "TEST", 403, 408]]], ["Gastrointestinal side effects from metformin can be eliminated for over 85% of patients with use of the newer extended-release formulations, and further with administration at .", [["Gastrointestinal", "ANATOMY", 0, 16], ["metformin", "CHEMICAL", 35, 44], ["metformin", "CHEMICAL", 35, 44], ["metformin", "SIMPLE_CHEMICAL", 35, 44], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Gastrointestinal side effects", "PROBLEM", 0, 29], ["metformin", "TREATMENT", 35, 44], ["the newer extended-release formulations", "TREATMENT", 100, 139]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprint the end of a meal.", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 323, 330], ["med", "ANATOMY", 102, 105]]], ["53 With the median time to hospitalization for Covid-19 being about 1 week, it is necessary to understand the duration of metformin use that conveys benefit, and whether it prevents Covid-19.", [["metformin", "CHEMICAL", 122, 131], ["metformin", "CHEMICAL", 122, 131], ["Covid-19", "CHEMICAL", 182, 190], ["metformin", "SIMPLE_CHEMICAL", 122, 131], ["Covid", "TEST", 47, 52], ["metformin", "TREATMENT", 122, 131], ["Covid", "TEST", 182, 187]]], ["Over 34% of adults in the US have prediabetes, 54 yet it is highly under-diagnosed as over 90% of them are not aware that they do.", [["prediabetes", "DISEASE", 34, 45], ["adults", "ORGANISM", 12, 18], ["prediabetes", "PROBLEM", 34, 45], ["prediabetes", "OBSERVATION", 34, 45]]], ["55 Thus metformin for prevention of Covid-19 may be reasonable as metformin may be indicated for many adults in the US anyway.", [["metformin", "CHEMICAL", 8, 17], ["Covid-19", "CHEMICAL", 36, 44], ["metformin", "CHEMICAL", 66, 75], ["metformin", "CHEMICAL", 8, 17], ["Covid-19", "CHEMICAL", 36, 44], ["metformin", "CHEMICAL", 66, 75], ["metformin", "SIMPLE_CHEMICAL", 8, 17], ["Covid-19", "SIMPLE_CHEMICAL", 36, 44], ["metformin", "SIMPLE_CHEMICAL", 66, 75], ["metformin", "TREATMENT", 8, 17], ["Covid", "TEST", 36, 41], ["metformin", "TREATMENT", 66, 75]]], ["Additionally, increased inflammation from adiposity, and obesity's association with increased risk of poor outcomes from Covid-19, metformin should also be assessed in patients of all BMI categories.LimitationsOur study has several limitations.", [["inflammation", "DISEASE", 24, 36], ["obesity", "DISEASE", 57, 64], ["metformin", "CHEMICAL", 131, 140], ["Covid-19", "CHEMICAL", 121, 129], ["metformin", "CHEMICAL", 131, 140], ["metformin", "SIMPLE_CHEMICAL", 131, 140], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["increased inflammation from adiposity", "PROBLEM", 14, 51], ["obesity", "PROBLEM", 57, 64], ["poor outcomes", "PROBLEM", 102, 115], ["Covid", "TEST", 121, 126], ["metformin", "TREATMENT", 131, 140], ["Our study", "TEST", 210, 219], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["inflammation", "OBSERVATION", 24, 36], ["adiposity", "OBSERVATION_MODIFIER", 42, 51], ["obesity", "OBSERVATION", 57, 64], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["poor", "OBSERVATION_MODIFIER", 102, 106]]], ["Although claims data show metformin prescribed as a home medication for at least 90 days within the last 12 months, it does not give information about adherence.LimitationsMetformin is sometimes purchased without insurance claims in this population because of its low cost, thus some individuals in our control group may have been exposed to the treatment, which would reduce the observed effect size.", [["metformin", "CHEMICAL", 26, 35], ["Metformin", "CHEMICAL", 172, 181], ["metformin", "CHEMICAL", 26, 35], ["Metformin", "CHEMICAL", 172, 181], ["metformin", "SIMPLE_CHEMICAL", 26, 35], ["Metformin", "SIMPLE_CHEMICAL", 172, 181], ["metformin", "TREATMENT", 26, 35], ["a home medication", "TREATMENT", 50, 67], ["Metformin", "TREATMENT", 172, 181], ["the treatment", "TREATMENT", 342, 355], ["the observed effect size", "PROBLEM", 376, 400], ["effect", "OBSERVATION_MODIFIER", 389, 395], ["size", "OBSERVATION_MODIFIER", 396, 400]]], ["Prescriptions for outpatient use of metformin cannot be extrapolated to starting metformin at Covid-19 diagnosis or inpatient use.", [["metformin", "CHEMICAL", 36, 45], ["metformin", "CHEMICAL", 81, 90], ["metformin", "CHEMICAL", 36, 45], ["metformin", "CHEMICAL", 81, 90], ["metformin", "SIMPLE_CHEMICAL", 36, 45], ["metformin", "SIMPLE_CHEMICAL", 81, 90], ["metformin", "TREATMENT", 36, 45], ["metformin", "TREATMENT", 81, 90]]], ["Retrospective analyses are subject to biases and unmeasured confounding.", [["Retrospective analyses", "TEST", 0, 22]]], ["While multicollinearity among potential confounders makes interpreting their independent associations with in-hospital mortality potentially difficult, adjustments for these confounders is necessary to minimize bias for estimating the causal effect of home metformin use on inhospital mortality.", [["metformin", "CHEMICAL", 257, 266], ["metformin", "CHEMICAL", 257, 266], ["metformin", "SIMPLE_CHEMICAL", 257, 266], ["home metformin", "TREATMENT", 252, 266]]], ["56, 57 Conclusion In a large de-identified claims database of adults with T2DM or obesity, metformin was associated with significantly decreased mortality in women hospitalized with Covid-19, with no significant mortality reduction in men.", [["T2DM", "DISEASE", 74, 78], ["obesity", "DISEASE", 82, 89], ["metformin", "CHEMICAL", 91, 100], ["metformin", "CHEMICAL", 91, 100], ["adults", "ORGANISM", 62, 68], ["metformin", "SIMPLE_CHEMICAL", 91, 100], ["women", "ORGANISM", 158, 163], ["men", "ORGANISM", 235, 238], ["women", "SPECIES", 158, 163], ["men", "SPECIES", 235, 238], ["T2DM", "PROBLEM", 74, 78], ["obesity", "PROBLEM", 82, 89], ["metformin", "TREATMENT", 91, 100], ["significantly decreased mortality", "PROBLEM", 121, 154], ["Covid", "TEST", 182, 187], ["significant mortality reduction", "PROBLEM", 200, 231], ["large", "OBSERVATION_MODIFIER", 23, 28], ["obesity", "OBSERVATION", 82, 89], ["no", "UNCERTAINTY", 197, 199], ["significant", "OBSERVATION_MODIFIER", 200, 211], ["mortality", "OBSERVATION", 212, 221]]], ["Mechanistic reasons that support a sex-specific reason for metformin to be protective in Covid-19 include anti-inflammatory effects on TNF\u03b1, IL-6, and possibly IL-10.", [["metformin", "CHEMICAL", 59, 68], ["metformin", "CHEMICAL", 59, 68], ["metformin", "SIMPLE_CHEMICAL", 59, 68], ["Covid-19", "SIMPLE_CHEMICAL", 89, 97], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 135, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 141, 145], ["IL-10", "GENE_OR_GENE_PRODUCT", 160, 165], ["TNF\u03b1", "PROTEIN", 135, 139], ["IL", "PROTEIN", 160, 162], ["metformin", "TREATMENT", 59, 68], ["anti-inflammatory effects", "TREATMENT", 106, 131], ["TNF\u03b1", "TEST", 135, 139], ["IL", "TEST", 141, 143]]], ["We also found that TNF\u03b1 inhibitors were associated with reduced mortality, this finding was not significant in all models, likely due to the small sample size.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 19, 23], ["TNF\u03b1", "PROTEIN", 19, 23], ["TNF\u03b1 inhibitors", "TREATMENT", 19, 34], ["reduced mortality", "PROBLEM", 56, 73], ["the small sample size", "PROBLEM", 137, 158], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["likely due to", "UNCERTAINTY", 123, 136], ["small", "OBSERVATION_MODIFIER", 141, 146], ["sample", "OBSERVATION_MODIFIER", 147, 153], ["size", "OBSERVATION_MODIFIER", 154, 158]]], ["Metformin has a good safety profile, .", [["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["Metformin", "TREATMENT", 0, 9]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprint availability, and needs to be prospectively assessed to understand mechanism, duration, and timing of treatment necessary for benefit.", [["CC", "CHEMICAL", 0, 2], ["treatment", "TREATMENT", 442, 451], ["med", "ANATOMY", 102, 105]]], ["Given obesity's pro-inflammatory effects that contribute to Covid-19 pathology, and the potential anti-inflammatory benefit of metformin in Covid-19, metformin should also be assessed in all BMI categories.(which was not certified by peer review).", [["obesity", "DISEASE", 6, 13], ["metformin", "CHEMICAL", 127, 136], ["Covid-19", "CHEMICAL", 140, 148], ["metformin", "CHEMICAL", 150, 159], ["metformin", "CHEMICAL", 127, 136], ["Covid-19", "CHEMICAL", 140, 148], ["metformin", "CHEMICAL", 150, 159], ["metformin", "SIMPLE_CHEMICAL", 127, 136], ["metformin", "SIMPLE_CHEMICAL", 150, 159], ["obesity", "PROBLEM", 6, 13], ["pro-inflammatory effects", "PROBLEM", 16, 40], ["Covid", "TEST", 60, 65], ["metformin", "TREATMENT", 127, 136], ["Covid", "TEST", 140, 145], ["metformin", "TREATMENT", 150, 159]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted June 28, 2020. . https://doi.org/10.1101/2020.06.19.20135095 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 364, 371], ["med", "ANATOMY", 102, 105]]]], "96abc8769d5840bdeac8590d795561706f34b4c4": [["During the currently ongoing Ebola virus disease (EVD) outbreak in the Democratic Republic of Congo, a clinical trial of potential treatments has commenced.", [["Ebola virus disease", "DISEASE", 29, 48], ["EVD", "DISEASE", 50, 53], ["Ebola virus", "ORGANISM", 29, 40], ["Ebola virus", "SPECIES", 29, 40], ["Ebola virus", "SPECIES", 29, 40], ["ongoing Ebola virus disease", "PROBLEM", 21, 48], ["potential treatments", "TREATMENT", 121, 141], ["Ebola virus disease", "OBSERVATION", 29, 48]]], ["This is a significant step toward improving outcomes for patients with the disease.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["the disease", "PROBLEM", 71, 82], ["disease", "OBSERVATION", 75, 82]]]], "bc8217a7183906261dc15337b14a300e37f7168e": [["Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisThe global concern is currently focused on the novel coronavirus, named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was isolated in China in January 2020.", [["SARS", "DISEASE", 21, 25], ["type 1 diabetes", "DISEASE", 33, 48], ["autoimmune pathogenesis", "DISEASE", 50, 73], ["acute respiratory syndrome coronavirus", "DISEASE", 155, 193], ["coronavirus", "ORGANISM", 126, 137], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 148, 195], ["SARS-CoV-2", "ORGANISM", 197, 207], ["severe acute respiratory syndrome coronavirus", "SPECIES", 148, 193], ["SARS-CoV-2", "SPECIES", 197, 207], ["COVID", "TEST", 11, 16], ["type 1 diabetes", "PROBLEM", 33, 48], ["autoimmune pathogenesis", "PROBLEM", 50, 73], ["the novel coronavirus", "PROBLEM", 116, 137], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 148, 193], ["SARS-CoV", "TEST", 197, 205], ["diabetes", "OBSERVATION", 40, 48], ["autoimmune", "OBSERVATION", 50, 60], ["global", "OBSERVATION_MODIFIER", 77, 83], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory syndrome", "OBSERVATION", 161, 181]]], ["This virus is responsible for an outbreak of pneumonia, defined as coronavirus disease 2019 (COVID-19), which appeared in Hubei province (China) at the end of 2019 and later spread worldwide [1] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisAlthough the disease supposedly originated from a zoonotic virus transmission by live wild animals, it became a person-to-person transmitted infection: the virus is mostly carried by asymptomatic or mild symptomatic people.", [["pneumonia", "DISEASE", 45, 54], ["coronavirus disease", "DISEASE", 67, 86], ["SARS", "DISEASE", 217, 221], ["type 1 diabetes", "DISEASE", 229, 244], ["autoimmune pathogenesis", "DISEASE", 246, 269], ["zoonotic virus transmission", "DISEASE", 319, 346], ["infection", "DISEASE", 410, 419], ["people", "ORGANISM", 485, 491], ["person", "SPECIES", 381, 387], ["person", "SPECIES", 391, 397], ["people", "SPECIES", 485, 491], ["This virus", "PROBLEM", 0, 10], ["pneumonia", "PROBLEM", 45, 54], ["coronavirus disease", "PROBLEM", 67, 86], ["COVID", "TEST", 93, 98], ["COVID", "TEST", 207, 212], ["type 1 diabetes", "PROBLEM", 229, 244], ["autoimmune pathogenesis", "PROBLEM", 246, 269], ["the disease", "PROBLEM", 278, 289], ["a zoonotic virus transmission", "TREATMENT", 317, 346], ["transmitted infection", "PROBLEM", 398, 419], ["the virus", "PROBLEM", 421, 430], ["mild symptomatic people", "PROBLEM", 468, 491], ["responsible for", "UNCERTAINTY", 14, 29], ["outbreak", "OBSERVATION_MODIFIER", 33, 41], ["pneumonia", "OBSERVATION", 45, 54], ["coronavirus disease", "OBSERVATION", 67, 86], ["diabetes", "OBSERVATION", 236, 244], ["autoimmune", "OBSERVATION", 246, 256], ["disease", "OBSERVATION", 282, 289], ["infection", "OBSERVATION", 410, 419], ["mild", "OBSERVATION_MODIFIER", 468, 472], ["symptomatic", "OBSERVATION_MODIFIER", 473, 484]]], ["In the majority of patients, the immune system can successfully defeat the infection.", [["immune system", "ANATOMY", 33, 46], ["infection", "DISEASE", 75, 84], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["the immune system", "TREATMENT", 29, 46], ["the infection", "PROBLEM", 71, 84], ["infection", "OBSERVATION", 75, 84]]], ["However, the clinical severity of COVID-19 is strictly related to coexisting conditions, which could determine a dysfunctional immune/inflammatory response to environmental factors [1, 2] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisDiabetes mellitus (DM) has been identified as one of the most common comorbidities associated with COVID-19: people with DM, especially type 2 diabetes, infected with SARS-CoV-2 are susceptible of worse clinical outcomes (higher hospitalization rate and mortality) [3] .", [["SARS", "DISEASE", 210, 214], ["type 1 diabetes", "DISEASE", 222, 237], ["Diabetes mellitus", "DISEASE", 262, 279], ["DM", "DISEASE", 281, 283], ["DM", "DISEASE", 383, 385], ["type 2 diabetes", "DISEASE", 398, 413], ["SARS", "DISEASE", 429, 433], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "GENE_OR_GENE_PRODUCT", 34, 42], ["people", "ORGANISM", 371, 377], ["SARS-CoV-2", "ORGANISM", 429, 439], ["people", "SPECIES", 371, 377], ["SARS-CoV", "SPECIES", 429, 437], ["COVID", "TEST", 34, 39], ["coexisting conditions", "PROBLEM", 66, 87], ["a dysfunctional immune/inflammatory response", "PROBLEM", 111, 155], ["COVID", "TEST", 200, 205], ["type 1 diabetes", "PROBLEM", 222, 237], ["autoimmune pathogenesisDiabetes mellitus (DM", "PROBLEM", 239, 283], ["DM", "PROBLEM", 383, 385], ["type 2 diabetes", "PROBLEM", 398, 413], ["SARS", "PROBLEM", 429, 433], ["inflammatory", "OBSERVATION_MODIFIER", 134, 146], ["diabetes", "OBSERVATION", 229, 237], ["diabetes", "OBSERVATION", 405, 413]]], ["Similarly, a major risk of hospitalization and Intensive Care Unit (ICU) admission was described in people with diabetes in 2010, during Influenza A (H1N1) pandemic, confirming the frailty of these patients due to the impaired immune response [4] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisOn the other hand, viral infections have been widely associated with type 1 diabetes (T1DM) pathogenesis.", [["diabetes", "DISEASE", 112, 120], ["Influenza A (H1N1) pandemic", "DISEASE", 137, 164], ["SARS", "DISEASE", 269, 273], ["type 1 diabetes", "DISEASE", 281, 296], ["autoimmune pathogenesisOn", "DISEASE", 298, 323], ["viral infections", "DISEASE", 340, 356], ["type 1 diabetes", "DISEASE", 390, 405], ["T1DM", "DISEASE", 407, 411], ["people", "ORGANISM", 100, 106], ["Influenza A (H1N1)", "ORGANISM", 137, 155], ["patients", "ORGANISM", 198, 206], ["hand", "ORGANISM_SUBDIVISION", 334, 338], ["people", "SPECIES", 100, 106], ["patients", "SPECIES", 198, 206], ["Influenza A (H1N1)", "SPECIES", 137, 155], ["SARS-CoV", "SPECIES", 269, 277], ["diabetes", "PROBLEM", 112, 120], ["pandemic", "PROBLEM", 156, 164], ["the impaired immune response", "PROBLEM", 214, 242], ["COVID", "TEST", 259, 264], ["SARS", "TEST", 269, 273], ["type 1 diabetes", "PROBLEM", 281, 296], ["autoimmune pathogenesisOn the other hand", "PROBLEM", 298, 338], ["viral infections", "PROBLEM", 340, 356], ["type 1 diabetes (T1DM) pathogenesis", "PROBLEM", 390, 425], ["diabetes", "OBSERVATION", 288, 296], ["autoimmune", "OBSERVATION", 298, 308], ["viral infections", "OBSERVATION", 340, 356], ["diabetes", "OBSERVATION", 397, 405]]], ["T1DM is an autoimmune disease characterized by progressive pancreatic \u03b2-cells destruction and insulin deficiency.", [["pancreatic \u03b2-cells", "ANATOMY", 59, 77], ["T1DM", "DISEASE", 0, 4], ["autoimmune disease", "DISEASE", 11, 29], ["insulin deficiency", "DISEASE", 94, 112], ["pancreatic \u03b2-cells", "CELL", 59, 77], ["insulin", "GENE_OR_GENE_PRODUCT", 94, 101], ["pancreatic \u03b2-cells", "CELL_TYPE", 59, 77], ["T1DM", "PROBLEM", 0, 4], ["an autoimmune disease", "PROBLEM", 8, 29], ["progressive pancreatic \u03b2-cells destruction", "PROBLEM", 47, 89], ["insulin deficiency", "PROBLEM", 94, 112], ["autoimmune disease", "OBSERVATION", 11, 29], ["progressive", "OBSERVATION_MODIFIER", 47, 58], ["pancreatic", "ANATOMY", 59, 69], ["\u03b2-cells destruction", "OBSERVATION", 70, 89], ["insulin deficiency", "OBSERVATION", 94, 112]]], ["In the past 30 years, T1DM incidence increased due to the exposure to both environmental and life-style factors which promote the generation of an autoimmune process against \u03b2-cells responsible for islet destruction and insulin depletion, resulting in hyperglycemia.", [["\u03b2-cells", "ANATOMY", 174, 181], ["islet", "ANATOMY", 198, 203], ["T1DM", "DISEASE", 22, 26], ["hyperglycemia", "DISEASE", 252, 265], ["\u03b2-cells", "CELL", 174, 181], ["islet", "MULTI-TISSUE_STRUCTURE", 198, 203], ["insulin", "GENE_OR_GENE_PRODUCT", 220, 227], ["\u03b2-cells", "CELL_TYPE", 174, 181], ["T1DM incidence", "PROBLEM", 22, 36], ["life-style factors", "TREATMENT", 93, 111], ["an autoimmune process", "PROBLEM", 144, 165], ["\u03b2-cells", "PROBLEM", 174, 181], ["islet destruction", "PROBLEM", 198, 215], ["insulin depletion", "PROBLEM", 220, 237], ["hyperglycemia", "PROBLEM", 252, 265], ["autoimmune", "OBSERVATION", 147, 157], ["insulin depletion", "OBSERVATION", 220, 237], ["hyperglycemia", "OBSERVATION", 252, 265]]], ["Specific T1DM autoantibodies can be detected months/years after their effective production in affected individuals.", [["T1DM", "DISEASE", 9, 13], ["T1DM autoantibodies", "PROTEIN", 9, 28], ["Specific T1DM autoantibodies", "PROBLEM", 0, 28], ["affected individuals", "PROBLEM", 94, 114]]], ["Moreover, T1DM onset can be further delayed, leading to a difficult recognition of the trigger factor [5] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisAn important evidence of the relationship between coronavirus and diabetes dates back to the SARS-CoV pandemic of 2003: hyperglycemia was described as an independent predictor of morbidity and mortality, in both diabetic and non-diabetic patients.", [["T1DM", "DISEASE", 10, 14], ["SARS", "DISEASE", 128, 132], ["type 1 diabetes", "DISEASE", 140, 155], ["autoimmune pathogenesisAn", "DISEASE", 157, 182], ["coronavirus", "DISEASE", 230, 241], ["diabetes", "DISEASE", 246, 254], ["SARS-CoV pandemic", "DISEASE", 273, 290], ["hyperglycemia", "DISEASE", 300, 313], ["diabetic", "DISEASE", 392, 400], ["non-diabetic", "DISEASE", 405, 417], ["coronavirus", "ORGANISM", 230, 241], ["patients", "ORGANISM", 418, 426], ["patients", "SPECIES", 418, 426], ["SARS-CoV", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 273, 281], ["T1DM onset", "PROBLEM", 10, 20], ["COVID", "TEST", 118, 123], ["SARS", "TEST", 128, 132], ["type 1 diabetes", "PROBLEM", 140, 155], ["autoimmune pathogenesisAn", "PROBLEM", 157, 182], ["coronavirus", "PROBLEM", 230, 241], ["diabetes dates", "PROBLEM", 246, 260], ["the SARS", "PROBLEM", 269, 277], ["hyperglycemia", "PROBLEM", 300, 313], ["diabetes", "OBSERVATION", 147, 155], ["hyperglycemia", "OBSERVATION", 300, 313]]], ["Hyperglycemia was found in patients with mild respiratory symptoms, even in those not treated with glucocorticoids, reinforcing hence the hypothesis of \u03b2-cells acute damage as a consequence of the virus replicative cycle in endocrine pancreas [6] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisMoreover, prospective studies of genetically predisposed individuals have reported an intriguing connection between viral infections and T1DM.", [["respiratory", "ANATOMY", 46, 57], ["endocrine pancreas", "ANATOMY", 224, 242], ["Hyperglycemia", "DISEASE", 0, 13], ["respiratory symptoms", "DISEASE", 46, 66], ["glucocorticoids", "CHEMICAL", 99, 114], ["acute damage", "DISEASE", 160, 172], ["SARS", "DISEASE", 269, 273], ["type 1 diabetes", "DISEASE", 281, 296], ["autoimmune pathogenesis", "DISEASE", 298, 321], ["viral infections", "DISEASE", 437, 453], ["T1DM", "DISEASE", 458, 462], ["patients", "ORGANISM", 27, 35], ["endocrine", "CELL", 224, 233], ["pancreas", "ORGAN", 234, 242], ["individuals", "ORGANISM", 378, 389], ["patients", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 269, 277], ["Hyperglycemia", "PROBLEM", 0, 13], ["mild respiratory symptoms", "PROBLEM", 41, 66], ["glucocorticoids", "TREATMENT", 99, 114], ["\u03b2-cells acute damage", "PROBLEM", 152, 172], ["the virus replicative cycle in endocrine pancreas", "PROBLEM", 193, 242], ["COVID", "TEST", 259, 264], ["SARS-CoV", "TEST", 269, 277], ["type 1 diabetes", "PROBLEM", 281, 296], ["autoimmune pathogenesis", "PROBLEM", 298, 321], ["prospective studies", "TEST", 331, 350], ["viral infections", "PROBLEM", 437, 453], ["T1DM", "PROBLEM", 458, 462], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["respiratory", "ANATOMY", 46, 57], ["symptoms", "OBSERVATION", 58, 66], ["pancreas", "ANATOMY", 234, 242], ["diabetes", "OBSERVATION", 288, 296], ["viral", "OBSERVATION_MODIFIER", 437, 442], ["infections", "OBSERVATION", 443, 453]]], ["In 2017, TEDDY study reported an increased risk of \u03b2-cell autoimmunity in a group of 87,327 patients with a recent respiratory infection, involving both the upper and the lower respiratory tract.", [["\u03b2-cell", "ANATOMY", 51, 57], ["respiratory", "ANATOMY", 115, 126], ["lower respiratory tract", "ANATOMY", 171, 194], ["autoimmunity", "DISEASE", 58, 70], ["respiratory infection", "DISEASE", 115, 136], ["\u03b2-cell", "CELL", 51, 57], ["patients", "ORGANISM", 92, 100], ["upper", "ORGANISM_SUBDIVISION", 157, 162], ["lower", "ORGANISM_SUBDIVISION", 171, 176], ["respiratory tract", "ORGANISM_SUBDIVISION", 177, 194], ["patients", "SPECIES", 92, 100], ["TEDDY study", "TEST", 9, 20], ["\u03b2-cell autoimmunity", "PROBLEM", 51, 70], ["a recent respiratory infection", "PROBLEM", 106, 136], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["\u03b2-cell autoimmunity", "OBSERVATION", 51, 70], ["respiratory", "ANATOMY", 115, 126], ["infection", "OBSERVATION", 127, 136], ["both", "ANATOMY_MODIFIER", 148, 152], ["upper", "ANATOMY_MODIFIER", 157, 162], ["lower", "ANATOMY_MODIFIER", 171, 176], ["respiratory tract", "ANATOMY", 177, 194]]], ["Overall, the 5.8% of enrolled patients developed persistent pancreatic islet autoimmunity, with single or multiple T1DM autoantibodies at seroconversion after 9 months from the respiratory infection.", [["pancreatic islet", "ANATOMY", 60, 76], ["respiratory", "ANATOMY", 177, 188], ["pancreatic islet autoimmunity", "DISEASE", 60, 89], ["T1DM", "DISEASE", 115, 119], ["respiratory infection", "DISEASE", 177, 198], ["patients", "ORGANISM", 30, 38], ["pancreatic islet", "MULTI-TISSUE_STRUCTURE", 60, 76], ["patients", "SPECIES", 30, 38], ["persistent pancreatic islet autoimmunity", "PROBLEM", 49, 89], ["multiple T1DM autoantibodies", "PROBLEM", 106, 134], ["the respiratory infection", "PROBLEM", 173, 198], ["persistent", "OBSERVATION_MODIFIER", 49, 59], ["pancreatic", "ANATOMY", 60, 70], ["islet autoimmunity", "OBSERVATION", 71, 89], ["multiple", "OBSERVATION_MODIFIER", 106, 114], ["T1DM", "OBSERVATION_MODIFIER", 115, 119], ["autoantibodies", "OBSERVATION", 120, 134], ["respiratory", "ANATOMY", 177, 188], ["infection", "OBSERVATION", 189, 198]]], ["Autoantibodies were more commonly detected in patients with severe respiratory disease, although mild symptomatic infections were also associated with autoimmunity.", [["respiratory", "ANATOMY", 67, 78], ["respiratory disease", "DISEASE", 67, 86], ["infections", "DISEASE", 114, 124], ["autoimmunity", "DISEASE", 151, 163], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["Autoantibodies", "PROBLEM", 0, 14], ["severe respiratory disease", "PROBLEM", 60, 86], ["mild symptomatic infections", "PROBLEM", 97, 124], ["autoimmunity", "PROBLEM", 151, 163], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["respiratory disease", "OBSERVATION", 67, 86], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["symptomatic", "OBSERVATION_MODIFIER", 102, 113], ["infections", "OBSERVATION", 114, 124]]], ["Interestingly, coronaviruses were identified as one the different pathogens involved [7] .", [["coronaviruses", "ORGANISM", 15, 28], ["coronaviruses", "PROBLEM", 15, 28], ["coronaviruses", "OBSERVATION", 15, 28]]], ["In 2018, a cohort study investigated the relationship between T1DM and both pandemic and seasonal influenza infections: although a clear association was not demonstrated, a twofold excess of incident T1DM was found among the 76,173 patients with pandemic H1N1 infection diagnosed by laboratory or specialist healthcare [8] .Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisAutoimmune insulitis and pancreatic \u03b2-cell destruction could be triggered by viral infections through several mechanisms.", [["pancreatic \u03b2-cell", "ANATOMY", 422, 439], ["T1DM", "DISEASE", 62, 66], ["pandemic", "DISEASE", 76, 84], ["influenza infections", "DISEASE", 98, 118], ["T1DM", "DISEASE", 200, 204], ["H1N1 infection", "DISEASE", 255, 269], ["SARS", "DISEASE", 345, 349], ["type 1 diabetes", "DISEASE", 357, 372], ["autoimmune pathogenesisAutoimmune insulitis", "DISEASE", 374, 417], ["pancreatic \u03b2-cell destruction", "DISEASE", 422, 451], ["viral infections", "DISEASE", 474, 490], ["patients", "ORGANISM", 232, 240], ["pancreatic \u03b2-cell", "CELL", 422, 439], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 345, 353], ["a cohort study", "TEST", 9, 23], ["T1DM", "PROBLEM", 62, 66], ["seasonal influenza infections", "PROBLEM", 89, 118], ["T1DM", "PROBLEM", 200, 204], ["pandemic H1N1 infection", "PROBLEM", 246, 269], ["COVID", "TEST", 335, 340], ["SARS-CoV", "TEST", 345, 353], ["type 1 diabetes", "PROBLEM", 357, 372], ["autoimmune pathogenesisAutoimmune insulitis", "PROBLEM", 374, 417], ["pancreatic \u03b2-cell destruction", "PROBLEM", 422, 451], ["viral infections", "PROBLEM", 474, 490], ["seasonal", "OBSERVATION_MODIFIER", 89, 97], ["influenza", "OBSERVATION", 98, 107], ["diabetes", "OBSERVATION", 364, 372], ["autoimmune pathogenesisAutoimmune insulitis", "OBSERVATION", 374, 417], ["pancreatic", "ANATOMY", 422, 432], ["\u03b2-cell destruction", "OBSERVATION", 433, 451], ["viral", "OBSERVATION_MODIFIER", 474, 479], ["infections", "OBSERVATION", 480, 490]]], ["The loss of \u03b2-cells may directly result from virus amplification cycle and/or viral antigens diffusion through the circulation.", [["\u03b2-cells", "ANATOMY", 12, 19], ["\u03b2-cells", "GENE_OR_GENE_PRODUCT", 12, 19], ["\u03b2-cells", "PROTEIN", 12, 19], ["viral antigens", "PROTEIN", 78, 92], ["The loss of \u03b2-cells", "PROBLEM", 0, 19], ["virus amplification cycle", "TEST", 45, 70], ["viral antigens diffusion through the circulation", "PROBLEM", 78, 126], ["circulation", "ANATOMY", 115, 126]]], ["This mechanism determines an aggressive immune response, which also involves surrounding exocrine pancreatic cells, leading frequently to fulminant T1DM [9, 10] .", [["exocrine pancreatic cells", "ANATOMY", 89, 114], ["T1DM", "DISEASE", 148, 152], ["exocrine pancreatic cells", "CELL", 89, 114], ["exocrine pancreatic cells", "CELL_TYPE", 89, 114], ["an aggressive immune response", "PROBLEM", 26, 55], ["fulminant T1DM", "PROBLEM", 138, 152], ["aggressive", "OBSERVATION_MODIFIER", 29, 39], ["immune response", "OBSERVATION", 40, 55], ["pancreatic cells", "ANATOMY", 98, 114]]], ["Moreover, \u03b2-cell damage may determine the release of sequestered islet antigens which consequently are expressed by antigen-presenting cells in the regional lymphnodes.Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisEspecially during chronic infections, the overexpression of the major histocompatibility complex class I proteins could be responsible for a prolonged presentation of \u03b2-cell epitopes to the immune system, increasing the risk of autoantibodies generation.", [["\u03b2-cell", "ANATOMY", 10, 16], ["islet", "ANATOMY", 65, 70], ["cells", "ANATOMY", 135, 140], ["lymphnodes", "ANATOMY", 157, 167], ["\u03b2-cell", "ANATOMY", 408, 414], ["immune system", "ANATOMY", 431, 444], ["SARS", "DISEASE", 189, 193], ["type 1 diabetes", "DISEASE", 201, 216], ["autoimmune pathogenesis", "DISEASE", 218, 241], ["chronic infections", "DISEASE", 259, 277], ["\u03b2-cell", "CELL", 10, 16], ["islet antigens", "GENE_OR_GENE_PRODUCT", 65, 79], ["cells", "CELL", 135, 140], ["lymphnodes", "CANCER", 157, 167], ["major histocompatibility complex class I", "GENE_OR_GENE_PRODUCT", 305, 345], ["sequestered islet antigens", "PROTEIN", 53, 79], ["antigen-presenting cells", "CELL_TYPE", 116, 140], ["major histocompatibility complex class I proteins", "PROTEIN", 305, 354], ["\u03b2-cell epitopes", "PROTEIN", 408, 423], ["autoantibodies", "PROTEIN", 469, 483], ["\u03b2-cell damage", "PROBLEM", 10, 23], ["sequestered islet antigens", "PROBLEM", 53, 79], ["COVID", "TEST", 179, 184], ["type 1 diabetes", "PROBLEM", 201, 216], ["autoimmune pathogenesis", "PROBLEM", 218, 241], ["chronic infections", "PROBLEM", 259, 277], ["\u03b2-cell epitopes", "PROBLEM", 408, 423], ["autoantibodies generation", "PROBLEM", 469, 494], ["regional", "ANATOMY_MODIFIER", 148, 156], ["lymphnodes", "ANATOMY", 157, 167], ["diabetes", "OBSERVATION", 208, 216], ["autoimmune", "OBSERVATION", 218, 228], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["infections", "OBSERVATION", 267, 277], ["autoantibodies generation", "OBSERVATION", 469, 494]]], ["Furthermore, viral epitopes sharing homologies with aminoacid sequences of autoantigens could lead to the production of cross-reactive antibodies' against \u03b2-cells, even after the viral infection is cleared (molecular mimicry hypothesis).Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisFinally, viral infection can contribute to a faster development of T1DM through cytokines release and T cells activation in individuals genetically predisposed to autoimmunity [10] .", [["\u03b2-cells", "ANATOMY", 155, 162], ["T cells", "ANATOMY", 412, 419], ["viral infection", "DISEASE", 179, 194], ["SARS", "DISEASE", 258, 262], ["type 1 diabetes", "DISEASE", 270, 285], ["autoimmune pathogenesis", "DISEASE", 287, 310], ["viral infection", "DISEASE", 319, 334], ["T1DM", "DISEASE", 377, 381], ["autoimmunity", "DISEASE", 473, 485], ["aminoacid", "CHEMICAL", 52, 61], ["\u03b2-cells", "CELL", 155, 162], ["T cells", "CELL", 412, 419], ["viral epitopes", "PROTEIN", 13, 27], ["autoantigens", "PROTEIN", 75, 87], ["cross-reactive antibodies", "PROTEIN", 120, 145], ["\u03b2-cells", "CELL_TYPE", 155, 162], ["cytokines", "PROTEIN", 390, 399], ["T cells", "CELL_TYPE", 412, 419], ["viral epitopes sharing homologies", "PROBLEM", 13, 46], ["aminoacid sequences of autoantigens", "PROBLEM", 52, 87], ["cross-reactive antibodies'", "PROBLEM", 120, 146], ["\u03b2-cells", "PROBLEM", 155, 162], ["the viral infection", "PROBLEM", 175, 194], ["COVID", "TEST", 248, 253], ["type 1 diabetes", "PROBLEM", 270, 285], ["autoimmune pathogenesis", "PROBLEM", 287, 310], ["viral infection", "PROBLEM", 319, 334], ["T1DM through cytokines release", "PROBLEM", 377, 407], ["T cells activation", "PROBLEM", 412, 430], ["autoimmunity", "PROBLEM", 473, 485], ["viral", "OBSERVATION_MODIFIER", 179, 184], ["infection", "OBSERVATION", 185, 194], ["diabetes", "OBSERVATION", 277, 285], ["autoimmune", "OBSERVATION", 287, 297], ["viral", "OBSERVATION_MODIFIER", 319, 324], ["infection", "OBSERVATION", 325, 334]]], ["Moreover, SARS-CoV-2 uses a spike protein binding the angiotensin converting enzyme (ACE2) to enter the cells, so that ACE2 downregulation resulting from the virus' bond determines enhanced inflammation and increased vascular permeability in the respiratory tract [2, 11] .", [["cells", "ANATOMY", 104, 109], ["vascular", "ANATOMY", 217, 225], ["respiratory tract", "ANATOMY", 246, 263], ["angiotensin", "CHEMICAL", 54, 65], ["inflammation", "DISEASE", 190, 202], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 54, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["cells", "CELL", 104, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["vascular", "MULTI-TISSUE_STRUCTURE", 217, 225], ["spike protein", "PROTEIN", 28, 41], ["angiotensin converting enzyme", "PROTEIN", 54, 83], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 119, 123], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["a spike protein binding", "PROBLEM", 26, 49], ["ACE2 downregulation", "PROBLEM", 119, 138], ["the virus' bond", "PROBLEM", 154, 169], ["enhanced inflammation", "PROBLEM", 181, 202], ["increased vascular permeability in the respiratory tract", "PROBLEM", 207, 263], ["enhanced", "OBSERVATION_MODIFIER", 181, 189], ["inflammation", "OBSERVATION", 190, 202], ["increased", "OBSERVATION_MODIFIER", 207, 216], ["vascular permeability", "OBSERVATION", 217, 238], ["respiratory tract", "ANATOMY", 246, 263]]], ["COVID-19 clinical features include: asymptomatic course, upper respiratory tract symptoms, acute pneumonia and death [2] .", [["upper respiratory tract", "ANATOMY", 57, 80], ["upper respiratory tract symptoms", "DISEASE", 57, 89], ["pneumonia", "DISEASE", 97, 106], ["death", "DISEASE", 111, 116], ["upper", "ORGANISM_SUBDIVISION", 57, 62], ["respiratory tract", "ORGANISM_SUBDIVISION", 63, 80], ["COVID", "TEST", 0, 5], ["asymptomatic course", "PROBLEM", 36, 55], ["upper respiratory tract symptoms", "PROBLEM", 57, 89], ["acute pneumonia", "PROBLEM", 91, 106], ["death", "PROBLEM", 111, 116], ["upper", "ANATOMY_MODIFIER", 57, 62], ["respiratory tract", "ANATOMY", 63, 80], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["pneumonia", "OBSERVATION", 97, 106]]], ["The severity of the pulmonary involvement, with secondary respiratory failure, has required major hospitalization and/or admission to ICU.Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisAs a result of the COVID-19 pandemic, health organizations and scientists are focused on the early diagnosis of the affected patients, the isolation of the healthy carriers and the development of effective therapies for more than 4 million people infected with SARS-CoV-2.", [["pulmonary", "ANATOMY", 20, 29], ["respiratory", "ANATOMY", 58, 69], ["respiratory failure", "DISEASE", 58, 77], ["SARS", "DISEASE", 159, 163], ["type 1 diabetes", "DISEASE", 171, 186], ["autoimmune pathogenesis", "DISEASE", 188, 211], ["SARS", "DISEASE", 472, 476], ["pulmonary", "ORGAN", 20, 29], ["patients", "ORGANISM", 336, 344], ["people", "ORGANISM", 451, 457], ["SARS-CoV-2", "ORGANISM", 472, 482], ["patients", "SPECIES", 336, 344], ["people", "SPECIES", 451, 457], ["SARS-CoV", "SPECIES", 472, 480], ["the pulmonary involvement", "PROBLEM", 16, 41], ["secondary respiratory failure", "PROBLEM", 48, 77], ["COVID", "TEST", 149, 154], ["type 1 diabetes", "PROBLEM", 171, 186], ["autoimmune pathogenesis", "PROBLEM", 188, 211], ["effective therapies", "TREATMENT", 407, 426], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["pulmonary", "ANATOMY", 20, 29], ["involvement", "OBSERVATION", 30, 41], ["secondary", "OBSERVATION_MODIFIER", 48, 57], ["respiratory failure", "OBSERVATION", 58, 77], ["diabetes", "OBSERVATION", 178, 186], ["autoimmune", "OBSERVATION", 188, 198]]], ["These efforts will not be probably attenuated until a vaccine becomes available.", [["a vaccine", "TREATMENT", 52, 61]]], ["However, the massive spread of the infection virus-induced diseases.", [["infection", "DISEASE", 35, 44], ["the infection virus", "PROBLEM", 31, 50], ["induced diseases", "PROBLEM", 51, 67], ["massive", "OBSERVATION_MODIFIER", 13, 20], ["spread", "OBSERVATION_MODIFIER", 21, 27], ["infection", "OBSERVATION", 35, 44]]], ["Given that T1DM pathogenesis has already been related to coronavirus respiratory infections [7, 8] , it is reasonable to suppose that an increasing incidence of T1DM may be triggered by this pandemic, with a worrisome T1DM outbreak in COVID-19 patients for the next months/years.Key-words: COVID-19, SARS-CoV-2, type 1 diabetes, autoimmune pathogenesisIn conclusion, awaiting for the availability of pharmacological preventive approaches, future studies are warranted to investigate the existence of a pathogenetic role of COVID-19 pandemic on T1DM onset.", [["respiratory", "ANATOMY", 69, 80], ["T1DM", "DISEASE", 11, 15], ["coronavirus respiratory infections", "DISEASE", 57, 91], ["T1DM", "DISEASE", 161, 165], ["T1DM", "DISEASE", 218, 222], ["SARS", "DISEASE", 300, 304], ["type 1 diabetes", "DISEASE", 312, 327], ["autoimmune pathogenesis", "DISEASE", 329, 352], ["T1DM", "DISEASE", 544, 548], ["coronavirus", "ORGANISM", 57, 68], ["patients", "ORGANISM", 244, 252], ["COVID-19", "ORGANISM", 523, 531], ["patients", "SPECIES", 244, 252], ["T1DM pathogenesis", "PROBLEM", 11, 28], ["coronavirus respiratory infections", "PROBLEM", 57, 91], ["T1DM", "PROBLEM", 161, 165], ["a worrisome T1DM outbreak", "PROBLEM", 206, 231], ["COVID", "TEST", 290, 295], ["type 1 diabetes", "PROBLEM", 312, 327], ["autoimmune pathogenesis", "PROBLEM", 329, 352], ["pharmacological preventive approaches", "TREATMENT", 400, 437], ["future studies", "TEST", 439, 453], ["COVID", "TEST", 523, 528], ["T1DM onset", "PROBLEM", 544, 554], ["coronavirus", "OBSERVATION_MODIFIER", 57, 68], ["infections", "OBSERVATION", 81, 91], ["increasing", "OBSERVATION_MODIFIER", 137, 147], ["diabetes", "OBSERVATION", 319, 327], ["autoimmune", "OBSERVATION", 329, 339]]], ["In the meantime, clinical practitioners should be aware of this contingency, giving more attention to individuals predisposed to autoimmunity.", [["autoimmunity", "DISEASE", 129, 141], ["autoimmunity", "PROBLEM", 129, 141]]]]}